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Bovine herpesvirus 1 (BHV-1) is a significant viral pathogen of cattle responsible 
for a variety of disease conditions, including: conjunctivitis, pneumonia, genital 
disorders, abortions, and shipping fever, a serious upper respiratory tract infection. 
Following acute infection in mucosal epithelium, BHV-1 establishes a lifelong latent 
infection in sensory ganglionic neurons. During latency, transcription is restricted to the 
latency related (LR) gene. Elevated corticosteroid levels due to stress and/or immune 
suppression can initiate reactivation from latency, resulting in virus shedding and spread 
to susceptible cattle. Additionally, administration of dexamethasone (Dex), a synthetic 
corticosteroid, to calves latently infected with BHV-1 reproducibly leads to reactivation 
from latency. During reactivation, productive viral gene expression is readily detected in 
sensory neurons, LR gene expression decreases, and infectious virus is secreted. 
However, as with other alpha-herpesviruses, the molecular mechanisms that occur during 
successful reactivation from latency are poorly understood. Therefore, this dissertation 
was aimed at the elucidation of the early events of the latency-reactivation cycle of alpha-
herpesviruses. Furthermore, the aim was to reveal the function of cellular transcription 
factors in the latency-reactivation cycle. Since BHV-1 is the only alphaherpesvirinae 
  
subfamily member that can be reproducibly induced to reactivate from latency, we were 
also interested in examining the effect of these cellular factors on other important 
members of this virus family. 
Collectively, studies presented in this dissertation characterized several cellular 
transcription factors that are induced in the trigeminal ganglia of latently infected cattle 
following treatment with Dex to induce reactivation from latency. These cellular 
transcription factors activate viral transcription and stimulate BHV-1 productive infection 
in cultured cells, suggesting they may facilitate the exit from latency. A subset of these 
cellular factors also regulates herpes simplex virus 1 (HSV-1) productive infection and/or 
promoter activity. Therefore, based on the data presented in this dissertation, we 
hypothesize that stressful stimuli promotes the exit from latency by activating specific 
cellular transcription factors, which consequently activate lytic viral gene expression and 
production of infectious virus. 
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I. Classification 
 The Herpesviridae family encompasses a group of large double-stranded DNA 
viruses with a broad host range including mammals, birds, reptiles, amphibians and fish 
(Roizmann et al., 1992). Common to all herpes viruses are basic similarities in their 
virion structure as well as certain aspects of their lifecycle. Herpes virus viral particles 
possess an icosahedral nucleocapsid of 100 nm in diameter, a cell derived envelope 
containing virally encoded glycoproteins, and a proteinaceous matrix of tegument 
proteins connecting the capsid to the envelope (Armstrong et al., 1961; Jones, 1998; 
Jones, 2003a; Tikoo et al., 1995).  Furthermore, herpes viruses share the ability to 
establish latent infections that lead to lifelong persistence of the virus.  Herpes viruses, 
however, differ in the composition and architecture of their genome, host range, duration 
of infection, cytopathology, and characteristics of latent infection (Roizman et al., 1981). 
Therefore, based on these characteristics, herpesviruses have been divided into three 
subfamilies designated alphaherpesvirinae, betaherpesvirinae, and gammaherpesvirinae. 
Alphaherpesvirinae have a variable host range with a short replication cycle that results 
in a rapidly spreading infection and cell lysis. In vivo, they establish latency primarily, 
but not exclusively, in ganglionic neurons from which they periodically reactivate 
producing a means of transmission of the virus to susceptible animals. Betaherpesvirinae 
have a narrow host range limited to a single species or genera.  The replication cycle is 
relatively long, showing a slow developing focus of infection in which the cells become 
enlarged before lysis. In vivo, latency is established in macrophages of the 
lymphoreticular tissues, the kidney, and secretory glands. Gammaherpesvirinae also have 
a restricted host range in vivo and in vitro and they primarily infect lymphocytes and 
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macrophage as well as some types of epithelial and fibroblast cells. The lytic cycle is 
variable, as is its cytopathology. The predominant outcome of virus infection is 
lymphocyte transformation {reviewed in (Roizman and Baines, 1991)}.  
 
II. Alphaherpesvirinae  
Alphaherpesvirinae represent the largest subfamily of the Herpesviridae family 
and comprise many different, but closely related pathogens of both man and animal. 
Eight herpesviruses have been identified to infect humans, and three belong to the 
alphaherpesvirinae subfamily: (i) herpes simplex virus type 1 (HSV-1), which is a 
ubiquitous pathogen causing mainly oral or genital lesions, (ii) herpes simplex virus type 
2 (HSV-2), which is closely related to HSV-1, and is one of the most common sexually 
transmitted viruses globally, causing mainly genital lesions, and (iii) varicella zoster virus 
(VZV), which causes chicken pox and upon reactivation, shingles. Important animal 
pathogens include: (i) pseudorabies virus  (PRV) or Aujeszky's disease virus in pigs, 
which causes neurological and respiratory symptoms as well as reproductive failure, (ii) 
equine herpesvirus type 1 in horses, which has a similar manifestation as pseudorabies 
virus, and (iii) bovine herpesvirus type 1 (BHV-1) in cattle, which causes respiratory and 
genital diseases. Of particular interest in this dissertation are HSV-1 and BHV-1. 
 
Herpes simplex virus 1 (HSV-1) 
HSV-1 belongs to the genus Simplex virus within the alphaherpesvirinae 
subfamily.  Its genome is approximately 152 kb with a GC content of 67% (Becker et al., 
1968; Kieff et al., 1971; Plummer et al., 1969). The genome architecture consists of two 
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covalently joined segments designated unique long (UL) and unique short (US). These 
unique segments are flanked by inverted repeat sequences: terminal repeats (TR) and 
internal repeats (IR; (Wadsworth et al., 1975). HSV-1 contains at least 84 open reading 
frames distributed throughout the genome on both strands, with genes located in the 
inverted repeat regions present in two copies (Figure 1.1).  These genes encode a variety 
of proteins involved in forming the virion nucleocapsid, tegument, and envelope, as well 
as regulating the replication cycle of the virus. 
 
 
 
 
Figure 1.1: Schematic of HSV-1 genome. 
 
 
HSV-1 possesses a linear, double-stranded DNA genome of 152 kb encoding more than 80 genes. 
The genome is composed of unique long (UL) and unique short (US) segments, which are flanked 
by inverted repeats. The inverted repeats are designated as follows: TRL: terminal repeat of the 
long segment; IRL: internal repeat of the long segment; IRS: internal repeat of the short segment; 
and TRS: terminal repeat of the short segment. The genome contains three packaging signals 
(shown in grey) that assist in packaging the DNA into virions. 
 
 
Primary infection with HSV-1 usually occurs in childhood, and approximately 
90% of adults in the United States are infected (Nahmias and Roizman, 1973). HSV-1 
infection can lead to a variety of disorders including recurrent genital and orofacial 
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lesions, keratitis, and conjunctivitis (Nahmias and Roizman, 1973). In fact, recurrent 
ocular HSV-1 infections are the major form of infectious corneal blindness in developed 
nations (Nesburn et al., 1983). HSV-1 infections can also cause gastrointestinal disorders, 
esophageal disorders, and approximately 25% of genital herpes (Gesser and Koo, 1997; 
Lohr et al., 1990). HSV-1 infections can also cause sporadic encephalitis; however, this 
condition is rare compared to other diseases resulting from infection. In addition, the 
virus establishes an asymptomatic latent infection in sensory neurons which serves as a 
reservoir for further cycles of peripheral lytic infections. Stress, trauma, and immune 
suppression can result in reactivation from latency resulting in virus shedding. In general, 
recurrent diseases caused by HSV-1 are the direct result of reactivation from latency 
(Asbell et al., 1984; Lewis et al., 1984; Sakaoka et al., 1995). For example, two-thirds of 
HSV-1 induced infections, corneal blindness, and encephalitis are the result of recurrent 
disease. To date, there is no HSV vaccine, and two recent genital herpes vaccine trials 
failed (Cohen, 2010; Stanberry and Rosenthal, 2002). 
 
Bovine herpesvirus 1 (BHV-1)  
 BHV-1 is classified in the genus Varcellovirus within the alphaherpesvirinae 
subfamily and shares a number of biological properties with HSV-1 (Jones, 2003a).  The 
BHV-1 genome is approximately 135 kb in length and contains a GC content of 72% 
(Tikoo et al., 1995). BHV-1 has at least 73 ORFs. The genome has similar architecture 
and gene arrangement as described for HSV-1 (See Figure 1.1).   
 BHV-1 is a significant viral pathogen of cattle that is responsible for a variety of 
disease conditions. The main clinical manifestations include: infectious bovine 
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rhinotracheitis (IBR), infectious pustular vulvovaginitis (IPV), infectious pustular 
balanopostitis (IPB), conjunctivitis, abortions, and generalized systemic infections 
{reviewed in (Muylkens et al., 2007)}. In rare occasions, the virus can cause fatal 
encephalitis.  BHV-1 is also one of the major etiological agents of bovine respiratory 
disease complex (BRDC), also known as “shipping fever”. Other members of the BRDC 
complex include bovine viral diarrhea virus (BVDV), bovine respiratory syncytial virus 
(BRSV), bovine adenovirus, and bovine parainfluenza virus type 3 (PI-3; Rosenquist, 
1983). BHV-1 infection, associated with one or more of these agents, is followed by 
immune suppression and secondary bacterial infection by opportunistic pathogens such as 
Haemophilus somnus, Mannheimia haemolytica or Mannheimia multocida (Babiuk et al., 
1988; Yates, 1982). Losses associated with BRDC are approximately $3 billion annually, 
and approximately 75% of morbidities and over 50% of mortalities in feedlot cattle are 
attributed to BRDC (Ishmael, 2001; Kapil, 1997; Powell, 2005).  BRDC is also 
recognized as a significant problem for dairy cattle and cow-calf operations. Thus, BRDC 
is considered to be the most economically important disease affecting the cattle industry. 
Although modified live vaccines are available, it should be noted that most commercially 
available vaccines can i) reactivate from latency, ii) induce abortions in cows, and iii) 
induce systemic and fatal infections in calves. Therefore, there is a need to develop novel 
modified live vaccines which do not reactivate from latency, yet protect cattle from 
clinical symptoms induced by virulent field strains.  
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III. Productive Infection  
Overview  
 Productive infection is initiated by a three step entry process following direct or  
aerosol contact of the virus with oral, respiratory, ocular or genital mucosal membranes. 
The first interaction involves low affinity virus attachment between gB and/or gC to cell 
surface structures such as heparin sulfate sugar moieties. This labile interaction is 
followed by the stable binding of gD to specific cellular receptors (HveB and HveC), 
allowing virus penetration by fusion of viral and cellular envelopes (Campadelli-Fiume 
and Menotti, 2007). Once in the cytosol, the de-enveloped nucleocapsid is then 
transported toward nuclear pores via dynein motor complexes associated with 
microtubules in order to permit viral DNA release into the nucleus (Dohner et al., 2002). 
In the nucleus, the viral genome replicates by three temporally regulated phases of 
transcription that yield: immediate early (IE) proteins that regulate viral transcription; 
early (E) proteins that replicate the viral genome; and late (L) proteins which are 
structural and comprise the virion particle. After the late phase of infection, viral capsids 
are assembled in the nucleus.  Exactly how the mature capsids leave the nucleus to gain 
secretory vesicles and how they obtain their final envelope is still a matter of debate. The 
current view of egress and capsid maturation is proposed in a three step model where the 
capsids bud through the inner nuclear membrane to gain their primary envelope. In order 
to gain access to the cytoplasm, the virions fuse their primary envelopes with the outer 
nuclear membrane. Once in the cytoplasm, naked capsids acquire their mature tegument 
and secondary envelope by budding into the trans- Golgi compartment.  The virus would 
then leave the cell through the secretory pathway. As with all alphaherpesvirinae 
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subfamily members, the cell is killed in the process of productive infection and the virus 
spreads cell to cell {reviewed in (Muylkens et al., 2007)}.  
 
HSV-1 Productive Infection 
 HSV-1 IE gene expression does not require protein synthesis and is stimulated by 
the tegument protein VP16 (O’Hare et al., 1993) and by active cyclin-dependent kinases 
(Schang et al., 1998; Schang et al., 1999). Five IE genes exist: infected cell protein 
[ICP]0, ICP4, ICP22, ICP27, and ICP47. ICP4 (Carrozza and DeLuca, 1996; DeLuca et 
al., 1985; DeLuca and Schaffer, 1985) and ICP27 (McCarthy et al., 1989; McMahan and 
Schaffer, 1990; Sacks et al., 1985) are required both in vivo and in vitro for virus growth. 
ICP4 represses IE gene expression (DeLuca and Schaffer, 1985; Gu et al., 1993; Michael 
and Roizman, 1993; O'Hare and Hayward, 1985; Roberts et al., 1988) and activates E or 
L gene expression by interacting with RNA polymerase II basal transcription factors (Gu 
and DeLuca, 1994; Smith et al., 1993). In the absence of ICP4, infection does not proceed 
beyond IE gene transcription (DeLuca et al., 1985; Preston, 1979). ICP27 is involved in 
several functions, including: the switch from early to late gene expression during virus 
replication, polyadenylation site selection and 3’ RNA processing, inhibition of mRNA 
splicing, and transport of intronless mRNA out of the nucleus {reviewed in (Weir, 
2001)}. ICP22 is important for viral growth in some cultured cells but not others (Long et 
al., 1999; Rice et al., 1995). Although the role of ICP22 in HSV-1 replication has not 
been
 
elucidated, evidence suggests that ICP22 alters the activities
 
of cellular proteins 
required for efficient virus replication (Advani et al., 2000a; Bruni et al., 1999; Bruni and 
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Roizman, 1998; Sears et al., 1985) and late gene expression (Orlando et al., 2006; 
Poffenberger et al., 1993; Rice et al., 1995; Sears et al., 1985).  
ICP0 is a promiscuous activator of gene expression that activates all three classes 
of viral promoters, but does not directly bind to DNA. ICP0 is not absolutely required for 
virus growth in cell culture. ICP0
 
null viruses replicate to nearly wild-type levels when 
cells are infected with a multiplicity of infection (MOI) greater than one. At MOIs below 
0.1, the same ICP0
 
null viruses establish quiescent infections in 99% of the cells they 
infect (Everett, 1989; Sacks and Schaffer, 1987). Such observations suggest that ICP0 
antagonizes a cellular repression mechanism to silence viral transcription. This repression 
capacity appears to be saturated with high copy numbers of viral genome (Everett, 1989). 
The mechanism by which ICP0 counteracts this process is unknown, but critical to its 
activity is a zinc RING finger domain that mediates E3 ubiquitin ligase activity which 
targets a number of cellular proteins for proteosome dependent degradation (Enquist et 
al., 1998; Everett, 2000; Everett et al., 1999b).  The list of proteins that may function as 
ICP0-antagonized repressors of HSV gene expression continues to grow and currently 
includes: PML (Chee et al., 2003; Everett et al., 2008; Everett et al., 2006; Gu and 
Roizman, 2009) Sp100 (Chelbi-Alix and de The, 1999), cyclin D3 (Kawaguchi et al., 
1997), IRF-3 and IRF-7 (Lin et al., 2004), centromeric proteins CENP-B and CENP-C 
(Everett et al., 1999a; Lomonte and Morency, 2007), HDAC1/2-CoREST-REST (Gu and 
Roizman, 2009), DNA-dependent protein kinase (Lees-Miller et al., 1996), and class II 
histone deacetylases (Lomonte et al., 2004).  
 ICP47 is the only IE protein that does not play a critical role in the regulation of 
HSV gene expression. Rather, ICP47 prevents transport of antigenic peptides into the 
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endoplasmic reticulum (Hill et al., 1995) and is crucial for neurovirulence because it 
inhibits CD8+ T-cell responses (Goldsmith et al., 1998).   
 The IE proteins stimulate production of the E genes, whose role is to increase 
nucleic acid metabolism. These proteins include thymidine kinase, viral DNA 
polymerase, and other enzymes involved in DNA metabolism. Viral DNA synthesis is 
detected 3 hours post-infection and continues for another 12 hours (Igarashi et al., 1993; 
Roizman et al., 1963; Roizman et al., 1965).  The optimal expression of L genes requires 
viral DNA synthesis (Harris-Hamilton and Bachenheimer, 1985; Honess and Roizman, 
1974; Honess and Roizman, 1975). The late genes encode structural components of the 
virion including nucleocapsid proteins, glycoproteins, and tegument proteins. In fully 
permissive tissue culture cells, the entire process takes approximately 18-20 hours.  
 
BHV-1 Productive Infection 
 Like HSV-1, BHV-1 gene expression is temporally regulated in three distinct 
phases. In bovine primary cell cultures, BHV-1 DNA synthesis initiates between 2 and 4 
hours post infection (hpi) and peaks at 4 to 6 hpi (Ghram and Minocha, 1986). Viral 
proteins are detectale at 4 hpi and increase until 6 and 8 hpi (Ghram and Minocha, 1986). 
            IE gene expression is stimulated by a virion component, bTIF, which is 
homologous to the HSV-1 encoded VP16. Two immediate early transcription units exist: 
IE transcription unit 1 (IETu1) and IETu2 (Misra et al., 1994; Misra et al., 1995). IETu1 
encodes functional homologs of two HSV-1 proteins, ICP0 and ICP4. Circ, a less 
abundant transcript, encodes a tegument associated protein and arises from the activation 
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of the IETu1 promoter across the junction of the circularized genome (Fraefel et al., 
1993; Fraefel et al., 1994). IETu2 encodes a protein similar to the HSV-1 IE gene, ICP22.  
The IE gene products have transcriptional regulatory functions (Jones, 2003a). 
bICP4 and bICP22 shut off expression of IETu1 and IETu2, while they activate the E 
promoter of bICP0 as well as other E and L genes (Schwyzer et al., 1993). bICP0 does 
not specifically bind DNA, yet is a potent activator of viral promoters (Everett, 2000; 
Wirth et al., 1992). Indeed, bICP0 is considered the major transcriptional regulatory 
protein encoded by BHV-1 because it activates expression of all three classes of viral 
promoters (Wirth et al., 1992) and it is expressed at high levels throughout infection 
(Everett, 2000; Fraefel et al., 1994). bICP0 also functions as a nonspecific enhancer of 
foreign (non-BHV) genes. This is in contrast to bICP4 which is a specific transactivator 
of BHV-1 E genes. Although bICP0 is not abundantly expressed during latency in tonsils 
(Winkler et al., 2000a) or in TG, it must be expressed for reactivation to occur (Jones et 
al., 2006). Construction of a bICP0 deletion virus, however, showed that similar to ICP0, 
bICP0 is important, but not required for growth in tissue culture (Geiser and Jones, 2005; 
Koppel et al., 1996). 
 
IV. Latency-Reactivation Cycle 
Overview 
A key characteristic of all alpha-herpesviruses is their ability to establish life-long 
latency within the infected host and periodically reactivate to facilitate transmission of 
virus to other susceptible hosts. Following infection and local replication at mucosal 
surfaces, HSV-1 or BHV-1 particles gain access to sensory nerve terminals innervating 
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the tissue (Enquist et al., 1998). The virus is then transported intra-axonally in a 
retrograde fashion to neuronal cell bodies in the trigeminal ganglia (TG), where latency is 
established. Although TG is the main site of latency for BHV-1 and other members of the 
alphaherpesvirinae subfamily, latent infection can also occur in non-neuronal sites, for 
example tonsils and lymph nodes (Winkler et al., 2000a). 
 In contrast to acute infection where all viral genes are expressed; latency is 
characterized by minimal viral gene expression, the absence of lytic viral proteins, and 
the absence of infectious virus production. Both the restriction of substantial viral gene 
expression and the maintenance of the viral genome over time during latency allow 
herpesviral infections to persist for the life of the host, even in the face of intense immune 
surveillance. Latently infected cells form a reservoir of virus that can periodically be 
induced to re-enter the lytic replication cycle and reactivate from latency. This latent 
stage and subsequent reactivations cause recurrent disease at peripheral sites and 
accounts for the high transmission rates and prevalence of herpesviruses in nature.  
 
Establishment of Latency 
The steps of the latency-reactivation cycle have been operationally divided into 
three major steps: establishment, maintenance, and reactivation.  Extensive viral gene 
expression and replication occur within the TG for approximately a week following 
infection of animal models with HSV-1 (Knotts et al., 1974; Kramer et al., 1998) or cattle 
with BHV-1 (Schang and Jones, 1997; Winkler et al., 2000a).  Around 7 days after 
infection, extensive viral gene expression is extinguished. Inhibition of IE gene 
expression reduces cellular toxicity and productive infection, favoring the establishment 
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of latency (discussed in more detail in the next section). Surviving neurons harbor latent 
viral genomes which are retained extra-chromosomally as circular episomes (Rock and 
Fraser, 1983; Rock and Fraser, 1985). In animal models of HSV-1 infection, the total 
number of cells harboring latent viral genomes is estimated to be approximately 1-5% of 
trigeminal ganglion neurons (Ackermann et al., 1982; Kutish et al., 1990a). The genome 
copy number within the infected neuron can range from <10-1,000 copies (Sawtell, 
1997). Increasing the viral input titer results in more neurons with greater numbers of 
viral genome copies; demonstrating a direct correlation between increasing viral input 
and the number of neurons in which latency is established. Productive replication within 
the TG also increases the number of latently infected neurons; however, replication is not 
required for the establishment of latency. For example, viral mutants that cannot replicate 
will establish latency, but at reduced levels (Coen et al., 1989; Efstathiou et al., 1989; 
Katz and Middle, 1990; Margolis et al., 1992; Sedarati et al., 1993; Steiner et al., 1990).  
The immune system also contributes to the establishment of latency by 
suppressing infection and limiting the spread of the virus at synaptic junctions. Following 
primary HSV-1 infection of mice, T-cells and other inflammatory lymphoid cells 
infiltrate the TG in large numbers between 7 and 10 days post infection (Erturk et al., 
1992; Liu et al., 1996; Shimeld et al., 1995b; Stumpf et al., 2001). During this period an 
increase in cells expressing interferon-gamma (IFN-gamma) and interleukin 4 (IL-4) is 
also observed. Chronic inflammatory infiltration of lymphocytes in TG of calves 
following infection with BHV-1 is also observed (Winkler et al., 2002a). The presence of 
lymphocytes in close association with latently infected ganglionic neurons suggests that 
the immune system may promote the establishment of latency, perhaps by inducing a 
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non-permissive environment. This is supported by the finding that IFN-gamma, tumor 
necrosis factor-alpha (TNF-alpha), and CD8+ T-cells repress HSV-1 productive infection 
(Cantin et al., 1999a; Cantin et al., 1999b; Cantin et al., 1995b; Halford et al., 1996b). 
The cytokine environment may also influence neuronal cell health and promote the 
maintenance of latency. 
 
Maintenance of Latency 
Maintenance of latency is a phase that lasts for the life of the host and is 
operationally defined as a period where infectious virus is not detected by standard virus 
isolation procedures. Maintaining a latent infection requires that the viral genome be 
perpetuated and the cell kept alive. As neurons are non-dividing, genome replication and 
faithful partitioning to daughter cells upon cell division is not a significant concern for 
alpha-herpesvirus latency as it is for other subfamily members. Perhaps to avoid cell 
death by apoptosis or immune recognition, abundant expression of viral genes that are 
required for productive infection does not occur.  However, many alphaherpesvirinae 
subfamily members, including HSV-1 and BHV-1, express abundant levels of a latency 
associated transcript (LAT) in neurons during this stage of latency (Jones, 1998; Jones, 
2003a; Jones et al., 2006).  
The HSV-1 LAT and the BHV-1 latency-related (LR) gene have a similar 
genomic position and are antisense to and partially overlap the ICP0 and bICP0 open 
reading frame respectively. The BHV-1 LR gene has two well defined ORFs (ORF-1 and 
ORF-2) and two reading frames lacking the initiating ATG (RF-B and RF-C). As a result 
of alternative splicing of poly(A)+ LR-RNA in the TG of infected calves, this RNA is 
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translated into more than one protein product (Devireddy and Jones, 1998; Hossain et al., 
1995a). LR gene products help to maintain latency by inhibiting apoptosis (Ciacci-
Zanella et al., 1999; Henderson et al., 2004a; Henderson et al., 2004b) and viral gene 
expression (Bratanich et al., 1992; Geiser et al., 2002). A mutant BHV-1 strain with three 
stop codons at the N terminus of ORF-2 does not express ORF-2 or RF-C and does not 
reactivate from latency (Inman et al., 2002; Jiang et al., 2004). These findings implied 
that the LR mutant virus was unable to infect neurons that support reactivation from 
latency or the LR mutant virus killed neurons that support reactivation from latency. 
Interestingly, higher rates of neuronal apoptosis occur in TG neurons during the 
establishment of latency following infection with the LR mutant (Lovato et al., 2003). 
Furthermore, in situ hybridization revealed that a small percentage of viral genome-
positive neurons are present in the TG of calves infected with the wt or LR rescued virus 
but not the LR mutant virus (Inman et al., 2002). These observations suggest that the anti-
apoptosis function of a protein encoded by the LR gene helps to establish and maintain 
latency in a pool of neurons that are capable of supporting reactivation from latency. 
(Ciacci-Zanella et al., 1999; Devireddy and Jones, 1999a; Geiser et al., 2008; Lovato et 
al., 2003; Shen and Jones, 2008; Winkler et al., 1999).  
HSV-1 LAT also interferes with apoptosis in vitro and in vivo by inhibiting both 
major apoptosis pathways (Ahmed et al., 2002; Henderson et al., 2002; Inman et al., 
2001a; Jin et al., 2003; Kang et al., 2003; Perng et al., 2000). Although HSV-1 encodes 
other anti-apoptosis genes (Us3, ICP27, and glycoproteins Us6 and Us5), LAT is the only 
anti-apoptosis gene that is abundantly expressed at the end of acute infection when 
latency is being established. The anti-apoptosis functions of LAT correlate with 
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promoting spontaneous reactivation because three different anti-apoptosis genes restore 
wt levels of spontaneous reactivation to a LAT null mutant (Jin et al., 2008; Jin et al., 
2005; Perng et al., 2002).  Additionally, insertion of the BHV-1 LR gene into the HSV-1 
LAT locus restores high levels of spontaneous reactivation in the rabbit eye model and in 
explant induced reactivation (Mott et al., 2003; Perng et al., 2002). Thus, the anti-
apoptosis activities of LAT and LR seem to be important for the latency-reactivation 
cycle.  
 
Reactivation from Latency 
Reactivation from latency is initiated by external stimuli (e.g. stress and 
immunosuppression) that stimulate viral gene expression. The stress induced by moving 
cattle from one location to another is an important stressful stimulus that is known to 
trigger reactivation from latency. During reactivation, three significant events occur: (i) 
productive viral gene expression is stimulated and can be readily detected in sensory 
neurons, (ii) LAT/LR gene expression decreases, and (iii) infectious virus is transported 
in an anterograde fashion to mucosal surfaces {reviewed in (Perng and Jones, 2010)}. 
The ability of herpes viruses to reactivate from latency results in recurrent disease and 
virus transmission. 
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V. Viral Gene Expression During Productive Infection vs. Reactivation from 
Latency. 
Regulation of IE Promoters in Neurons versus Nonneuronal Cell Types 
The regulated pattern of gene expression during productive infection has been 
extensively studied in permissive cell types in culture (Clements et al., 1977; Honess and 
Roizman, 1974). Unlike other large DNA viruses, herpesvirus IE genes are not controlled 
by constitutively active promoters within the context of the viral genome. Rather, a 
tegument protein packaged in the virion serves to activate IE gene expression {reviewed 
in (Wysocka and Herr, 2003)}. Upon viral envelope fusion with the cellular membrane, 
tegument proteins are shed in the cytosol and are the first to encounter and interact with 
the intracellular environment. The tegument protein VP16, also known as bTIF in BHV-
1, is responsible for initiating IE viral gene expression. VP16 associates with host cell 
factor 1 (HCF-1) in the cytoplasm and this complex translocates to the nucleus where it 
recognizes the cellular transcription factor Oct-1 (Octamer binding protein 1) bound to 
TAATGARAT (where R is a purine) motifs located in the promoters of all IE genes 
(Kristie et al., 1989; LaMarco and McKnight, 1989). This brings the potent VP16 acidic 
activation domain in the vicinity of the transcription start site of these genes in order to 
recruit and stabilize elements of the basal transcription complex (Goodrich et al., 1993; 
Ingles et al., 1991; Klemm et al., 1995; Lin et al., 1991; Uesugi et al., 1997).  
In addition to recruiting RNA polymerase II, the VP16/HCF/Oct-1 complex also 
controls the histone occupancy, positioning, and modification at viral IE promoters 
(Hancock et al., 2010; Herrera and Triezenberg, 2004; Peng et al., 2010). Viral genomes 
packaged into virions and delivered to the nuclei of infected cells are devoid of cellular 
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histone proteins (Leinbach and Summers, 1980; Oh and Fraser, 2008). However, 
chromatinization occurs rapidly upon nuclear entry and is maintained throughout 
infection. The acidic activation domain of VP16 interacts with cellular chromatin 
remodeling complexes and decreases histone occupancy on viral IE promoters 
(Memedula and Belmont, 2003; Neely et al., 1999). Additionally, the VP16/HCF/Oct-1 
complex controls the post-translational modifications of the cellular histones bound to the 
viral genome. VP16 interacts with the cellular histone acetyltransferases (HATs) CBP 
and p300 to increase the markers of active euchromatin by acetylation of histones 
associated with viral IE promoters (Barlev et al., 1995; Kraus et al., 1999; Kundu et al., 
2000; Memedula and Belmont, 2003; Utley et al., 1998). Therefore, VP16 is required for 
efficient IE gene expression during the initiation of productive infection. 
Viral mutants defective in VP16 or IE gene expression do not readily enter 
productive replication after infection in tissue culture cells, but are retained in a non-
replicating ‘quiescent’ state. This has led to the hypothesis that establishment of latency 
is the consequence of a failure to initiate IE gene expression. This view is supported by in 
vivo studies in which an ectopic ICP0 promoter was used to drive the expression of the 
Cre recombinase. ICP0 promoter activation led to Cre expression and the subsequent 
Cre-mediated activation of the LacZ reporter from the cellular genome (Proenca et al., 
2008). This technique revealed that less than a third of latently infected neurons exhibit 
detectable levels of ICP0 expression sometime during infection of the neuron and 
establishment of latency. In vivo studies using wild type viruses show that during acute 
infection, two populations of neurons can be identified, those expressing viral antigens, 
and those expressing latency associated transcripts (LAT), suggesting an early divergence 
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of lytic and latent pathways (Lachmann, 2003; Sawtell and Thompson, 1992; Speck and 
Simmons, 1991; Speck and Simmons, 1992). 
This lack of IE gene expression has become an area of intense research: why is 
there not transcription of IE genes in sensory neurons? As mentioned previously, IE 
genes are induced by a combination of host and viral factors. It is conceivable that the 
lack of IE gene expression could be due to i) a lack of the viral VP16, ii) a lack of 
essential host factors (HCF-1 and Oct-1), and/or iii) direct repression of the IE gene 
promoter (as opposed to a lack of induction).   
Evidence from another alphaherpesvirinae subfamily member (PRV) suggests 
that viral nucleocapsids arrive at the neuronal cell body largely devoid of VP16 
(Diefenbach et al., 2008; Luxton et al., 2005). Furthermore, any tegument-derived VP16 
must pair with HCF in the cytoplasm and then translocate to the nucleus. HCF is 
expressed in neurons; however, unlike other cell types where the protein is mainly 
nuclear, HCF has a strict cytoplasmic localization in neurons (Kristie et al., 1999). HCF 
is sequestered in the cytoplasm through its association with neuronal proteins Zhangfei 
(Akhova et al., 2005; Lu and Misra, 2000b) and Luman (Lu et al., 1997; Lu and Misra, 
2000a), and is often found associated with the Golgi apparatus (Kolb and Kristie, 2008). 
This has led to the proposition that there may be sequestration of VP16 in the cytoplasm, 
which would restrict IE transcription (Kristie et al., 1999).  
In addition to the loss of functional VP16 in  the nucleus, Oct-1 expression is 
lower in sensory neurons compared to non-neuronal cells, and a number of proteins 
related to Oct-1 (e.g. Oct-2; Brn-1-4) that fail to complex with VP16 may repress IE gene 
activation (Efstathiou and Preston, 2005; Lillycrop et al., 1994; Preston, 2000). 
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Therefore, it appears that VP16 function is compromised during the establishment of 
latency, thus decreasing the likelihood of IE gene expression in neurons.  
Viral factors are also believed to play a role in the restriction of viral gene 
expression in sensory neurons. As mentioned previously, LAT and the LR gene overlap 
and are antisense to ICP0 suggesting it represses IE gene expression (Bratanich et al., 
1992; Mador et al., 1998; Stevens, 1987b; Thompson and Sawtell, 1997). It has been 
demonstrated that BHV-1 LR represses the transactivation of IETu1 (Bratanich et al., 
1992). LR also encodes at least two micro-RNAs which inhibit bICP0 expression and 
reduce viral replication (Jaber et al., 2010). LAT also encodes micro-RNAs that inhibit 
ICP0 and ICP4 protein expression (Umbach et al., 2009). Other experiments have shown 
that IE gene expression is repressed and latency is established in LAT-null viruses (Ho 
and Mocarski, 1989; Javier et al., 1988; Lachmann et al., 1999; Steiner et al., 1989). 
Therefore, it is reasonable to predict that viral factors, especially LAT/LR, as well as 
cellular factors cooperate to mediate the block in IE gene expression, aiding in the 
establishment of latency in sensory neurons. 
 
Viral Gene Expression During Reactivation from Latency 
             Restriction of IE gene expression that occurs in sensory neurons must be 
overcome for reactivation from latency to occur. While VP16 is crucial for IE gene 
expression during lytic infection, studies in the early 1990’s led to the dogma that VP16 
is not required for reactivation from latency (Ecob-Prince et al., 1993a; Sears et al., 1991; 
Steiner et al., 1990). This conclusion was based on the observations that a VP16 mutant 
lacking transactivation potential can efficiently reactivate from latency (Ecob-Prince et 
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al., 1993a; Steiner et al., 1990). This was further supported by the later observation that 
viral nucleocapsids arrive at the neuronal cell body largely devoid of VP16 (Diefenbach 
et al., 2008; Luxton et al., 2005),  and VP16 is not expressed during latency. Thus, it was 
concluded that VP16’s function in initiating the lytic cycle is fulfilled by another viral 
function or a host cell factor during reactivation from latency.                
There are two hypotheses regarding the initiation of the lytic cycle during 
reactivation from latency. The first hypothesis proposes that reactivation of latent virus 
may be the result of changes in cellular transcriptional regulators induced by systemic 
stress, which consequently stimulate the expression of the viral IE gene, ICP0.  ICP0 then 
serves to initiate reactivation from latency (Amelio et al., 2006; Cai and Schaffer, 1989; 
Jordan and Schaffer, 1997; Leib et al., 1989). Exogenous expression of ICP0, 
independent of other viral gene products, can initiate HSV-1 (Halford et al., 2001) or 
HSV-2 (Zhu et al., 1990) reactivation from latency using an in vitro system. Furthermore, 
ICP0 mutant viruses clearly fail to reactivate from latency (Cai et al., 1993; Halford and 
Schaffer, 2001). However, this virus also has severe defects in productive infection and 
establishes latency at reduced levels, making interpretation of the results more 
complicated. Using a procedure to equalize ICP0 mutant and wild-type genome numbers, 
Halford and Schaffer (Halford and Schaffer, 2001) conclude that ICP0 is required for 
efficient reactivation in explants of latently infected TG as well as primary cultures of 
latently infected TG cells. The requirement of ICP0 in reactivation from latency remains 
controversial, however, as differing readouts of reactivation (explant vs in vivo studies) 
give contradictory results into the requirement for ICP0 during reactivation from latency 
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(Cai et al., 1993; Halford and Schaffer, 2001; Miller et al., 2006; Thompson and Sawtell, 
2006). 
 The second hypothesis for HSV-1 reactivation proposes that viral early gene 
expression and DNA replication precedes and is necessary for efficient IE gene 
expression during reactivation from latency (Kosz-Vnenchak et al., 1993; Pesola et al., 
2005).  This is supported by in vivo and in vitro studies which report a novel program of 
gene expression during reactivation from latency (Devi-Rao et al., 1994; Nichol et al., 
1996; Tal-Singer et al., 1997). Tal-Singer et al. (Tal-Singer et al., 1997) detected E and 
leaky L genes prior to IE genes during HSV reactivation from latency in infected TG. 
Nichol et al. (Nichol et al., 1996) found that an inhibitor of viral replication, ACV, 
inhibited IE and E gene expression in primary neuronal cells but not in Vero cells. 
Therefore, which cellular factors play a role in the initiation of reactivation and which 
viral genes are among the first be expressed (i.e. the IE bICP0 or E replication genes) is 
yet unknown and an area of intense research. 
Cell culture systems have been developed to study the latency-reactivation cycle; 
however, most are poor models for in vivo latency and reactivation. For example, in 
1971, Stevens and Cook co-cultured TG explants with an HSV-1 permissive cell line in a 
functional assay to verify latent infection. While this technique was useful for evaluating 
establishment of latency, it could not be adopted as a useful  reactivation model, as 
reactivation was induced without treatment (Stevens and Cook, 1971). Neonatal sensory 
neuron cultures were later developed to study reactivation. This model was better suited 
as it maintained latency until administration of a specific stressor (Smith et al., 1992; 
Wilcox and Johnson, 1988). This model is not without drawbacks, however, as it differs 
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substantially from adult ganglionic neurons in vivo. For example, nearly 100% of the 
cells in the neonatal culture can become latently infected. In the TG, only 5-10% of the 
cells are neurons, and only 1-5% of these neurons are latently infected following HSV-1 
infection (Ackermann et al., 1982; Kutish et al., 1990a). Other cell culture based systems 
were described in which primary cell cultures were established from the TG of a mouse 
latently infected with HSV-1. Explant was performed in the presence of an anti-viral drug 
(BVDU), and latency was maintained until reactivation stimuli was applied (Halford et 
al., 1996a; Moriya et al., 1994). However, the state of non-permissivity induced in 
explanted ganglia in the presence of anti-viral drugs is not equivalent to the non-
permissive state of the neuronal cells in vivo. Additionally, LAT is not abundantly 
expressed in any of these in vitro latency models. Therefore, these model systems may 
mimic some, but certainly not all, aspects of in vivo latency. 
The prevailing hypotheses regarding the initiation of the lytic cycle during 
reactivation have come almost exclusively from systems using explanted ganglia. 
Although this technique has been widely used, questions have been raised about the 
validity of results obtained from these experiments. It has become increasing clear that 
the explantation process significantly alters neurons, inducing rapid, widespread changes 
in neuronal physiology. This complicates the interpretation of results obtained from 
explanted ganglia. Therefore, Thompson and Sawtell have recently re-examined the two 
prevailing hypotheses of reactivation using in vivo reactivation and single neuron 
approaches. Using this technique, they provide evidence that the exit from latency does 
not require a viral DNA pre-amplification stage (Sawtell et al., 2006) or functional ICP0 
(Thompson and Sawtell, 2006). Reactivation has traditionally been defined as infectious 
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virus production. In these studies they divided reactivation into two phases: initiation of 
lytic viral gene expression and infectious virus production. While ICP0 and viral DNA 
replication were required for infectious virus production, they did not appear to play a 
role in the initiation of lytic viral gene expression. If the two protagonists in the 
reactivation debate (ICP0 and DNA replication) are not responsible for the initial events 
of reactivation, then what is?  
Thompson et al. propose that de novo synthesis of VP16 is responsible for the 
initial events of reactivation (Thompson et al., 2009). A caveat to this hypothesis is that a 
virus with a mutation in the VP16 acidic activation domain can efficiently reactivate from 
latency using explant models for reactivation (Ecob-Prince et al., 1993b; Steiner et al., 
1990). However, this same mutant fails to reactivate in heat stressed mice (Thompson et 
al., 2009), highlighting the differences between explant studies and in vivo assays. In this 
experiment they show that in using two different reporter viruses they detect VP16 
promoter activity before IE gene production following heat stress induced reactivation 
(Thompson et al., 2009). Therefore, while VP16 is expressed as a late protein during 
productive infection, its promoter appears to be activated prior to IE genes during 
reactivation. Furthermore, this appears to be specific for the VP16 promoter, as the late 
promoter which drives expression of VP5 could substitute for the VP16 promoter during 
productive infection in vitro and during acute ocular infections in mice, but was severely 
impaired for replication in mouse TG. This is interesting as it implies that de novo 
synthesis of VP16 may be required for the short period of replication observed in the TG 
before the establishment of latency.  
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As mentioned previously, VP16 does not act alone in IE gene activation. 
Interestingly, cellular stress also leads to HCF-1 subcellular relocalization from the 
cytoplasm to the nucleus. This is important, as VP16, synthesized in the cytoplasm, is 
unable to enter the nucleus if binding to HCF-1 is mutated, or if the nuclear localization 
signal of HCF is deleted (LaBoissiere and O'Hare, 2000). Under these circumstances, IE 
gene expression is inhibited. Additionally, Oct1 levels and DNA-binding activity are 
induced following UV exposure or ganglia explant, two stimuli that result in herpesvirus 
reactivation. This suggests that VP16 may function similarly during reactivation as 
during productive infection, with the only difference being the source of VP16 (tegument 
delivered or newly synthesized).  
The dependence on cellular factors for reactivation provides an opportunity for 
the virus to integrate information about the state of the host cell into the control of its 
own lytic program. The stress induced cellular factors that regulate HSV-1 VP16 
expression during reactivation and the promoter sequences that are important for the 
regulated expression of VP16 in neurons have not been identified. Furthermore, whether 
or not these findings extend to other alphaherpesvirinae subfamily members (such as 
BHV-1) is yet to be determined. 
 
VI. Corticosteroid Induced Reactivation from BHV-1 Latency 
One particularly intriguing feature of BHV-1 infection is that administration of 
dexamethasone (Dex), a synthetic corticosteroid, to calves or rabbits latently infected 
with BHV-1 reproducibly leads to reactivation from latency (Rock et al., 1992). 
Corticosteroid mediated BHV-1 reactivation is likely a significant mechanism underlying 
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the survival of BHV-1 in nature as well. Naturally occurring stressful conditions lead to 
epinephrine release from the sympathetic nervous system and glucocorticoid release from 
the adrenal gland. This increase in endogenous corticosteroids is known to result in 
reactivation and viral shedding in latently infected animals (Davies and Carmichael, 
1973). Therefore, understanding the molecular mechanisms by which Dex causes 
reactivation can shed light on how natural stress also leads to reactivation from latency.  
Glucocorticoids are known regulators of both cellular and viral gene expression 
and, in addition, they are known to be potent immunosuppressive agents in vivo 
(Rousseau and Baxter, 1979; Yamamoto, 1985). The manner by which Dex induces 
BHV-1 reactivation is unknown; however, recent studies in human disease models have 
shed some light on the molecular mechanisms by which glucocorticoids exert their 
effects. 
Glucocorticoids regulate transcription via glucocorticoid receptors (GR). 
Glucocorticoids enter the cell and bind to inactive GR in the cytosol. Two active GR 
molecules then form a dimer that couples to FKBP52 and dynein, which mediate the 
transport of the GR complex into the nucleus (Smith et al., 2000; Wochnik et al., 2005). 
In the nucleus, the GR dimmer binds to a DNA sequence known as the glucocorticoid 
response element (GRE) to stimulate or silence gene expression (Buckingham, 2006; 
Jeffery, 2004). Besides its action as a transcription factor, the GR mediates its effects by 
binding to and modifying the function of other transcription factors, including: NF-kB 
(Heck et al., 1997; McKay and Cidlowski, 1998), activator protein 1 (AP-1) (Heck et al., 
1994), Smad or Mad-related proteins, and STAT family members leading to 
transcriptional repression of target genes.  These interactions are referred to as trans-
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repression because DNA binding activity of GR is not required.  Since NF-kB, AP-1, and 
STAT activate expression of many inflammatory cytokines and interferon, 
glucocorticoids and corticosteroids are anti-inflammatory and immune-suppressive (De 
Bosscher, 2000; Newton and Holden, 2007; Ohmann et al., 1987; Scheinman et al., 
1995). 
In cattle treated with Dex to initiate reactivation from latency, Dex represses LR 
promoter activity (Jones et al., 1990) and reduces LR-RNA levels, which culminates in a 
reduction of the number of infected cells that express LR-RNA at 18-21 hours after 
treatment (Rock et al., 1992).  A single injection of Dex also leads to lytic cycle transcript 
expression in neurons and tonsil within 6 hours after treatment of latently infected calves 
(Winkler et al., 2002a; Winkler et al., 2000a).  Dex treatment of latently infected calves 
also induces apoptosis of T cells that persist in TG after infection (Winkler et al., 2002b).  
Persistence of T cells in TG of humans or mice latently infected with HSV-1 also occurs 
(Cantin et al., 1995a; Halford et al., 1996b; Liu et al., 1996; Shimeld et al., 1995a; 
Shimeld et al., 1996; Shimeld et al., 1997; Theil, 2003), and persistent CD8+ T cells in 
TG produce factors (presumably cytokines) that inhibit reactivation from latency 
(Khanna et al., 2003; Knickelbein et al., 2008; Liu et al., 2001; Liu et al., 2000b; 
Prbhakaran, 2005).  In summary, Dex may alter the neuronal cell environment by 
activating cellular genes that are able to promote reactivation from latency or repress 
transcription of genes which actively suppress viral gene expression. Additionally, 
activated GR may bind to cellular transcription factors to alter their function. These 
events may promote viral gene expression and subsequent reactivation. Dex may also 
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reduce expression of T cell factors that help maintain latency. However, the exact 
molecular mechanisms leading to reactivation from latency remains to be determined. 
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Goal of this study  
 The mechanism by which alphaherpesvirinae subfamily members reactivate from 
latency remains one of the most clinically relevant, yet least understood aspects of herpes 
virus infection. Cell culture systems for human herpesviruses, in which virus reactivation 
occur have been described. However, most are poor models of in vivo latency and 
reactivation.  BHV-1 offers a unique opportunity to study the latency-reactivation cycle 
in vivo. First, BHV-1 can be studied in its natural host. Second, BHV-1 can be 
predictably reactivated from all latently infected animals following a single intravenous 
dose of the synthetic corticosteroid, dexamethasone (Dex) (Inman et al., 2002; Jones, 
1998; Jones, 2003a; Jones et al., 2006; Jones et al., 2000; Rock et al., 1992). Thus, the 
ability of Dex to consistently initiate reactivation from latency makes BHV-1 a useful 
model to identify cellular factors that stimulate reactivation from latency. Since BHV-1 is 
the only alpha-herpesvirus member that can be reproducibly induced to undergo 
reactivation from latency, these findings have impact on other important members of this 
virus family, including HSV-1. Therefore, the overall goal of the studies in this 
dissertation was to use BHV-1 as a model to characterize the early phases of the latency-
reactivation cycle of alphaherpesvirinae subfamily members. 
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Chapter 2 
 
Dexamethasone Treatment of Calves Latently Infected with Bovine Herpesvirus 1 
(BHV-1) Leads to Activation of the bICP0 Early Promoter, in part by the Cellular 
Transcription Factor C/EBP-alpha.  
 
 
These studies are included in a manuscript published in 2009 in the Journal of Virology, 
volume 83, pages 8800-8809.  
 
The authors of the manuscript are Aspen Workman, Sandra Perez, Alan Doster,
 
and 
Clinton Jones 
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ABSTRACT 
Sensory neurons within trigeminal ganglia are the primary site for bovine 
herpesvirus 1 (BHV-1) latency.  During latency, viral gene expression is restricted to the 
latency related (LR) gene and ORF-E.  We previously constructed a LR mutant virus that 
expresses LR RNA, but not any of the known LR proteins.  In contrast to calves latently 
infected with wt BHV-1 or the LR rescued virus, the LR mutant virus does not reactivate 
from latency following dexamethasone (DEX) treatment.  We also demonstrated that 
bICP0, but not bICP4, transcripts were consistently detected in TG of calves infected 
with the LR mutant or LR rescued virus following DEX treatment.  Calves latently 
infected with the LR rescued virus, but not the LR mutant virus, expressed late 
transcripts, which correlated with shedding of infectious virus following DEX treatment.  
The bICP4 and bICP0 genes share a common immediate early promoter suggesting this 
promoter was not consistently activated during DEX induced reactivation from latency.  
The bICP0 gene also contains a novel early promoter, suggesting this promoter is 
activated during reactivation from latency. In this study, we found that the bICP0 E 
promoter was activated by DEX in mouse neuroblastoma cells.  Expression of a cellular 
transcription factor, C/EBP-alpha, was stimulated by DEX, and C/EBP-alpha expression 
was necessary for DEX induction of bICP0 early promoter activity.  C/EBP-alpha 
directly interacted with bICP0 early promoter sequences that were necessary for trans-
activation by C/EBP-alpha.  In summary, DEX treatment of latently infected calves 
induced cellular factors that stimulated bICP0 early promoter activity.  Activation of 
bICP0 early promoter activity does not necessarily lead to late gene expression and virus 
shedding.  
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INTRODUCTION 
Bovine herpesvirus 1 (BHV-1) is a significant viral pathogen of cattle that is 
responsible for a variety of disease conditions, which include conjunctivitis, pneumonia, 
genital disorders, or abortions.  BHV-1 also causes rhinotracheitis, a serious upper 
respiratory tract infection, and infection can initiate shipping fever, a potentially fatal 
polymicrobial disease (Tikoo et al., 1995).  Like other members of the alpha-
herpesvirinae subfamily, BHV-1 establishes lifelong latency in trigeminal ganglionic 
neurons following acute replication in mucosal epithelium.  Reactivation from latency 
occurs periodically, resulting in virus shedding and spread to susceptible cattle. 
Reactivation can occur after stress or corticosteroid treatment, which mimics stress (Rock 
et al., 1992; Sheffy and Davies, 1972).   
Viral gene expression is temporally regulated in three distinct phases: immediate 
early (IE), early (E), or late (L), reviewed in (Jones, 1998; Jones, 2003b).  IE gene 
expression is stimulated by a virion component, bTIF, which interacts with a cellular 
transcription factor (Oct-1) to transactivate IE gene expression (Misra et al., 1994; Misra 
et al., 1995).  Two IE transcription units exist: IE transcription unit 1(IEtu1) and IEtu2 
(Wirth et al., 1992; Wirth et al., 1991).  IEtu1 encodes functional homologues of two 
HSV-1 proteins, ICP0 and ICP4.  IEtu2 encodes a protein that is similar to the HSV-1 IE 
gene, ICP22 (Fraefel et al., 1994).  BHV-1 encoded ICP0 (bICP0) is translated from an 
IE (IE2.9) or E mRNA (E2.6) because an IE promoter (IEtu1 promoter) and E promoter 
regulate bICP0 RNA expression (Fraefel et al., 1994; Wirth et al., 1992; Wirth et al., 
1989; Wirth et al., 1991).  The IE promoter regulates IE expression of bICP4 and bICP0.  
Expression of bICP4 leads to repression of IEtu1 promoter activity whereas bICP0 
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activates its own E promoter and all other viral promoters.  Thus bICP0 is considered to 
be the major regulatory protein that stimulates productive infection (Fraefel et al., 1994; 
Wirth et al., 1992; Wirth et al., 1989; Wirth et al., 1991). 
 The latency related (LR) gene is abundantly transcribed in trigeminal ganglia 
(TG) of latently infected calves (Kutish et al., 1990a; Rock et al., 1992; Rock et al., 
1987b).  LR-RNA is anti-sense with respect to the bICP0 gene (Jones, 1998; Jones, 
2003a; Jones et al., 2006) and encodes at least three proteins.  LR gene products inhibit 
mammalian cell growth (Geiser and Jones, 2005; Schang et al., 1996), productive 
infection (Bratanich et al., 1992; Geiser et al., 2002; Schang et al., 1996), and apoptosis 
(Ciacci-Zanella et al., 1999; Henderson et al., 2004a).  While expression of LR proteins is 
necessary for inhibiting apoptosis (Inman et al., 2002), protein expression is not 
necessary for inhibiting cell growth or productive infection.  The LR gene has two open 
reading frames (ORF1 and ORF2), and two reading frames that lack an initiating ATG 
(RF-B and RF-C).  A mutant BHV-1 virus with 3 stop codons at the beginning of ORF2 
was constructed to test whether LR protein expression regulates the latency-reactivation 
cycle in cattle (Inman et al., 2002).  The LR mutant virus grows to similar titers as wt 
BHV-1 or the LR rescued virus in cultured bovine cells indicating LR gene products are 
not required for growth.  ORF2 and RF-B are expressed when bovine cells are infected 
with wt or the LR rescued virus, but not with the LR mutant virus (Hossain et al., 1995b; 
Jiang et al., 1998; Jiang et al., 2004).  ORF1 expression is reduced, but not totally 
eliminated following infection of cultured cells with the LR mutant virus (Meyer et al., 
2007b).  Calves infected with the LR mutant virus exhibit diminished clinical symptoms, 
and reduced shedding of infectious virus in the eye, tonsil, or TG (Inman et al., 2002; 
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Inman et al., 2001b; Perez et al., 2005).  The LR mutant virus prematurely expresses LR-
RNA relative to rescued or wt BHV-1, which correlates with an enhanced IFN response 
in cells infected with the LR mutant virus (Perez et al., 2008).  
Stress, in part due to increased corticosteroid levels, and/or immune suppression 
can initiate reactivation from latency.  During reactivation from latency, productive viral 
gene expression is readily detected in sensory neurons, LR gene expression decreases, 
and infectious virus can be detected in nasal or ocular swabs (Jones, 1998; Jones, 2003a; 
Jones et al., 2006).  Administration of dexamethasone (DEX), a synthetic corticosteroid, 
to calves or rabbits latently infected with BHV-1 reproducibly leads to activation of viral 
gene expression and reactivation from latency (Inman et al., 2002; Jones, 1998; Jones, 
2003a; Jones et al., 2006; Jones et al., 2000; Rock et al., 1992).  After DEX treatment, 
many neurons express lytic viral genes, but only a small subset of the neurons that 
express viral genes appear to produce infectious virus (Rock et al., 1992).  Thus, the 
ability of DEX to consistently initiate reactivation from latency makes BHV-1 a useful 
model to identify cellular factors that stimulate reactivation from latency.   
Calves latently infected with the LR mutant virus do not shed detectable levels of 
infectious virus after DEX treatment (Inman et al., 2002).  At a molecular level, two 
possibilities seemed feasible to explain this observation.  First, TG neurons latently 
infected with the LR mutant virus may express a subset of lytic viral genes after DEX 
treatment, but infectious virus is not produced.  Secondly, DEX treatment of calves 
latently infected with the LR mutant virus does not stimulate lytic viral gene expression. 
Therefore, we tested whether calves latently infected with the LR mutant virus express 
viral genes in TG following DEX treatment.  Expression of bICP0, but not bICP4, RNA 
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was consistently detected in TG following DEX treatment of calves infected with the LR 
mutant virus or wt BHV-1.  The late gC transcript was detected after infection with the 
wt BHV-1 but not the LR mutant, and this correlated with reactivation. The presence of 
bICP0 transcript in the absence of bICP4 transcript suggested the bICP0 E promoter may 
be activated during reactivation from latency (Workman et al., 2009); see Figure 2.1A). 
Therefore, in this study we were interested in understanding the transcriptional regulation 
of the bICP0 E promoter. We found that in transient transfection assays, DEX stimulated 
bICP0 E promoter activity.  Furthermore, the ability of DEX to induce expression of a 
cellular transcription factor (C/EBP-alpha) was important for stimulating bICP0 E 
promoter activity.  
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MATERIALS AND METHODS 
Cells and Virus 
Murine neuroblastoma 2A (neuro-2A) and rabbit skin (RS) cells were grown in 
Earle’s modified Eagle’s medium (EMEM) supplemented with 5% fetal calf serum 
(FCS). Bovine kidney (CRIB) cells were grown in EMEM supplemented with 10% FCS.  
All media contained penicillin (10 U/ml) and streptomycin (100 μg/ml). 
 The Cooper strain of BHV-1 (wt virus) was obtained from the National 
Veterinary Services Laboratory, Animal and Plant Health Inspection Services, Ames, 
Iowa.   
 
Plasmids  
The C/EBP-alpha wt plasmid contains the wt sequence of mouse C/EBP-alpha in 
an adenoviral vector (pAdTrack) that contains mammalian promoter/enhancer sequences 
(Sood, 2009).  The C/EBP-alpha mutant plasmid contains a mutation in the C/EBP-alpha 
ORF that produces a single amino acid change (R290A) in C/EBP-alpha, which results in 
the loss of DNA binding activity (Sood, 2009).  The empty vector pcDNA3.1 was 
purchased from Invitrogen. 
Six DNA reporter constructs were generated by PCR using wt BHV-1 genome as 
template and a common 3’ primer (5'- ctcgag CCTGCTGGGCGACACAAACAACAGA 
-3') with 5’ primers: EP-943, 5'- ggtaccGCGACGGCGGCAATAAAGACGAGTC -3';  
EP-638, 5'- ggtaccGCCCTCGGTCTCGGTCGGAG-3';  
EP-172, 5'-gggtaccGCCTTGCGTGGGGGGTTTCG-3';  
EP-143, 5’-gggtaccAGCCGGGGGGTGCGGGCC-3’;  
37 
 
EP-133, 5’-gggtaccTGCGGGCCT TTCGCCG-3’; or 
EP-71, 5’-gggtaccGCTCCCGGCGCGTCA-3’.  
The promoter fragments were cloned into the promoterless vector pCAT-Basic (E1871; 
Promega) at the unique XhoI and KpnI sites to generate plasmids EP-943, EP-638, EP-
172, EP-143, EP-133, and EP-71 (Figure 2.1).  The numbers in the plasmid name refers 
to the length of the bICP0 early promoter fragment inserted into the CAT vector.  Two 
additional constructs, EP-50 and EP-42, were created using synthesized duplex 
sequences.  Duplex oligonucleotides were digested with XhoI and KpnI and cloned into 
the promoter-less vector pCAT-Basic.  E promoter inserts were confirmed by DNA 
sequencing (Genomics Core Research Facility-UNL).  Plasmids were prepared from 
bacterial cultures by alkaline lysis and two rounds of cesium chloride centrifugation. 
 
Measurement of chloramphenicol acetyltransferase (CAT) activity 
Neuro-2A cells grown in 60 mm dishes were co-transfected with the designated 
plasmids as indicated in the respective figure legends.  Neuro-2A cells were transfected 
with NeuroTransIt (MIR2145; Mirus), according to the manufacturer’s instructions.  
Where indicated, cells were cultured in the presence of 1 uM water soluble DEX (D2915; 
Sigma) at the time of transfection. After 48 hours, cell extract was prepared by three 
freeze/thaw cycles in 0.25 M Tris-HCl, pH 7.4.  Cell debris was pelleted by 
centrifugation, and protein concentrations determined.  CAT activity was measured in the 
presence of 0.1 uCi [
14
C]-chloramphenicol (CFA754; Amersham Biosciences) and 0.5 
mM AcetylCoA (A2181; Sigma).  The reaction was incubated at 37
o
 C for 15 minutes to 
2 hours depending on the activator used.  All forms of chloramphenicol were separated 
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by thin-layer chromatography.  CAT activity was quantified using a Bio-Rad Molecular 
Imager FX (Molecular Dynamics, CA).  Levels of CAT activity are expressed as fold 
induction relative to the vector control. 
 
SDS-PAGE and Western Blotting 
At 48 hours after
 
transfection, whole cell lysate was prepared.  Cells were washed 
with phosphate-buffered saline
 
and suspended in NP-40 lysis buffer (100 mM Tris [pH 
8.0], 1 mM EDTA,
 
100 mM NaCl, 1% NP-40, 1 mM phenylmethylsulfonyl fluoride, and
 
one tablet of complete protease inhibitor [Roche Molecular Biochemicals]
 
per 10 ml).  
Cell lysate was incubated on ice for 30 min, sonicated, and then clarified
 
by 
centrifugation at 10,000 x g at 4°C for 15 min. Protein
 
concentrations were quantified by 
the Bradford assay. For SDS-PAGE, proteins
 
were mixed with an equal amount of 1x 
sample loading buffer
 
(62.5 mM Tris-HCl [pH 6.8], 2% sodium dodecyl sulfate, 50 mM
 
dithiothreitol, 0.1% bromophenol blue, 10% glycerol) and boiled
 
for 5 min. Proteins were 
separated in a 12% SDS-PAGE gel. After electrophoresis, proteins were transferred
 
onto 
a polyvinylidene difluoride membrane (Immobilon-P; Millipore) and blocked for 4 hours 
in 5% nonfat dry milk with Tris-buffered saline-0.1% Tween 20 (TBS-T).  Membranes 
were then incubated with primary antibody overnight at 4
o 
C. The C/EBP-alpha antibody 
(14AA; Santa Cruz Biotechnology) was diluted 1:500 in the blocking solution.  An 
antibody directed against -actin (Santa Cruz Biotechnology, Santa Cruz, CA) was used 
as a loading control. After 45 minutes of washing with TBS-T, the blots were incubated 
with donkey anti-rabbit horseradish peroxidase-conjugated immunoglobulin G 
(Amersham Biosciences), which was diluted 1:1000 in 5% nonfat milk in TBS-T. Blots 
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were washed 45 minutes with TBS-T and exposed to Amersham ECL reagents, and then 
autoradiography performed.  
 
siRNA transfection for Western Blotting and CAT Assay 
Mouse C/EBP-alpha siRNA containing a pool of 3 target-specific 20-25 
oligonucleotide siRNAs designed to reduce gene expression (sc-37048; Santa Cruz 
Biotechnology) were used in this study. The Block-iT-Fluorescent Oligo was used as a 
control siRNA (44-2926; Invitrogen). It is a fluorescent conjugated control containing a 
scrambled sequence that does not degrade any known cellular RNA.  
Neuro-2A cells grown in 60 mm dishes were co-transfected with 1 ug of EP-172 
with either 100nM mouse C/EBP-alpha siRNA or the fluorescent control siRNA.  After 4 
hours, the transfection mixture was removed and replaced by fresh media. At 48 hours 
post transfection, cell extract was collected for Western blot analysis or CAT assays. 
 
Measurement of virus titers in bovine cells. 
 RS cells grown in 60 mm dishes were transfected with 100nM mouse C/EBP-
alpha siRNA, the fluorescent control siRNA, or transfection reagent alone. After 4 hours, 
the complex was removed and replaced by fresh media. After 24 hours, cells were 
infected with wt BHV-1 at a moi of 0.1 and incubated for an additional 24 hours. Media 
and cells were collected and subjected to two freeze/thaw cycles.  Cell debris was 
pelleted and the supernatant titrated on CRIB cells (bovine kidney) that were plated onto
 
6-well plates 24 h prior to virus infection (90% confluence at the time of infection). After 
1 h of adsorption
 
at 37°C, cells were rinsed with phosphate-buffered saline
 
(PBS) and 
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overlaid with a 50:50 mixture of 1.4% Sea Plaque Agar in PBS and EMEM 
supplemented with 10% FCS. 
 
Electrophoretic Mobility Shift Assay (EMSA) 
 Neuro-2A whole cell lysate was prepared by lysing cells with NP40 lysis buffer. 
Thirty micrograms of protein extract were incubated in a volume of 16 ul of binding 
buffer (10mM Tris-HCl pH8, 150mM KCl, 0.5mM EDTA, 0.1% Triton X-100, 12.5% 
glycerol) in the presence of 1 ug poly(dI-dC) (P4929; Sigma), and 0.5pmols of double 
stranded DNA probe labeled with 10 uCi of -32P-ATP.  Incubation was for 1 hour at 
room temperature.  For supershift experiments, 5 ug of antibody (C/EBP-alpha, sc-61X 
or C/EBP-beta, sc-150X; Santa Cruz Biotechnology) were added to the reaction after 30 
minutes and allowed to incubate an additional 30 minutes.  The DNA-protein complexes 
were electrophoresed on a 5% polyacrylamide gel in 0.5X TBE for 3 hours at 160 volts.  
To improve band resolution, 1.5M sodium acetate pH 5.3 was added to the lower buffer 
chamber during electrophoresis. The gel was exposed to a phophoimager plate and 
analyzed using a Bio-Rad Molecular Imager FX.  The bICP0 E probes used for EMSA 
were:  
C1: GCCTTGCGTGGGGGGTTTCGCCTTGGGGCAGC, 
C2:TGCGGGCCCTTTCGCCGCCCG,  
C3: TCTGTTGTTTGTGTCGCCCA 
An oligonucleotide containing 3 consensus C/EBP-alpha binding sites, 
CGCAATATTGCGCAATATTGCAAT, was used as a positive control for binding to 
C/EBP-alpha. 
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RESULTS 
DEX activates the bICP0 E promoter 
Previous studies demonstrated that during reactivation from latency, bICP0 
mRNA is detected while bICP4 mRNA is not readily detected (Workman et al., 2009). 
The bICP4 and bICP0 genes share a common IE promoter, suggesting this promoter was 
not consistently activated during DEX induced reactivation. bICP0 also contains a novel 
E promoter (Fraefel et al., 1994; Wirth et al., 1992; Wirth et al., 1989; Wirth et al., 1991). 
This suggested that the bICP0 E promoter may be preferentially activated during 
reactivation from latency (see Figure 2.1A). We hypothesize that DEX treatment may 
stimulate expression of cellular factors that subsequently activate the bICP0 E promoter.  
To test this hypothesis, the bICP0 promoter construct was transfected into mouse 
neuroblastoma cells (neuro-2A) and treated with DEX after transfection.  For these 
studies, 8 constructs containing upstream sequences of the bICP0 E promoter were used 
(Figure 2.1B).  The basal level of promoter activity for EP-943 was slightly higher than 
EP-638 and at least 2 times higher than EP-172 or EP-133.  Basal promoter activity of 
EP-71, EP-50, and EP-42 was at least 4 fold less than EP-943.     
Two E promoter constructs EP-172 and EP-133 were activated by DEX more than 
4 fold in neuro-2A cells (Figure 2.2A).  More extensive deletions (constructs EP-71 or 
EP-40) were not activated by DEX.  The larger E promoter constructs, EP-943 and EP-
638, were activated less than 2 fold by DEX.  As a comparison, three IEtu1 promoter 
constructs were tested for DEX induction (Figure 2.2B).  None of the constructs were 
activated by DEX more than 2 fold.  As expected, the empty vector (pCAT basic) was not 
activated by DEX (Figure 2.2A and B).   
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DEX activates a cellular transcription factor, C/EBP-alpha, in neuro-2A cells. 
A previous study demonstrated that the cellular transcription factor C/EBP-alpha 
is stimulated when latently infected calves are treated with DEX (Meyer et al., 2007b).  
Furthermore, C/EBP-alpha stimulates productive infection when over-expressed (Meyer 
et al., 2007b), and C/EBP-alpha plus bICP0 or bTIF stimulates IEtu1 promoter activity 
more efficiently that just the viral trans-activator alone (Meyer and Jones, 2009).  To test 
whether DEX induced C/EBP-alpha protein expression in neuro-2A cells, cells were 
treated with 1 uM DEX and Western blots performed.  Twenty-four hours after DEX 
treatment, C/EBP-alpha protein expression was consistently induced (Figure 2.3A).  
Conversely, -actin protein levels were similar regardless of DEX treatment.   
A plasmid that expresses C/EBP-alpha, but not a DNA binding mutant of C/EBP-
alpha, trans-activated three bICP0 E promoter constructs (EP-172, EP-133, and EP-143) 
4 to 5 fold (Figure 2.3B).  Constructs with additional deletions (EP-71, EP-50, and EP-
42) were only trans-activated 2 fold.  The larger bICP0 E promoter constructs, EP-943 
and EP-638, were trans-activated 2-3 fold by C/EBP-alpha.  As expected, pCAT-basic 
was not trans-activated by C/EBP-alpha.   
 
C/EBP-alpha expression is important for DEX induced activation of the bICP0 E 
promoter. 
 To test whether induction of C/EBP-alpha by DEX was important for activating 
bICP0 E promoter activity, neuro-2A cells were transfected with a siRNA directed 
against C/EBP-alpha and then the ability of DEX to induce bICP0 E promoter activity 
was measured.  A C/EBP-alpha siRNA (Figure 4A, lane C/EBP), but not a control siRNA 
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(-Ctl lane), reduced C/EBP-alpha protein levels after DEX treatment.  As expected, -
actin controls were similar regardless of the siRNA transfected into neuro-2A cells.  
bICP0 E promoter activity (EP-172) was not stimulated by DEX when cells were 
transfected with the C/EBP-alpha siRNA (Figure 2.4B).  Conversely, the control siRNA 
had little or no effect on DEX induction of the bICP0 E promoter.  
Over-expression of C/EBP-alpha stimulates plaque formation 3-5 fold (Meyer et 
al., 2007b) suggesting that silencing C/EBP-alpha expression would reduce the levels of 
plaquing efficiency.  In several independent studies, the C/EBP-alpha siRNA (Figure 
2.4C), but not the control siRNA inhibited productive infection approximately 3 fold. In 
summary, these studies suggested C/EBP-alpha expression was necessary for DEX 
induced bICP0 E promoter activity and efficient productive infection.   
 
C/EBP-alpha interacts with the bICP0 E promoter.  
Electrophoretic mobility shift assays (EMSA) were performed to determine 
whether C/EBP-alpha directly interacted with sequences in the bICP0 E promoter.  Since 
C/EBP-alpha was expressed at low levels in neuro-2A cells, a C/EBP-alpha expression 
plasmid was transfected into neuro-2A cells to induce protein levels (Figure 2.5A), and 
then extracts prepared to test whether C/EBP-alpha interacted with the bICP0 E 
promoter.  As a control, an oligonucleotide that contained 3 consensus C/EBP-alpha 
binding sites was used.  As expected, binding to the C/EBP-alpha consensus 
oligonucleotide was enhanced when C/EBP-alpha was over-expressed in neuro-2A cells 
(Figure 2.5B, lane 2).  An antibody that recognizes C/EBP-alpha (lane 3), but not C/EBP-
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beta (lane 4), “super-shifted” the DNA-protein complex confirming that a stable 
interaction occurred. 
Enhanced binding to the EP-172 promoter was also detected after over-expression 
of C/EBP-alpha (Figure 2.5C, lane 2 versus 1).  Addition of a specific antibody directed 
against C/EBP-alpha (lane 3), but not C/EBP-beta (lane 4), super-shifted the induced 
band.  Although the C/EBP-alpha antibody super-shifted a band when the EP-133 
fragment was used as a probe (EP-133 panel, lane 3), binding was less efficient compared 
to the EP-172 probe.  When the EP-72 fragment was used as a probe, a faint super-shifted 
band was detected (Figure 2.5C, lane 3) that was readily detected when the gel was 
exposed for longer times (Figure 2.5D, lane 3).   
The bICP0 E promoter contains three C/EBP-alpha like binding sites clustered near 
the 5’ terminus of EP-172 and a putative site downstream of the TATA box (Figure 
2.6A).  To test whether C/EBP-alpha interacted with these individual domains, 
oligonucleotides spanning these domains (see Figure 2.6A for sequence of C1-C3 
olignonucleotides) were synthesized and EMSA performed (Figure 2.6B).  Super-shift 
assays using a C/EBP-alpha specific antibody (Figure 2.7B, lanes A), but not the C/EBP-
beta antibody (lanes B), suggested that C/EBP-alpha interacted with the C1 and C2 
oligonucleotides.  Prolonged exposure of the autoradiograph revealed that C/EBP-alpha 
interacted less efficiently with the C3 olignonucleotide (Figure 2.6C).  In several 
independent studies, the band super-shifted by the C/EBP-alpha antibody was more 
distinct relative to samples not treated with antibody suggesting that the antibody 
stabilized the interaction between C/EBP-alpha and bICP0 E promoter sequences.  As 
expected, the consensus C/EBP-alpha probe interfered with C/EBP-alpha specific binding 
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(data not shown).  In summary, this study indicated that at least 3 different elements 
within the bICP0 E promoter interacted with C/EBP-alpha.    
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DISCUSSION 
 We previously demonstrated that viral gene expression was stimulated in TG of 
calves latently infected with the LR mutant virus after DEX treatment (Workman et al., 
2009).  The inability to detect infectious virus in ocular or nasal swabs after calves 
latently infected with the LR mutant virus were treated with DEX (Inman et al., 2002) 
correlated with lack of gC transcription after DEX treatment (Workman et al., 2009).  
These findings implied that the LR mutant virus was unable to infect neurons that support 
reactivation from latency, or the LR mutant virus killed neurons that support reactivation 
from latency.  Interestingly, higher rates of neuronal apoptosis occur in TG neurons near 
the end of acute infection (establishment of latency) following infection with the LR 
mutant virus (Lovato et al., 2003).  Furthermore, in situ hybridization revealed that a 
small percent of viral genome positive neurons are present in TG of calves infected with 
wt or the LR rescued virus, but not the LR mutant virus (Inman et al., 2002).  These 
observations suggested that the anti-apoptosis activity of a protein encoded by the LR 
gene promotes survival of a specific subset of neurons that can yield infectious virus after 
DEX treatment (Ciacci-Zanella et al., 1999; Devireddy and Jones, 1999a; Geiser et al., 
2008; Lovato et al., 2003; Shen and Jones, 2008; Winkler et al., 1999).  Neurons that 
contain few copies of viral genomes do not support extensive viral gene expression 
during acute infection, and consequently they survive acute infection and permit 
establishment of viral latency, regardless of whether LR gene products are expressed.  
The finding that different populations of neurons in TG of mice are more permissive for 
HSV-1 is consistent with the prediction that a subset of neurons in TG contain specific 
cellular factors that support reactivation from latency. 
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 Relative to other alpha-herpesvirus members, the organization of the BHV-1 ICP4 
and ICP0 genes is unique because a common IE promoter drives expression of bICP0 and 
bICP4 (Wirth et al., 1992) (Figure 2.1A).  bICP0 also contains an E promoter located 
near the 5’ end of the coding exon of bICP0.  Although it was not well understood why 
the bICP0 gene contains two promoters, we assumed this was necessary to ensure that 
constitutive expression of bICP0 occurred during productive infection.   
 DEX treatment appeared to stimulate cellular factors, which then activated the 
bICP0 E promoter in TG of latently infected calves (Workman et al., 2009) and mouse 
neuroblastoma (neuro-2A) cells (Figure 2.2).  Previous studies demonstrated that DEX 
treatment of calves latently infected with BHV-1 leads to C/EBP-alpha expression 
(Meyer et al., 2007b), which correlated with reactivation from latency and activation of 
the bICP0 E promoter. The finding that C/EBP-alpha siRNAs inhibited the ability of 
DEX to activate the bICP0 E promoter supported the conclusion that C/EBP-alpha was 
necessary for stimulating bICP0 E promoter activity after DEX treatment.  DEX can 
activate C/EBP-alpha in several distinct cell types (Cram et al., 1998; Hausman, 2000; 
Ramos et al., 1996), including neuro-2A (Figure 2.3) and TG neurons (Meyer et al., 
2007b).  Three distinct regions of the bICP0 E promoter interacted with C/EBP-alpha as 
judged by EMSA and super-shift studies.  Based on transient transfection assays, we 
suggest that at least two of the C/EBP-alpha binding sites were necessary for efficient 
trans-activation by C/EBP-alpha.  The weak binding site in the C3 olignucleotide (Figure 
2.6A) was not sufficient for activation by C/EBP-alpha because EP-71, EP-50, and EP-42 
were not trans-activated by C/EBP-alpha (Figure 2.4B).  The C/EBP-alpha binding sites 
in the bCP0 E promoter appeared to be low affinity binding sites compared to the 
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consensus site because 30 ug of nuclear extract was necessary to observe C/EBP-alpha 
induced binding with EP-172 whereas only 5 ug of protein in nuclear extracts was 
necessary to detect inducible binding to an oligonucleotide containing three consensus 
C/EBP-alpha sites (Figure 2.5).  The weak C/EBP-alpha binding sites in the bICP0 E 
promoter may inhibit activation of the E promoter during latency unless the neuronal 
environment is conducive for reactivation from latency. 
 The larger bICP0 E promoter constructs (EP-943 and EP-638) were not efficiently 
activated by C/EBP-alpha or by DEX treatment.  However, EP-943 and EP-638 promoter 
constructs had 2-3 higher levels of basal promoter activity.  We suggest there may be cis-
acting negative regulatory elements located in the upstream region of the bICP0 early 
promoter that interfere with the ability of C/EBP-alpha to activate promoter activity.  
Furthermore, cellular transcription factors that stimulate the larger promoter constructs 
may interfere with the ability of C/EBP-alpha to activate E promoter activity.  Since the 
bICP0 E promoter overlaps bICP4 protein coding sequences, these additional bICP4 
protein-coding sequences may not be a part of the true bICP0 E promoter, and 
consequently may interfere with transient transfection reporter assays.   
 A protein encoded by an alternatively spliced LR-RNA stably interacts with 
C/EBP-alpha (Meyer et al., 2007b).  The finding that C/EBP-alpha stimulates productive 
infection (Meyer et al., 2007b), the IEtu1 promoter (Meyer and Jones, 2009), and the 
bICP0 E promoter suggests that interactions between the LR protein and C/EBP-alpha 
help to extinguish viral transcription, thus promoting the establishment and maintenance 
of latency.  DEX represses LR-RNA (Rock et al., 1992) and LR promoter activity (Jones 
et al., 1990) suggesting that LR gene products do not directly stimulate reactivation from 
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latency.  However, reduced levels of LR proteins following DEX induction of 
reactivation may allow C/EBP-alpha to stimulate viral gene expression.  Although 
C/EBP-alpha appears to be an important component in the DEX induced signaling 
cascade that stimulates viral gene expression, it seems clear that additional DEX 
inducible cellular proteins are required for infectious virus to be produced.  
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Figure 2.1.  Schematic of IEtu1 and bICP0 E promoter constructs used in this study.   
Panel A:  Positions of bICP4 and bICP0 transcripts are shown.  The immediate early 
transcription unit 1 (IEtu1) encodes bICP4 (IE/4.2) and bICP0 (IE/2.9) (Wirth et al., 
1989; Wirth et al., 1991).  The IEtu1 promoter activates IE expression of IE/4.2 and 
IE/2.9 (denoted by the black rectangle).  E/2.6 is the early transcript that encodes bICP0 
and an early promoter activates expression of this transcript (Wirth et al., 1992).  Exon 2 
(e2) of bICP0 contains all of the protein coding sequences of bICP0.  The dashed lines 
are intron sequences. 
Panel B:  bICP0 E promoter constructs were prepared as described in the materials and 
methods.  Position of putative C/EBP-alpha binding sites and TATA box are shown.  
Basal promoter activity was measured in neuro-2A cells. 
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Figure 2.1. 
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Figure 2.2. DEX induces bICP0 E promoter activity. 
Panel A.  Neuro-2A cells were transfected with 1ug of the designated bICP0 E promoter 
construct.  Cells were cultured in EMEM containing 1% FBS and 1 uM dexamethasone 
(DEX) at the time of transfection.  At 48 hours post transfection, cells were collected and 
processed for CAT activity as described in the materials and methods. CAT activity of 
cells treated with EMEM containing no DEX was set to 1 fold. All other values are 
expressed as fold activation with respect to their control. The results are the average of 
three independent experiments. 
Panel B:  IEtu1 promoter constructs were assessed for DEX induction as described in 
panel A.  Description of the IEtu1 promoter constructs was described previously (Geiser 
and Jones, 2003; Meyer and Jones, 2009; Misra et al., 1994).   IETu1-CAT contains 
IETu1 promoter sequences that were cloned upstream of pSV0CAT (a promoter minus 
CAT expression vector, and this plasmid was provided by V. Misra (Saskatoon, Canada). 
Two deletion constructs, ∆1024 IETu1 and ∆1391 IETu1 have 1024 or 1391 bp removed 
from the 5’ terminus, respectively. 
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Figure 2.2. 
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Figure 2.3. DEX induces C/EBPalpha expression in cultured cells and C/EBP-
alpha activates the bICP0 early promoter. 
Panel A. Neuro-2A cells were treated with 1 uM DEX and cell lysate collected at various 
times after treatment (hours). One hundred ug of protein were electrophoresed and 
Western blot analysis performed using a C/EBPalpha or -actin antiserum that was 
diluted 1:500. The molecular weight marker is in kilodaltons.  
Panel B. Neuro-2A cells were co-transfected with 1ug of the designated bICP0 E 
promoter construct and 0.1 ug of wt C/EBP-alpha (filled columns) or the DNA binding 
mutant of C/EBP-alpha (mut C/EBP-alpha) (open columns). Constant amounts of DNA 
were used for all transfections by adding pcDNA3.1, a blank expression vector.  At 48 
hours post transfection, cells were collected and processed for CAT activity as described 
in the materials and methods. CAT activity of the cells transfected with the control pCAT 
basic vector was given a value of one. All other values are expressed as fold activation 
with respect to the control. The results are the average of four independent experiments. 
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Figure 2.3. 
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Figure 2.4.  The C/EBP-alpha siRNA inhibits the ability of DEX to stimulate bICP0 
E promoter activity.  
Panel A. Neuro-2A cells were co-transfected with 1ug of C/EBP-alpha and either 100nM 
C/EBP-alpha siRNA or the control siRNA.  At 48 hours post transfection, cells were 
collected and lysed with NP-40 lysis buffer, and 30 ug protein electrophoresed by 12% 
SDS-PAGE. Proteins in the gel were transferred onto a PVDV membrane and probed 
with the C/EBP-alpha antiserum that was diluted 1:500.  Molecular weight marker is in 
kilodaltons. 
Panel B. Neuro-2A cells were co-transfected with 1 ug of EP-172 and with 100nM 
C/EBP siRNA or a control siRNA as described in the materials and methods.  Four 
hours later the transfection complex was removed and replaced by fresh media containing 
1 uM DEX.  At 48 hours post transfection, cells were collected and processed for CAT 
activity. CAT activity of cells transfected with the control pCAT basic vector was given a 
value of one. All other values are expressed as fold activation with respect to the control.  
The results are the average of three independent experiments. 
Panel C:  RS cells were transfected with the C/EBP-alpha siRNA (100 nm), the control 
siRNA (100 nm), or no siRNA.  Twenty-four hours after transfection, cultures were 
infected with wt BHV-1 at a moi of 0.1.  At 24 hours after infection, plaque assays were 
performed as described in the materials and methods. 
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Figure 2.4. 
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Figure 2.5. C/EBP-alpha directly interacts with the bICP0 E promoter. 
Panel A.  Neuro-2A cells were transfected with 1ug of C/EBP.  At 48 hours post 
transfection, cells were collected and lysed with NP-40 lysis buffer. Thirty or 100 ug 
protein were electrophoresed by 12% SDS-PAGE. Proteins in the gel were transferred 
onto a PVDV membrane and probed with the C/EBP-alpha antiserum that was diluted 
1:500. Molecular weight marker is in kilodaltons. 
Panel B. EMSA was performed using a double stranded DNA probe containing three 
consensus C/EBP-alpha binding sites.  The probe was incubated with 5 ug of neuro-2A 
cell lysate (lane 1) or neuro-2A cell lysate in which C/EBP-alpha was over-expressed 
(lanes 2-4).  The super-shift was visualized by adding C/EBP-alpha (lane 3) or C/EBP-
beta antibodies (lane 4) to the binding reaction as described in the materials and methods. 
The arrow denotes the position of the super-shift while the circle represents the C/EBP-
alpha inducible band. 
Panel C. EMSA was performed using the bICP0 E promoter fragments derived from EP-
172, EP-133 or EP-72.  The lanes are the same as described in panel B.  
Panel D.  To better visualize the super-shift for EP-72, autoradiography was for 24 hours 
versus 4 as shown in panel C.  
 
 
 
 
 
 
59 
 
 
Figure 2.5. 
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Figure 2.6.  Interactions between segments of the bICP0 E promoter and C/EBP-
alpha. 
Panel A.  Schematic of EMSA probes C1, C2, and C3.  C1 contains two putative C/EBP-
alpha binding sites found within EP-172. C2 contains the other putative C/EBP-alpha 
binding site found upstream of the TATA box. C3 contains a putative C/EBP-alpha 
binding site downstream of the TATA box.  The consensus C/EBP binding site in the rat 
CYPD5 promoter (Lees-Miller et al., 1996) is shown as a comparison to the putative sites 
in the bICP0 E promoter. 
Panel B. EMSA using C1, C2, or C3 probes.  Probes were incubated with 30 ug of 
Neuro-2A cell lysate. Antibodies directed against C/EBP-alpha (A) or C/EBP-beta (B) 
were used in super-shift assays as described in the materials and methods section. 
Panel C. To better visualize the super-shift for C2 and C3, autoradiography was 
performed for 24 hours versus 4 hours as shown in panel B. 
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Figure 2.6. 
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Chapter 3 
 
Bovine Herpesvirus 1 (BHV-1) Productive Infection and bICP0 Early Promoter 
Activity are Stimulated by E2F1. 
 
 
These studies are included in a manuscript published in 2010 in the Journal of Virology, 
volume 84, pages 6308-6317.  
 
The authors of the manuscript are Aspen Workman and Clinton Jones 
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ABSTRACT 
 Bovine herpes virus 1 (BHV-1) is an important viral pathogen of cattle.  Like 
other alpha-herpesvirinae subfamily members, BHV-1 establishes latency in sensory 
neurons, and has the potential to reactivate from latency.  Dexamethasone (DEX) 
treatment of latently infected calves or rabbits consistently leads to reactivation from 
latency.  The BHV-1 transcript encoding the infected cell protein 0 (bICP0) is 
consistently detected during reactivation from latency, in part, because the bICP0 early 
promoter is activated by DEX.  During DEX-induced reactivation from latency, cyclin 
expression is stimulated in infected sensory neurons.  Cyclin dependent kinase activity 
phosphorylates Rb (retinoblastoma tumor suppressor gene product) family proteins and 
consequently releases the E2F family of transcription factors suggesting that E2F family 
members stimulate productive infection and/or reactivation from latency.  In this study, 
we provide evidence that repression of E2F1 by a specific siRNA reduced productive 
infection approximately 5 fold.  E2F1 or E2F2 stimulated bICP0 early promoter activity 
at least 100 fold in transient transfection assays.  Two E2F responsive regions (ERR) 
were identified within the early promoter: one adjacent to the TATA box (ERR1) and one 
approximately 600 base pairs upstream from the TATA box (ERR2).  Mobility shift 
assays suggested that E2F interacts with ERR1 and ERR2.  E2F1 protein levels were 
increased at late times after infection, which correlated with enhanced binding to a 
consensus E2F binding site, ERR1, or ERR2.  Collectively, these studies suggested that 
E2F1 stimulates productive infection and bICP0 early promoter activity, in part because 
E2F family members interact with ERR1 and ERR2.   
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INTRODUCTION 
Bovine herpesvirus 1 (BHV-1) is a significant viral pathogen of cattle that can 
cause conjunctivitis, rhinotracheitis, pneumonia, genital disorders, or abortions.  BHV-1 
also initiates shipping fever, a potentially fatal polymicrobial disease (Tikoo et al., 1995).  
Like other members of the alpha-herpesvirinae subfamily, BHV-1 establishes lifelong 
latency in trigeminal ganglionic neurons following acute replication in mucosal 
epithelium.  Reactivation from latency occurs periodically, resulting in virus shedding 
and spread to susceptible cattle.  Reactivation from latency can occur after stress or 
corticosteroid treatment, which mimics stress (Rock et al., 1992; Sheffy and Davies, 
1972).  Dexamethasone (DEX), a synthetic corticosteroid, reproducibly induces 
expression of BHV-1 lytic cycle genes and reactivation from latency in calves or rabbits 
(Inman et al., 2002; Jones, 1998; Jones, 2003a; Jones et al., 2006; Jones et al., 2000; 
Rock et al., 1992). 
During productive infection of cultured cells, viral gene expression is temporally 
regulated in three distinct phases: immediate early (IE), early (E), or late (L), reviewed in 
(Jones, 1998; Jones, 2003b).  IE gene expression is stimulated by a virion component, 
bTIF, which interacts with a cellular transcription factor (Oct-1) to transactivate IE gene 
expression (Misra et al., 1994; Misra et al., 1995).  Two IE transcription units exist: IE 
transcription unit 1(IEtu1) and IEtu2 (Wirth et al., 1992; Wirth et al., 1989; Wirth et al., 
1991).  IEtu1 encodes functional homologues of two HSV-1 proteins, ICP0 and ICP4.  
IEtu2 encodes a protein that is similar to the HSV-1 IE gene, ICP22 (Fraefel et al., 1994).  
BHV-1 encoded ICP0 (bICP0) is translated from an IE (IE2.9) or E mRNA (E2.6) 
because an IE promoter (IEtu1 promoter) and E promoter regulate bICP0 RNA 
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expression (Fraefel et al., 1994; Wirth et al., 1992; Wirth et al., 1989; Wirth et al., 1991).  
The IE promoter regulates IE expression of bICP4 and bICP0.  Expression of the bICP4 
protein represses IEtu1 promoter activity whereas bICP0 activates its own E promoter 
and all other viral promoters.  A recent study demonstrated that during DEX induced 
reactivation from latency bICP0 mRNA, but not bICP4, was consistently detected 
(Workman et al., 2009).  In part, this was due to the fact that the bICP0 promoter is 
activated by DEX induction of the cellular transcription factor CAAT enhancer binding 
protein alpha (c/EBP-alpha) (Workman et al., 2009).  bICP0 transcription appears to be 
stimulated during reactivation from latency by cellular transcription factors that trans-
activate the bICP0 E promoter.  Since bICP0 is the major regulatory protein that 
stimulates BHV-1 productive infection (Fraefel et al., 1994; Wirth et al., 1992; Wirth et 
al., 1989; Wirth et al., 1991), identification of cellular factors that stimulate the bICP0 E 
promoter may help us understand the early stages of reactivation from latency.   
 The E2F family of transcription factors contain a conserved DNA-binding 
domain, acidic transcriptional activation domain, and a Rb binding site (Harbour and 
Dean, 2000).  Functional E2F binding sites are present in the promoters of nearly all 
genes that control cell cycle progression (Nevins et al., 1997; Ohtani et al., 1995a; 
Schulze et al., 1995; Wells et al., 1997).  Several lines of evidence suggest that the E2F 
family of transcription factors may stimulate BHV-1 productive infection and 
reactivation from latency.  First, during DEX induced reactivation from latency, sensory 
neurons that express abundant levels of lytic cycle genes also express certain cyclins 
(cyclin E and cyclin A for example) (Winkler et al., 2000c).  Phosphorylation of Rb 
family members by cyclin dependent kinase/cyclin complexes leads to E2F release, and 
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consequently certain E2F family members are then able to activate transcription 
(Attwooll et al., 2004; Harbour and Dean, 2000; Nevins et al., 1997; Weintraub et al., 
1992).  Furthermore, over-expression of E2F4 stimulates BHV-1 productive infection and 
E2F1 or E2F2 trans-activates IEtu1 promoter activity (Geiser and Jones, 2003).  Finally, 
the HSV-1 TK (thymidine kinase) promoter is activated by E2F1 by virtue of a GC rich 
motif, not a consensus E2F binding site (Chang et al., 2005).   
In this study, we demonstrated that siRNAs directed against E2F1 reduced 
productive infection.  In transient transfection assays, E2F1 or E2F2 activated bICP0 E 
promoter activity more than 100 fold.  Two E2F responsive regions were identified 
within the bICP0 E promoter.  These studies suggest that E2F1 and E2F2 stimulate 
productive infection, in part, by activating bICP0 E promoter activity. 
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MATERIALS AND METHODS 
Cells and viruses   
Murine neuroblastoma 2A (neuro-2A) and rabbit skin (RS) cells were grown in 
Earle’s modified Eagle’s medium (EMEM) supplemented with 5% fetal calf serum 
(FCS). Bovine kidney cells (CRIB) were grown in EMEM supplemented with 10% FCS.  
All media contained penicillin (10 U/ml) and streptomycin (100 μg/ml).   
The Cooper strain of BHV-1 (wt virus) was obtained from the National 
Veterinary Services Laboratory, Animal and Plant Health Inspection Services, Ames, 
Iowa.  Stock cultures of BHV-1 were prepared in CRIB cells. 
A BHV-1 mutant containing the Lac Z gene in place of the viral gC gene was 
obtained from S. Chowdury (Baton Rouge, LA) (gCblue virus).  The virus grows to 
similar titers as the wild type parent virus and expresses the Lac Z gene as a true late 
gene. 
 
Plasmids   
Plasmids expressing E2F1 or E2F2, pCMV-E2F1 and pCMV-E2F2 respectively,  
were obtained from J.R. Nevins (Duke University, Durham, USA).  The empty vector 
pcDNA3.1 was purchased from Invitrogen. 
Six bICP0 E promoter constructs were prepared by PCR amplification as 
previously described (Workman et al., 2009). The promoter fragments were cloned into 
the promoterless vector pCAT-Basic (E1871; Promega) at the unique XhoI and KpnI 
sites to generate plasmids EP-943, EP-638, EP-172, EP-143, EP-133, and EP-71 (Figure 
2C). For this study, 2 additional constructs were prepared.  EP-50 and EP-42 were 
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synthesized (IDT; Iowa) and contained a XhoI and KpnI restriction site.  Duplex 
oligonucleotides were digested with XhoI and KpnI and cloned into the promoter-less 
vector pCAT-Basic.  The numbers in the plasmid name refer to the length of the bICP0 E 
promoter fragment inserted into the CAT vector.  The deletions were made from the 5’ 
terminus of the bICP0 promoter. 
Two additional bICP0 E promoter constructs were generated using the wt BHV-1 
genome as a template and a common 3’ primer (5’-
ctcgagCCTGCTGGGCGACACAAACAACAGA-3’) with the following 5’ primers: EP-
398, 5’-ggggtaccAAGACGCAGAACCCCG-3’; EP-328, 5’-ACCCAGGGGCGGAGC-
3’.  The promoter fragments were cloned into the promoterless vector pCAT-Basic as 
described above.  The DNA sequence of the E promoter inserts was confirmed by DNA 
sequencing (Genomics Core Research Facility-UNL).  All plasmids were prepared from 
bacterial cultures by alkaline lysis and two rounds of cesium chloride centrifugation.   
To further localize bICP0 E promoter elements that are responsive to E2F, 
upstream regions of the bICP0 E promoter (E2F responsive regions; ERR) were cloned 
into a minimal promoter CAT vector (E186A; Promega) containing the SV40 early 
promoter cloned upstream of CAT.  
ERR1 constructs: ERR1/40 was created using synthesized duplex sequences 
(IDT, Iowa). Duplex oligonucleotides were digested with XhoI and KpnI and cloned into 
the minimal promoter CAT vector. 
ERR2 constructs:  ERR2/254 was generated by PCR using the forward primer 
5’-GCGACGGCGGCAATAAAGACGAGT-3’ with the reverse primer 5’-
CGGGGTTCTGCGTCTTGGC-3’. ERR2/180, ERR2/120, ERR2/1-60 and ERR2/61-120 
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were created using synthesized duplex sequences (IDT, Iowa).  Duplex oligonucleotides 
were digested with KpnI and XhoI and cloned into the minimal promoter CAT vector at 
the unique KpnI and XhoI sites.  The identity of each construct was confirmed by DNA 
sequencing (Genomics Core Research Facility-UNL). A schematic of ERR1 and ERR2 
constructs are shown in Figures 4 and 5 respectively.  All plasmids were prepared from 
bacterial cultures by alkali lysis and two rounds of cesium chloride centrifugation.  
 
Measurement of chloramphenicol acetyltransferase (CAT) activity   
Neuro-2A cells grown in 60 mm dishes were co-transfected with the designated 
plasmids as indicated in the respective figure legends.  Neuro-2A cells were transfected 
with NeuroTransIt (MIR2145; Mirus), according to the manufacture’s instructions.  After 
48 hours, cell extract was prepared by three freeze/thaw cycles in 0.25 M Tris-HCl, pH 
7.4.  Cell debris was pelleted by centrifugation, and protein concentrations determined.  
CAT activity was measured by incubating with 0.1 uCi  [
14
C]-chloramphenicol (CFA754; 
Amersham Biosciences) and 0.5 mM AcetylCoA (A2181; Sigma).  The reaction was 
incubated at 37
o
 C for 15 to 30 minutes.  All forms of chloramphenicol were separated by 
thin-layer chromatography.  CAT activity was quantified using a Bio-Rad Molecular 
Imager FX (Molecular Dynamics, CA).  Levels of CAT activity are expressed as fold 
induction relative to the vector control. 
 
Electrophoretic Mobility Shift Assay (EMSA) 
  Neuro-2A cells were transfected with 100 ng of E2F1 using NeuroTransIT 
(Mirus) according to the manufacturer’s instructions. At 48 hours after transfection, 
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whole cell lysate was prepared.  Cells were washed with phosphate-buffered saline
 
and 
suspended in NP-40 lysis buffer (100 mM Tris [pH 8.0], 1 mM EDTA,
 
100 mM NaCl, 
1% NP-40, 1 mM phenylmethylsulfonyl fluoride, and
 
one tablet of complete protease 
inhibitor [Roche Molecular Biochemicals]
 
per 10 ml).  Cell lysate was incubated on ice 
for 30 min, sonicated, and then clarified
 
by centrifugation at 10,000 x g at 4°C for 15 
min.  
CRIB cells were infected with wt BHV-1 at a moi of 5 and cultured in EMEM 
containing 10% FCS. At various times after infection, cells were collected and suspended 
in NP-40 lysis buffer. Cell lysate was incubated on ice for 30 min, sonicated, and then 
clarified
 
by centrifugation at 10,000 x g at 4°C for 15 min.  Protein concentrations were 
quantified by the Bradford assay. 
Twenty micrograms of protein extract were incubated in a volume of 16 ul of 
binding buffer (10 mM Tris-HCl pH8, 150 mM KCl, 0.5 mM EDTA, 0.1% Triton X-100, 
12.5% glycerol) in the presence of 1 ug poly(dI-dC) (P4929; Sigma), and 0.5 pmols of 
double stranded DNA probe labeled with 10 uCi of -32P-ATP.  Incubation proceeded for 
1 hour at room temperature.  For competition assays, 500 ng of cold E2F1 consensus 
probe or a C/EBP-alpha consensus probe were incubated with cell lysate for 20 minutes 
prior to addition of radiolabeled probe.  DNA-protein complexes were run on a 5% 
polyacrylamide gel in 0.5X TBE for 3 hours at 100 volts.  To improve band resolution, 
1M sodium acetate pH 5.3 was added to the lower buffer chamber during electrophoresis.  
The gel was exposed to a phosphoimager plate and analyzed using Bio-Rad Molecular 
Imager FX.  Probes used for EMSA are as follows: 
E2F Consensus: ATTTAAGTTTCGCGCCCTTTCTCAA 
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C/EBP-alpha Consensus: CGCAATATTGCGCAATATTGCAAT 
40 bp probe of bICP0 E promoter that was used to construct ERR1/40: 
CGGCGCCCTGCCCCCGCCCCGCCCCCCCGCCCTCGCGGCC  
1-60 bp probe of bICP0 E promoter that was used to construct ERR2/1-60: 
CCGGCGCGCGGCGCGCGGGGCGGGCCCCGGGGCGCGAAGCCCGGGAGGGAC
GCGGGCGTG. 
 
SDS-PAGE and Western Blotting of E2F expression 
 RS cells were transfected with 1 ug of pcDNA3.1 empty vector, 100 mM E2F1 
siRNA (sc-35247; Santa Cruz Biotechnology) or control siRNA (44-2926; Invitrogen) 
using Lipofectamine 2000 according to the manufacture’s specifications (11668-019; 
Invitrogen).  The Block-iT-Fluorescent Oligo was used as a control siRNA (44-2926; 
Invitrogen). It is a fluorescent conjugated control containing a scrambled sequence that 
does not reduce the levels of any known mammalian gene.  At 48 hours after
 
transfection, 
whole cell lysate was prepared as previously described (Workman et al., 2009). Protein
 
concentrations were quantified by the Bradford assay. Standard 12% SDS-gels were 
prepared and used for these studies.  Proteins were transferred to PVDF membrane 
(milipore), blocked for 4 hours in 5% nonfat dry milk with Tris-buffered saline-0.1% 
Tween 20 (TBS-T), and incubated with primary antibody overnight at 4
o 
C. The E2F1 
antibody (sc-193X; Santa Cruz Biotechnology) was diluted 1:10,000 in blocking solution. 
The E2F2 antibody (sc-633X; Santa Cruz Biotechnology) was diluted 1:10,000 in 
blocking solution. Antisera directed against cleaved caspase 3 (Cell Signaling, 96618), 
was also used for these studies at a 1: 10,000 dilution in blocking solution.  After 45 
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minutes of washing with TBS-T, blots were incubated with donkey anti-rabbit 
horseradish peroxidase-conjugated immunoglobulin G (Amersham Biosciences), which 
was diluted 1:2000 in 5% nonfat milk in TBS-T.  Blots were washed 45 minutes with 
TBS-T and exposed to Amersham ECL reagents, and then autoradiography performed.  
The -actin protein was used as a loading control, and this protein was detected using a 
polyclonal antiserum (Santa Cruz Biotechnology, Santa Cruz, CA).  
 
Analysis of Lac Z gene expression in productively infected cells 
  RS cells grown in 60 mM dishes were transfected with 1 ug of blank pcDNA3.1 
vector, 100 nM E2F1 siRNA or 100 nM control siRNA using Lipofectamine 2000 
according to the manufacture’s specifications (11668-019; Invitrogen).  At 24 hours after 
transfection, cells were transfected with 1 ug of gCBlue virus genome. After 24 hours, 
cells were fixed (2% Formaldehyde, 0.2% Glutaraldehyde in PBS), stained (1% bluo-gal, 
5 mM Kferric, 5 mM Kferro, 0.5 M MgCl2 in PBS), and the number of blue cells was 
counted as described previously (Geiser et al., 2002; Geiser and Jones, 2003).  The 
number of blue cells in cultures expressing the blank vector was set to 100.  To calculate 
percent plaque formation, the number of blue cells in cultures transfected with the E2F1 
or control siRNA were divided by the number of blue cells in cultures transfected with 
the blank vector.  The results are an average of three independent experiments.   
 
Confocal Microscopy 
 CRIB cells were infected with wt BHV-1 at a moi of 5.   At 16 hours after 
infection, cells were fixed in 4% para-formaldehyde
 
for 10 minutes, followed by three 
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washes with phosphate-buffered
 
saline (PBS).  Cells were permeabilized by incubating 
with 100% ethanol
 
at -20°C for 5 min.  Coverslips were then washed three times
 
and 
blocked in 3% BSA in
 
PBS for 1 h to reduce non-specific binding.  The E2F1 primary 
antibody (sc-193X; Santa Cruz Biotechnology) was diluted 1:3,000 in PBS with 0.05% 
Tween 20 and 1% BSA and incubated on coverslips for 2 hours at room temperature. 
After three washes, coverslips were incubated with Cy5-conjugated donkey anti-rabbit 
antibody (A-31573; Invitrogen) at a dilution of 1:400 for 1 h in the dark. After slides 
were washed, DAPI (4',6'-diamidino-2-phenylindole) staining was performed to visualize 
the nucleus. Coverslips were then mounted on slides using Gelmount
 
aqueous mounting 
medium (17985-10; Electrom Microscopy Sciences).  Images were obtained with a Bio-
Rad confocal
 
laser-scanning microscope (MRC-1024ES).
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RESULTS 
Suppression of E2F1 reduced the levels of productive infection 
 Our previous studies indicated that over-expression of E2F4, but not E2F1 or 
E2F2, stimulated BHV-1 productive infection (Geiser and Jones, 2003).  In contrast, the 
same study demonstrated that E2F1 and E2F2, but not E2F4, stimulated the IEtu1 
promoter.  Since E2F1 and E2F2, but not E2F4, are potent trans-activators (Attwooll et 
al., 2004; Chang et al., 2005; Harbour and Dean, 2000), this result was surprising.  Over-
expression of E2F1 can induce apoptosis (Attwooll et al., 2004; Nip et al., 1997) 
suggesting E2F1 and E2F2 were unable to stimulate productive infection because they 
were toxic to transfected cells.  
 To test whether E2F1 specific siRNA affected productive infection, rabbit skin 
cells (RS) were transfected with E2F1 siRNA and BHV-1 genomic DNA.  RS cells were 
used for these studies because they are permissive for BHV-1 and can be transfected 
efficiently.  For this study, we used the gCblue BHV-1 virus strain, which contains the 
Lac Z gene inserted downstream of the gC promoter.  At 24 h after transfection, cells 
were fixed and the number of -Gal+ cells identified.  This time point was used to 
minimize the number of virus positive cells that result from virus spread.  At later times, 
many -Gal+ cells lift off the dish making it difficult to count virus positive cells (Geiser 
et al., 2002; Inman et al., 2001b).  The number of -Gal+ cells directly correlates with the 
number of plaques produced following transfection with the gCblue virus (Geiser et al., 
2002; Inman et al., 2001b).  Relative to a control siRNA, cotransfection of E2F1 siRNA 
with BHV-1 genomic DNA reduced the number of -Gal+ cells approximately 4 fold 
(Figure 3.1A).  The control siRNA reduced the number of -Gal+ cells approximately 
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20% compared to results obtained when RS cells were transfected with just BHV-1 DNA.  
Western blot analysis demonstrated that the E2F1 siRNA, but not the control siRNA 
reduced E2F1 steady state protein levels (Figure 3.1B).  Conversely, the E2F1 specific 
siRNA had no obvious effect on E2F2 or -actin protein levels.  The E2F1 siRNA 
reduced the percent of cells in S phase at 24 hours after transfection, (data not shown) 
suggesting that in RS cells there is a correlation between reducing E2F1 protein levels 
and cell cycle progression. 
 
The bICP0 E promoter is trans-activated by E2F   
 As with HSV-1 or HSV-2, there are two copies of the bICP0 and bICP4 genes in 
the BHV-1 repeats (Figure 3.2A).  However, the organization of the BHV-1 ICP4 and 
ICP0 genes is unique because a common IE promoter (IEtu1 promoter) drives expression 
of bICP0 and bICP4 mRNA (Wirth et al., 1992) (Figure 3.2B).  bICP0 also contains an E 
promoter located near the 5’ end of the bICP0 coding exon (e2).  Recent evidence 
indicated that the bICP0 E promoter, but not the IEtu1 promoter, is stimulated by DEX 
treatment (Workman et al., 2009).  Expression of the cellular transcription factor C/EBP-
alpha is stimulated by DEX, thus stimulating bICP0 E promoter activity.  Since 
repression of E2F1 protein levels by specific siRNAs reduced productive infection, we 
hypothesized that E2F1 may trans-activate the bICP0 early promoter. 
 To test this hypothesis, neuro-2A cells were cotransfected with a bICP0 E 
promoter construct (Figure 3.2C) plus an E2F1 or E2F2 expression plasmid, and CAT 
activity measured.  Neuro-2A cells were use for this study because these cells are 
neuronal-like and it was of interest to begin to understand whether E2F regulates gene 
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expression in neurons.  E2F1 and E2F2 are potent stimulators of E2F-responsive 
promoters (Attwooll et al., 2004; Harbour and Dean, 2000; Nevins et al., 1997; 
Weintraub et al., 1992), and thus were used for these studies.  E2F1 trans-activated the 
EP-943 and EP-638 promoter constructs approximately 200 fold, and E2F2 trans-
activated the same promoter constructs more than 100 fold (Figure 3.2C).  EP-172, EP-
143, and EP-133 were trans-activated by E2F1 more than 40 fold and at least 11 fold by 
E2F2.  EP-72, EP-50, EP-42, and the promoter minus CAT vector (pCATbasic) were not 
trans-activated by E2F1 or E2F2. 
 Transfection of neuro-2A cells with increasing concentrations of a plasmid 
expressing E2F1 led to increased levels of cleaved caspase 3 in neuro-2A cells (Figure 
3.2D).  Although low levels of cleaved caspase 3 were detected in mock transfected cells, 
increasing levels of E2F1 correlated with increased levels of cleaved caspase 3, which is 
considered to be the point of “no return” during apoptosis (Shimeld et al., 1996).  We 
believe that low levels of apoptosis in mock-transfected cells was due to the fact that 
these cells have a tendency to lift off the plate if they are not sub-cultured every 3-4 days 
and the stress of transfection.  Cultures that were transfected with the highest levels of 
E2F1 contained cells that were rounded up and appeared to be dead.  When neuro-2A 
cells were cotransfected with 0.1 or 1 ug E2F1, many cells had a similar morphology as 
mock-transfected cells (data not shown).  Although E2F1 can induce apoptosis (Attwooll 
et al., 2004; Nip et al., 1997), we do not believe that merely inducing apoptosis accounts 
for trans-activation of the bICP0 E promoter by E2F1 because we used low levels of 
E2F1 (0.1 ug) for the trans-activation studies and this amount of E2F1 did not alter the 
morphology of neuro-2A cells or dramatically increase cleaved caspase 3 levels relative 
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to mock transfected cells (Figure 3.2D).  Furthermore, Bax, a known apoptotic gene 
(Shimeld et al., 1996), did not trans-activate the bICP0 E promoter (data not shown). 
 The ability of E2F1 or E2F2 to trans-activate the IEtu1 promoter was also 
examined because a previous study demonstrated that E2F1 trans-activated the IEtu1 
promoter 15-20 fold in bovine testicle cells (Geiser and Jones, 2003).  However, in 
neuro-2A cells, E2F1 or E2F2 trans-activated the three IEtu1 promoters (Figure 3.3A) 
only 3-5 fold (Figure 3.3B).  In summary, this study demonstrated that E2F1 or E2F2 
efficiently trans-activated the bICP0 E promoter, but not the IEtu1 promoter, in neuro-2A 
cells.  
 
The bICP0 E promoter contains two E2F responsive regions 
 The results in Figure 3.2 suggested that the bICP0 E promoter contained two 
separate E2F responsive regions: 1) E2F responsive region 1 (ERR1) that spanned the 5’ 
terminal 60 bases of EP-133, and 2) E2F responsive region 2 (ERR2) located at or near 
the 5’ terminus of EP-638.  To test whether ERR1 conferred E2F responsiveness to a 
heterologous promoter, 40 bp spanning the 5’ terminus of EP-133 to EP-71 were 
synthesized and cloned upstream of a CAT reporter construct containing a minimal SV40 
E promoter construct (see figure 3.4A for a schematic of the predicted ERR1 region). 
This construct (ERR1/40) was transactivated by E2F1 approximately 5 fold (Figure 
3.4B).  A 60 base pair fragment between EP-133 and EP-71 was not trans-activated more 
efficiently than ERR1/40 (data not shown).  In contrast, the SV40 E promoter (SV40 
min-CAT) was not efficiently trans-activated by E2F1. 
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 Sequences spanning the 5’ terminus of EP-638 and adjacent regions within EP-
943 (ERR2) were also synthesized and then cloned into the SV40 min-CAT construct 
(see Figure 3.5A for a schematic of these constructs).  The construct containing 254 bp of 
the bICP0 E promoter (ERR2/254), 180 bp of the E promoter (ERR2/180), or 120 bp of 
the E promoter (ERR2/120) was trans-activated by E2F1 approximately 20 fold (Figure 
3.5B).  The 120 bp fragment within ERR2 was further divided into two equal pieces 
(ERR2/1-60 and ERR2/61-120) and then tested for trans-activation by E2F1.  ERR2/1-
60, but not ERR2/61-120, was trans-activated by E2F1 more than 15 fold (Figure 3.5B).  
In summary, these studies identified a 60 bp fragment within ERR2 that was trans-
activated by E2F1 when cloned upstream of a minimal SV40 E promoter.   
 In Figure 3.6A and B, the DNA sequence of ERR1 and ERR2 is shown.  ERR1 is 
located within sequences that are present in EP-133 but lacking in EP-72.  Within this 
region, there are two regions of overlapping Sp1 binding sites (Figure 3.6A).  The E2F 
transcriptional activator is a heterodimer consisting of an E2F family member and a Dp 
family member (Attwooll et al., 2004; Harbour and Dean, 2000; Nevins et al., 1997).  
The core DNA binding site of an E2F/Dp heterodimer is (g/cGCGCc/g) (Zheng et al., 
1999).  Within ERR1, there is one E2F/Dp core consensus sequence.  Two LSF (late 
SV40 transcription factor) binding sites, a transcription factor that interacts with the 
SV40 21 base repeats and activates late transcription (Kwon et al., 2006), and binding 
sites for a transcription factor that preferentially interacts with CAC sequences were also 
identified.  Finally, a Yi binding site, which is present in the mouse thymidine kinase 
promoter was detected (Dou et al., 1991).  Proteins that interact with the Yi binding site 
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exhibit G1/S phase inducible binding.  Within sequences of ERR1/40, binding sites for 
E2F/Dp, Sp1 Yi, LSF, and CAC are clustered.   
 Within the first 60 bp of ERR2 (Figure 3.6B), 5 Sp1 binding sites were identified: 
3 match those of the mouse Erk1 gene (Pages et al., 1995), 1 is present in the SV40 E 
promoter (Gidoni, 1984), and one is a target for binding to SP1 (Thiesen and Bach, 
1990).  In addition, 5 core E2F/Dp binding sites were present.  Four of these are 
overlapping and located near the 5’ terminus of this fragment.  Conversely, nucleotides 
spanning nucleotides 61-120 of ERR2, which were not efficiently trans-activated by 
E2F1, contained just 2 E2F/Dp consensus binding sites and one Sp1 binding site present 
in the human heat shock binding protein 70 promoter (Greene et al., 1987).  In summary, 
these studies suggested that a cluster of E2F/Dp core binding sites and Sp1 binding sites 
located within the 60 bp of ERR2 may be important for E2F mediated trans-activation.   
 
Cellular factors interact with ERR1 and ERR2 
 To test whether E2F interacts with ERR1 or ERR2, electrophoretic mobility shift 
assays (EMSA) were performed with oligonucleotides derived from ERR1, ERR2, or a 
consensus E2F binding site and whole cell extracts prepared from neuro-2A cells.  
Shifted bands were readily detected when the respective probes were incubated with 
neuro-2A cell extracts (Figure 3.7A, shifted bands denoted by the brackets).  E2F 
interacted with the E2F consensus probe as well as ERR1 and ERR2 probes because an 
oligonucleotide containing a consensus E2F binding site, but not a C/EBP-alpha binding 
site, competed for binding of nuclear factors (Figure 3.7A).   
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 Additional studies were performed to test whether productive infection stimulated 
binding to the E2F consensus binding site, ERR1, or ERR2.  For these studies, we used 
bovine kidney cells (CRIB) because they are permissive for BHV-1, whereas neuro-2A 
cells are not.  At 16 or 24 hours after infection, increased binding to the E2F consensus, 
ERR1, and ERR2 was observed (Figure 3.7B, enhanced binding denoted by the closed 
circles).  A consensus E2F sequence, but not a C/EBP-alpha binding site, reduced the 
intensity of certain bands when incubated with the respective radioactive probes (Figure 
3.7B).  Although these studies indicated that E2F interacted with ERR1 or ERR2, this 
was not readily detectable until late stages of productive infection suggesting E2F family 
members were not the major activators of bICP0 E promoter activity. 
 Western blot analysis determined that E2F1 protein levels, but not E2F2, 
increased during the course of productive infection (Figure 3.8).  At 16 and 24 hours after 
infection, E2F1 protein levels were dramatically higher, which correlated with enhanced 
binding to the E2F consensus, ERR1, or ERR2 oligonucleotide.  Confocal microscopy 
was performed to determine if E2F1 was detected in the nucleus of infected cells at 16 
hours after infection (Figure 3.8B).  Higher levels of E2F1 were detected in infected 
cells, and the E2F1 protein was localized in the nucleus, which was in agreement with the 
Western blot studies shown in Figure 3.8A.  Previous studies have demonstrated that 
BHV-1 E transcripts (thymidine kinase and ribonucleotide reductase) are readily detected 
at 2 hours after infection (moi of 0.02) using poly dT as a primer for RT-PCR (Schang 
and Jones, 1997).  Using a moi of 5, most CRIB cells were rounded up and some were 
beginning to detach from the dish between 16-24 hours after infection (Figure 3.8B). 
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DISCUSSION 
 In this study, we demonstrated that the bICP0 E promoter, but not the IEtu1 
promoter, was trans-activated by E2F1 or E2F2 more than 100 fold in neuro-2A cells.  
Silencing of E2F1 reduced virus infection approximately 4 fold indicating E2F1 has the 
potential to stimulate productive infection.  Previous studies also suggested that E2F 
family members stimulated BHV-1 productive infection (Geiser and Jones, 2003; 
Winkler et al., 2000a).  With respect to HSV-1 productive infection, E2F that is not 
associated with Rb family members increase following infection of human cells (C33-A) 
(Hilton et al., 1995).  Relocalization of E2F4 to the nucleus occurs in C33-A and U2-OS 
human cells following HSV-1 infection (Olgiate et al., 1999).  Further support for E2F4 
playing a role in HSV-1 replication comes from the findings that infection of p107
-/-
/p130
-/-
 mouse cells leads to reduced infectious virus (Ehmann et al., 2001).  In primary 
human fibroblasts or Hela cells, the subcellular distribution of E2F4 is altered following 
HSV-1 infection, which is assumed to inactivate E2F-4 activity (Advani et al., 2000a).  
This same study also concluded that HSV-1 infections leads to post-translational 
modification of E2F1 and E2F5, translocation of E2F family members from the nucleus 
to the cytoplasm, and reduced E2F binding to consensus E2F binding sites.  In contrast, 
enhanced binding to a consensus E2F binding site was detected at late times after 
infection with BHV-1 (Figure 3.7B).  Many DNA synthetic genes are activated by E2F 
family members (Harbour and Dean, 2000) suggesting transient induction of E2F family 
members may stimulate viral synthesis in highly differentiated cells.  It is also possible 
that induction of E2F binding activity occurs because BHV-1 induces p53 dependent 
apoptosis during productive infection (Devireddy and Jones, 1999b).   
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 The bICP0 E promoter contained two separate regions that were trans-activated 
by E2F: an upstream region that was localized to a 60 bp fragment (ERR2) and sequences 
located near the 5’ terminus of the EP-133 construct (ERR1).  Since ERR2 was trans-
activated by E2F1 approximately 20 fold, but EP-638 was trans-activated approximately 
200 fold by E2F1 we suggest that other sequences within the bICP0 E promoter play a 
role in trans-activation by E2F.  EMSA assays suggested that E2F interacted with ERR1 
and ERR2 because a consensus E2F sequence, but not a C/EBP-alpha binding site, 
competed for binding of nuclear factors (Figure 3.7).  ERR2 contains 5 core E2F/Dp 
binding sites (Figure 6B) (Zheng et al., 1999) suggesting these elements may be 
important for E2F mediated trans-activation.  The 5 Sp1 binding sites located in ERR2 
may also be crucial for trans-activation because E2F family members can interact with 
and trans-activate certain promoters containing GC rich motifs that resemble Sp1 binding 
sites.  For example, E2F1 can trans-activate GC rich motifs in the HSV-1 thymidine 
kinase promoter (Chang et al., 2005) and the human ASK (activator of S phase kinase) 
gene encoding the regulatory subunit for human cdc7-related kinase (Yamada et al., 
2002).  In addition, a subunit of the mouse DNA polymerase alpha promoter contains a 
GC rich element that is crucial for cell cycle regulation (Nishikawa et al., 2000).  Finally, 
3 GC rich motifs in the human thymidine kinase promoter are bound by E2F, and are 
crucial for cell cycle dependent expression (Tommasi and Pfeifer, 1997).  Not all GC rich 
promoters are trans-activated by E2F because we previously demonstrated that the BHV-
1 IEtu2 promoter was not efficiently trans-activated by E2F1 or E2F2 (Geiser and Jones, 
2003).   
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 In trigeminal ganglia of latently infected calves, bICP0 transcription is stimulated 
from the E promoter during DEX induced reactivation from latency regardless of whether 
infectious virus is detected (Workman et al., 2009).  In addition, the bICP0 E promoter is 
stimulated by DEX, in part because of the cellular transcription factor C/EBP-alpha.  
Conversely, the IEtu1 promoter does not appear to be as active during reactivation from 
latency because bICP4 is not consistently detected.  This may be important because 
activating bICP0, but not bICP4, during the early stages of reactivation may allow BHV-
1 to “test the waters” and determine whether important cellular factors are present for 
producing infectious virus without extensive viral gene expression occurring, which 
could lead to neuronal death.  If bICP4 and bICP0 are expressed equally, extensive viral 
gene expression may occur in too many neurons that cannot support production of 
infectious virus.  The ability of E2F1 or E2F2 to strongly trans-activate the bICP0 E 
promoter, but not the IEtu1 promoter, may play role in this process.  It will be of interest 
to test whether E2F1 or E2F2 can cooperate with bICP0 or bICP4 to stimulate E or L 
genes since they also contain GC rich promoters. 
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Figure 3.1. Suppression of E2F1 reduced the levels of BHV-1 productive infection. 
Panel A:  RS cells were transfected with pcDNA3.1 empty vector, 100 nM E2F1 siRNA, 
or 100 nM control siRNA. Twenty-four hours later, cells were transfected with 1 ug of 
gCBlue BHV-1 DNA.  At 24 hours after transfection, cells were fixed and B-gal positive 
cells were counted.  The results constitute the average of four independent experiments. 
Panel B.  RS cells were transfected with 100 nM E2F1 siRNA or 100 nM control siRNA.  
At 48 hours after transfection, cells were collected and lysed with NP-40 lysis buffer, and 
100 ug of protein was electrophoresed by 12% SDS-PAGE.  Proteins in the gel were 
transferred onto a polyvinylidene difluoride membrane and probed with the E2F1 
antiserum that was diluted 1:10,000.  As controls, 100 ug cell lysate was probed with 
antiserum that specifically recognized E2F2 or -actin. 
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Figure 3.2.  Schematic of IEtu1 and bICP0 E promoter constructs used in this study.   
Panel A:  Location of the unique long (L) and unique short (S) regions of the BHV-1 
genome.  The repeats are denoted by the open rectangles.  Genes encoding bICP0 and 
bICP4 are present within the repeats. Panel B:  Positions of bICP4 and bICP0 transcripts 
are shown.  The immediate early transcription unit 1 (IEtu1) encodes bICP4 (IE/4.2) and 
bICP0 (IE/2.9) (Wirth et al., 1989; Wirth et al., 1991).  The IEtu1 promoter activates IE 
expression of IE/4.2 and IE/2.9 (denoted by the black rectangle).  E/2.6 is the early 
transcript that encodes bICP0 and an early promoter activates expression of this transcript 
(Wirth et al., 1992).  Exon 2 (e2) of bICP0 contains all of the protein coding sequences of 
bICP0.  The dashed lines are intron sequences. Panel C:  bICP0 E promoter constructs 
were prepared as described in the materials and methods.  Position of putative SP1 
binding sites, E2F like sites, and TATA box are shown.   Neuro2-A cells were co-
transfected with 1 ug of the designated bICP0 E promoter/CAT construct and 0.1 ug of 
E2F1 or E2F2 expression plasmid.  DNA amounts were equalized for all transfections 
using pcDNA3.1, a blank expression vector.  At 48 hours post transfection, cells were 
collected and processed for CAT activity as described in the Materials and Methods.  
CAT activity of cells transfected with the control CAT vector was set to one for each 
experiment.  All other values are expressed as fold activation with respect to the control. 
The results are the average of three independent experiments. Panel D:  Neuro-2A cells 
were transfected with 0.1 ug E2F1 (lane 2), 1 ug E2F1 (lane 3), 5 ug E2F1 (lane 4), or 10 
ug E2F1 (lane 5).  At 48 hours after transfection whole cell lysate was prepared and 200 
ug protein/lane was used for Western Blot assays.  Antisera directed against E2F1, 
cleaved caspase 3 (Cell Signaling, 96618), or -actin was used for these studies. 
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Figure 3.3.  E2F trans-activation of IEtu1 promoter deletion mutants. 
Panel A.  Schematic of IEtu1cat constructs used to identify regions of the promoter that 
are responsive to E2F1.  IETu1-CAT contains IETu1 promoter sequences cloned 
upstream of pSV0CAT (a promoter minus CAT expression vector).  V. Misra, Saskatoon, 
Canada, provided the IEtu1cat plasmid.  Two deletion constructs 1024 and 1391 IEtu1 
have 1024 or 1391 bp removed from the 5’ terminus.  The location of cis-acting 
sequences within IEtu1cat and the details of the respective plasmid constructs were 
described previously (Misra et al., 1994).   
Panel B:  Neuro-2A cells were cotransfected with an IETu1 promoter construct (1 ug 
DNA) and the E2F1 or E2F2 (0.1 ug) expression plasmid as described in Figure 1C.  
CAT activity of cells transfected with the control CAT vector was set to one for each 
experiment.  All other values are expressed as fold activation with respect to the control. 
The results are the average of three independent experiments.   
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Figure 3.4: Localization of ERR1 within the bICP0 E promoter 
Panel A.  Schematic of the bICP0 E promoter and the positions of EP-133 and EP-71.  A 
40 nucleotide fragment that spans EP-133 and EP-71 was synthesized and cloned 
upstream of the SV40 E promoter (ERR1/40).   
Panel B: Neuro-2A cells were co-transfected with 1ug of the designated fragment of the 
bICP0 E promoter cloned upstream of the SV40 minimal promoter CAT vector 
(ERR1/40) and 1 ug of the E2F1 expression plasmid. At 48 hours post transfection, cells 
were collected and processed for CAT activity as described in the Materials and Methods.  
CAT activity of cells transfected with the control CAT vector was set to one fold. All 
other values are expressed as fold activation with respect to the control.  Experiments 
constitute the average of three independent experiments.  
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Figure 3.5. Localization of ERR2 within the bICP0 E promoter 
Panel A: To localize sequences within ERR2 that are responsive to E2F1, bICP0 E 
promoter sequences were cloned into a minimal promoter CAT vector containing an 
SV40 promoter cloned upstream of the CAT gene as described in the Materials and 
Methods.  
Panel B: Neuro-2A cells were co-transfected with 1ug of the designated fragment of the 
bICP0 E promoter cloned upstream of the SV40 minimal promoter CAT vector and 1 ug 
of E2F1.  At 48 hours post transfection, cells were collected and processed for CAT 
activity as described in the Materials and Methods.  CAT activity of cells transfected with 
the control CAT vector was set to one fold.  All other values are expressed as fold 
activation with respect to the control. Experiments constitute the average of three 
independent experiments.  
 
 
 
 
 
 
 
 
 
 
 
93 
 
Figure 3.5. 
 
 
EP-
943
SV40 min CAT
ERR2/254
ERR2/180
ERR2/120
ERR2/1-60
ERR2/61-120
0
5
10
15
20
25
30
minCAT ERR2/254 ERR2/180 ERR2/120 ERR2/1-
60
ERR2/61-
120
minCat       ERR2/254     ERR2/180    ERR2/120     ERR2/1-60    ERR2/61-120 
F
o
ld
 A
ct
iv
a
ti
o
n
A
B
ERR2
EP-638 EP-398
94 
 
Figure 3.6.  Nucleotide sequence of ERR1 and ERR2 within the bICP0 E promoter. 
Panel A:  Nucleotide sequences spanning sequences from EP-133 to the 5’ terminus of 
the bICP0 E mRNA.  The vertical black arrows denote sequences used in the ERR1/40 
construct.  
Panel B:  Nucleotide sequences spanning ERR2.  The 120 nucleotides that span ERR2 
are shown to allow a comparison between the first 60 nucleotides that comprised the 
minimal fragment that was efficiently stimulated by E2F1 and the last 60 nucleotides that 
was not efficiently trans-activated by E2F1.  Shown are locations of Sp1 binding sites 
from various promoters, C/EBP-alpha binding sites previously identified within the 
bICP0 E promoter (Workman, 2009),, Sp1 sites from the designated promoters, Yi 
consensus binding sites (CCNCNCCCN), E2F/DP core binding sites, CAC binding sites, 
and LSF binding sites. 
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Figure 3.7.  Interaction between E2F and ERR1 or ERR2. 
Panel A:  EMSA was performed using a probe that contains a consensus E2F binding 
site (E2F consensus), sequences spanning ERR1/40 (ERR1), or ERR2/1-60 (ERR2), 
which were described in the materials and methods. The respective 
32
P-radiolabeled 
probe was incubated with 20 ug of Neuro-2A cell lysate that was transfected with the 
E2F1 expression construct (100 ng). For competition assays, 500 ng of the cold E2F 
consensus probe (lane E2F) or the C/EBP-alpha consensus probe (lane C) was incubated 
with cell extracts as described in the Materials and Methods. Brackets indicate the region 
of shifted bands. 
Panel B:  CRIB cells were infected with wt BHV-1 at a moi of 5 for 8, 16, or 24 hours. 
The respective 
32
P radiolabeled probes, E2F binding sites (E2F consensus), sequences 
spanning ERR1/40 (ERR1), or ERR2/1-60 (ERR2), were incubated with 20 ug of CRIB 
cell lysate (lane M) or CRIB cell lysate prepared from cells infected for 8, 16, or 24 hours 
after infection. For competition assays, 500 ng of the cold E2F consensus probe (lane 
E2F) or C/EBP-alpha consensus probe (lane C) was incubated with cell extracts as 
described in the Materials and Methods.  Brackets indicate the region of shifted bands, 
and the closed circles denote shifted bands that were reduced when incubated with the 
cold E2F consensus probe.  
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Figure 3.8.  Analysis of E2F1 protein levels during productive infection. 
Panel A:  Western blot analysis of E2F1, E2F2, and -actin expression following 
infection with BHV-1.  CRIB cells were infected with wt BHV-1 at a moi of 5 for 2, 4, 8, 
16, or 24 hours.  Lanes M2 and M24 are mock-infected cells that were collected 2 and 24 
hours after the other cells were infected with BHV-1.  One hundred ug total cell lysate 
was loaded for each lane.   
Panel B:  CRIB cells were infected with wt BHV-1 at a moi of 5.  At 16 hours after 
infection, cells were fixed in 4% para-formaldehyde and stained for confocal microscopy 
as described in the Materials and Methods. E2F1 primary antibody was used at a 1:3,000 
dilution and Cy5-conjugated donkey anti-rabbit secondary antibody was used at a 1:400 
dilution. 
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Figure 3.8.  
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Chapter 4 
 
Analysis of the Cell Cycle Regulatory Protein E2F1 after Infection of Cultured Cells 
with Bovine Herpesvirus 1 (BHV-1) or Herpes Simplex Virus Type 1 (HSV-1).  
 
 
This work has recently been accepted for publication in the journal Virus Research. 
 
The authors of this manuscript are Aspen Workman and Clinton Jones. 
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ABSTRACT 
The E2F family of transcription factors control the expression of genes involved 
in cell cycle progression and cell death. During the transition from G1 to S phase in the 
cell cycle, there is a sequential activation of cyclin-dependent kinases, which 
phosphorylate the retinoblastoma (Rb) protein, causing the release and activation of E2F. 
Previous studies indicated that (i) bovine herpes virus 1 (BHV-1) productive infection 
increases E2F1 protein levels, (ii) viral promoter activity is trans-activated by E2F1 or 
E2F2, and (iii) silencing E2F1 reduces the efficiency of productive infection. In this 
study, the effect of herpes simplex virus type 1 (HSV-1) productive infection on E2F 
protein levels and regulation of E2F dependent transcription was compared to BHV-1 
infection in the same permissive cell line, rabbit skin (RS) cells.  Silencing E2F1 with a 
specific siRNA reduces HSV-1 productive infection approximately 10 fold in RS cells. 
Furthermore, total E2F1 protein levels increased during productive infection.  In contrast 
to RS cells infected with BHV-1, a fraction of total E2F1 protein was localized to the 
cytoplasm in HSV-1 infected RS cells.  Furthermore, E2F1 did not efficiently trans-
activate the HSV-1 ICP0 or ICP4 promoter.  When RS cells were transfected with an E2F 
reporter construct or the cyclin D1 promoter and then infected with BHV-1, promoter 
activity increased after infection.  In contrast, HSV-1 infection of RS cells had little effect 
on E2F dependent transcription and cyclin D1 promoter activity was reduced.  In 
summary, these studies indicated that silencing E2F1 reduced the efficiency of HSV-1 
and BHV-1 productive infection, but only BHV-1 infection induced E2F dependent 
transcription. 
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INTRODUCTION 
Bovine herpes virus 1 (BHV-1) and herpes simplex virus type 1 (HSV-1) are 
alphaherpesvirinae subfamily members that establish latency in sensory neurons. In 
contrast to small DNA tumor viruses, alphaherpesvirinae subfamily members do not 
appear to promote entry into the S phase of the cell cycle.  For example, HSV-1 encodes 
several genes, ICP0, ICP27, ICP22/US1.5, and UL13, which inhibit cell cycle progression 
(Advani et al., 2000b; Flemington, 2001; Hobbs and DeLuca, 1999; Lomonte and 
Everett, 1999; Orlando et al., 2006; Song et al., 2001). However, drugs that interfere with 
cyclin dependent kinase activity, roscovitine and olomucine, reduce the efficiency of 
HSV-1 productive infection (Schang et al., 1998; Schang et al., 1999).  Therefore, 
although herpesviruses block cell cycle progression into S phase, it appears that they 
require certain cell cycle regulatory proteins to facilitate efficient replication. 
This is exemplified by recent studies suggesting that the E2F family of transcription 
factors stimulate BHV-1 productive infection and reactivation from latency. The E2F 
family of transcription factors contains cell cycle regulatory proteins that interact with 
retinoblastoma (Rb) family members (Harbour and Dean, 2000).  During cell cycle 
progression from G1 to S phase, phosphorylation of Rb family members by cyclin 
dependent kinase/cyclin complexes leads to E2F release, and consequently certain E2F 
family members (E2F1, -2, or -3) activate transcription (Attwooll et al., 2004; Harbour 
and Dean, 2000; Nevins et al., 1997; Weintraub et al., 1992).  Consensus E2F binding 
sites are present in the promoters of many cellular genes that control cell cycle 
progression (DeGregori et al., 1995; Nevins et al., 1997; Ohtani et al., 1995b; Schulze et 
al., 1995; Wells et al., 1997).  Despite the herpesvirus induced block in cell cycle 
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progression, BHV-1 requires E2F family members for efficient productive infection. For 
example, a siRNA directed against E2F1 inhibits BHV-1 productive infection, E2F1 
protein levels and binding activity increase after infection, and E2F1 or E2F2 stimulates 
the bICP0 early promoter more than 100 fold (Workman and Jones, 2010).  Furthermore, 
over-expression of E2F4 stimulates BHV-1 productive infection and E2F1 or E2F2 trans-
activates IEtu1 (immediate early transcription unit 1) promoter activity (Geiser and Jones, 
2003).  Furthermore, during dexamethasone induced reactivation from BHV-1 latency, 
sensory neurons that express abundant levels of lytic cycle genes also express cyclin E 
and cyclin A (Winkler et al., 2000b).  This suggests that transient induction of E2F 
dependent transcription by alphaherpesvirinae subfamily members may enhance 
productive infection in highly differentiated cells, such as neurons. Although these 
studies suggest that increased E2F protein levels and binding activity were important for 
productive infection, BHV-1 may also increase E2F1 protein levels because productive 
infection leads to p53 dependent apoptosis (Devireddy and Jones, 1999a). 
With respect to HSV-1 productive infection, “free” E2F (not associated with Rb 
family members) increases following infection of a human tumor cell line (C33-A) 
(Hilton et al., 1995).  Re-localization of E2F4 to the nucleus occurs in human tumor cell 
lines (C33-A and U2-OS) following HSV-1 infection (Olgiate et al., 1999).  Further 
support for E2F4 playing a role in HSV-1 replication comes from the findings that 
infection of mouse cells that lack p107
-/-
 and p130
-/-
, two Rb family members that are 
known to interact with E2F4, leads to reduced infectious virus (Ehmann et al., 2001).  In 
primary human fibroblasts or Hela cells, the subcellular distribution of E2F4 is altered 
following HSV-1 infection, which is assumed to inactivate E2F4 (Advani et al., 2000b).  
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This same study also concluded that HSV-1 infection leads to post-translational 
modification of E2F1 and E2F5, translocation of E2F family members from the nucleus 
to the cytoplasm, and reduced E2F binding to consensus E2F binding sites.  Based on 
these observations, HSV-1 appears to inactivate E2F dependent signaling. 
In this study, we compared the effects of HSV-1 versus BHV-1 infection on E2F1 
and E2F dependent transcription in the same cell line.  Like BHV-1, an E2F1-specific 
siRNA reduced HSV-1 productive infection following infection of rabbit skin cells.  
Although BHV-1 and HSV-1 both increased E2F1 protein levels, a significant amount of 
E2F1 protein was localized in a cytoplasmic fraction following HSV-1 infection.  
Conversely, E2F1 was localized to the nucleus following BHV-1 infection.  BHV-1, but 
not HSV-1, infection of rabbit skin cells enhanced E2F dependent transcription. 
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MATERIAL AND METHODS 
Cells and viruses 
Murine neuroblastoma 2A (neuro-2A), human embryonic lung (HEL), and rabbit 
skin (RS) cells were grown in Earle’s modified Eagle’s medium (EMEM) supplemented 
with 5% fetal calf serum (FCS). Bovine kidney cells (CRIB) were grown in EMEM 
supplemented with 10% FCS.  All media contained penicillin (10 U/ml) and streptomycin 
(100 μg/ml).   
The Cooper strain of BHV-1 (wt virus) was optained from the National 
Veterinary Services Laboratory, Animal and Plant Health Inspection Services, Ames, 
Iowa.  Stock cultures of BHV-1 were prepared in CRIB cells.  
The HSV-1 McKrae strain was obtained from S. Wechsler (U of California-
Irvine). Stock cultures of the McKrae strain were prepared in RS cells.   
 
Plasmids and measurement of promoter activity in transfected cells 
Plasmids expressing E2F1 or E2F2, pCMV-E2F1 and pCMV-E2F2 respectively,  
were obtained from J.R. Nevins (Duke University, Durham, USA). CAT constructs used 
in this study, HSV-1 ICP0-CAT (pAB5) and ICP4-CAT, were previously described 
(Devireddy and Jones, 2000).  Luciferase promoter constructs used in this study, 
pGL3basic, VP16-luc, gC-Luc, UL42-Luc and ICP6-Luc, were obtained from P. Schaffer 
and have been previously described (Kushnir et al., 2010).  The empty vector pcDNA3.1 
was purchased from Invitrogen. 
Measurement of chloramphenicol acetyltransferase (CAT) activity in neuro-2A 
cells was performed as described previously (Workman and Jones, 2010; Workman et al., 
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2009; Workman et al., 2011).  Luciferase activity in transfected neuro-2A cells was 
performed using the Promega Luciferase Assay System as described by the manufacturer 
(E4030; Promega).  
For productive infection assays, RS cells were transfected with an E2F-responsive 
promoter construct using Lipofectamine 2000 according to the manufacturer’s 
instructions. Twenty-four hours later, cells were infected with BHV-1 or HSV-1 at a moi 
of 0.1, 0.5, or 5 for 24 hours.  Cells were then collected and processed as above for 
luciferase activity.  Data for CAT and luciferase activity were averaged from the results 
of multiple transfections performed in at least three independent experiments.  
 
SDS-polyacryamide gels and Western Blotting of E2F Expression 
RS cells or HEL cells were infected with wt BHV-1 or HSV-1 at the moi 
indicated in the respective figure legend and cell lysate collected at various times (hours) 
after infection. Whole cell lysate was prepared as described previously (Workman and 
Jones, 2010; Workman et al., 2011), and protein concentrations were quantified by the 
Bradford assay.  Standard 8% SDS-polyacrylamide gels were used to analyze E2F1 
protein levels as described previously (Workman and Jones, 2010; Workman et al., 
2011).  The E2F1 antibody (sc-193X; Santa Cruz Biotechnology) was diluted 1:10,000 in 
blocking solution.  An antibody directed against -actin (Santa Cruz Biotechnology, 
Santa Cruz, CA) was used as a loading control. 
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Nuclear and Cytoplasmic Fractionation 
RS cells were infected with BHV-1 or HSV-1 at a moi of 0.1, 0.5, or 5 for 8, 16 or 
24 hours. Cells were harvested by centrifugation at 1,000 rpm for 5 min and washed 
twice in cold phosphate buffered saline (PBS). Cells were then suspended in buffer A (50 
mM NaCl, 10 mM HEPES pH8, 500 mM sucrose, 1 mM EDTA, 0.5% NP40), vortexed 
briefly, and centrifuged at 5,000-x g for 2 minutes.  The supernatant was collected and 
saved as the cytoplasmic fraction. The nuclear pellet was washed twice with low salt 
buffer B (50 mM NaCl, 10 mM HEPES pH8, 25% glycerol, 0.1 mM EDTA).  The pellet 
was then suspended in high salt lysis buffer C (350 mM NaCl, 10 mM HEPES pH8, 25% 
glycerol, 0.1 mM EDTA).  Lysis was carried out at 4
0
 C for 30 min. Supernatant was 
cleared by centrifuging at 13,000 rpm for 15 minutes at 4
0
 C.  Protein concentrations 
were quantified by the Bradford assay and standard 8% SDS-polyacrylamide gels were 
used as described above to analyze E2F1 protein levels. An antibody directed against 
histone H3 (abcam; ab1191) was diluted 1:500 and used a control for fractionation 
studies. 
 
Analysis of HSV-1 productive infection 
RS cells grown in 60 mM dishes were transfected with 1 μg of blank pcDNA3.1 
vector, 100 nM E2F1 siRNA (sc-35247; Santa Cruz Biotechnology) or 100 nM control 
siRNA (44-2926; Invitrogen) using Lipofectamine 2000 according to the manufacture’s 
specifications.  At 24 hours after transfection, cells were transfected with 2 μg of the 
HSV-1 viral genome. Forty-eight hours after transfection cells were collected and 
subjected to three rounds of freeze/thaw cycles. Cell debris was pelleted by 
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centrifugation, and the supernatant was analyzed by plaque assay on RS cells using 10 
fold dilutions.  
 
Cell Cycle Analysis by Flow Cytometry using the Telford Method 
 RS cells grown in 60 mM dishes were transfected with 100 nM E2F1 siRNA or a 
control siRNA using Lipofectamine-2000 according to the manufacture’s specifications. 
At 24 hours or 48 hours after transfection, an aliquot of 1x10
6
 RS cells were pelleted, 
then suspended in 1 mL of ice-cold 70% ethanol, and rotated at 4 degrees for 30 minutes.  
Cells were then pelleted and suspended in Telford reagent (100 mM EDTA, 0.1% 
TritonX-100, 75 mM Propidium Iodide, and 2.5 U/mL RNAse A in PBS pH 7.4) and 
rotated at 4 degrees for 2 hours. Cells were then analyzed using a Becton Dickson FACS 
caliber flow cytometer.  The data was analyzed using what program Cell Quest.  
 
Alkaline Phosphatase (CIAP) treatment 
 Whole cell lysate was collected as described above. Twenty μg of infected cell 
lysate was treated with 10 U of alkaline phosphatase (04 898 133 001; Roche) and 
incubated at 37 degrees for 30 minutes. Reactions were stopped by the addition of SDS-
polyacrylamide gel loading buffer. Samples were boiled for 5 minutes and assayed by 
immunoblotting. 
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RESULTS  
An E2F1 specific siRNA reduced the levels of HSV-1 productive infection. 
Silencing E2F1 decreases the levels of BHV-1 productive infection, in part, 
because E2F1 stimulates the bICP0 early (E) promoter more than 100 fold in transient 
transfection assays (Workman and Jones, 2010).  Since BHV-1 and HSV-1 are both 
alphaherpesvirinae subfamily members, we hypothesized that both viruses require 
similar transcription factors, including E2F1, for efficient productive infection.  To test 
whether E2F1 influenced HSV-1 productive infection, we examined the effect of an 
E2F1 specific siRNA on viral growth in rabbit skin (RS) cells, which supports productive 
infection by BHV-1 and HSV-1.  RS cells are not transformed by a known oncogene, 
they can be readily transfected with siRNA and plasmids (Workman and Jones, 2010), 
and thus are well suited for these studies.  Relative to the control siRNA, co-transfection 
of the E2F1 siRNA with the HSV-1 genome reduced the number of plaques more than 
10-fold (Figure 4.1A).  In contrast, the control siRNA slightly increased the number of 
plaques produced.  
Previous studies demonstrated that the E2F1 specific siRNA reduced E2F1 
protein levels, but not E2F2 or -actin protein levels (Workman and Jones, 2010). 
Additional studies were performed to evaluate the effect of the E2F1 siRNA on the cell 
cycle in uninfected cells. The E2F1 siRNA reduced the percent of cells in S phase less 
than 2 fold at 24 hours after transfection (Figure 4.1B).  However, silencing of E2F1 did 
not stimulate apoptosis or cell death, in general.  By 48 hours after transfection, there was 
no difference in the percent of cells in S phase regardless of the treatment.  In summary, 
these studies demonstrated that silencing E2F protein levels reduced HSV-1 productive 
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infection, which was consistent with previous studies that examined the effect of the 
same siRNA on BHV-1 productive infection (Workman and Jones, 2010). 
 
Analysis of E2F1 trans-activation of HSV-1 promoter constructs 
 Previous studies revealed E2F1 trans-activated the BHV-1 bICP0 E promoter 
more than 100 fold in transient transfection assays (Workman and Jones, 2010). Two 
E2F1 responsive regions (ERR) were identified within the bICP0 E promoter, one 
adjacent to the TATA box (ERR1) and one approximately 600 bp upstream of the TATA 
box (ERR2).  When cloned upstream of a simple HSV-1 thymidine kinase promoter, 
ERR1 stimulated promoter activity 6 fold whereas ERR2 stimulate promoter activity 
more than 20 fold.  Mobility shift assays provided further evidence that E2F1 interacted 
directly with these sequences (Workman and Jones, 2010).  Therefore, we hypothesized 
that E2F1 may stimulate promoters of important HSV-1 regulatory genes.   
To test this hypothesis, neuro-2A cells were cotransfected with an HSV-1 ICP0 or 
ICP4 promoter construct plus an E2F1 expression plasmid, and CAT activity was 
measured.  Neuro-2A cells were use for this study because these cells are neuronal-like 
and thus it was of interest to begin to understand whether E2F regulates gene expression 
in neurons.  Furthermore, E2F1 over-expression is not as toxic in neuro-2A cells when 
compared to RS cells (data not shown).  The HSV-1 ICP0 promoter was activated only 3 
fold by E2F1 (Figure 4.2A).  The ICP4 promoter was consistently lower than basal 
activity when cotransfected with E2F1 (Figure 4.2A). 
 We next examined whether reducing E2F1 protein levels by the E2F1 specific 
siRNA had an effect on ICP0 and ICP4 basal promoter activity.  The HSV-1 promoter 
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constructs had high basal activity in neuro-2A cells compared to BHV-1 promoter 
constructs. Consequently, we may have underestimated the effects of E2F1 on ICP0 and 
ICP4 promoter activity.   Neuro-2A cells were cotransfected with the designated 
promoter-CAT construct and the E2F1 siRNA or a control siRNA (cont-si).  At 48 hours 
after transfection, cells were collected and CAT activity measured.  The E2F1 specific 
siRNA reduced ICP0 promoter activity approximately 60%: whereas the control siRNA 
did not reduce ICP0 promoter activity (Figure 4.2B).  The E2F1 siRNA reduced ICP4 
promoter activity by approximately 40%.  In contrast, the control siRNA reduced ICP4 
promoter activity less than 20% (Figure 2B).  
 Finally, we tested whether E2F1 had an effect on a panel of HSV-1 promoter-
luciferase constructs.  Of those examined, the early UL42 promoter was activated 
approximately 2.5 fold (Figure 4.2C).  UL42 encodes a protein that stimulates the viral 
DNA polymerase (Gottlieb and Challberg, 1994).  Since E2F1 activates expression of 
genes that are necessary for DNA replication (DeGregori et al., 1995), this result 
suggested that under certain conditions E2F1 may promote expression of certain viral 
genes that are necessary for DNA replication.  The late VP16 and gC promoters as well 
as the early ICP6 promoter were not activated by E2F1.  In summary, the HSV-1 
promoters we examined were not efficiently trans-activated by E2F1 in neuro-2A cells.  
 
Analysis of E2F1 protein levels during productive infection  
Previous studies demonstrated that E2F1 protein levels increased during BHV-1 
productive infection in bovine kidney cells (Workman and Jones, 2010).  Additional 
studies were performed to directly compare the effect of BHV-1 or HSV-1 productive 
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infection on E2F1 protein levels in RS cells.  RS cells were infected with BHV-1 or 
HSV-1 using a moi of 5 and whole cell lysate was collected at the designated times post-
infection.  Western blot analysis revealed that BHV-1 increased E2F1 protein levels by 
16 hours after infection {(Workman and Jones, 2010) and (Figure 4.3A)}.  Higher levels 
of E2F1 were detected in RS cell within 8 hours after infection with HSV-1 using a moi 
of 5 (Figure 4.3B).  When RS cells were infected with HSV-1 at a moi of 0.5 (Figure 
4.3C) or 0.1 (data not shown), enhanced E2F1 levels were not readily detected until 16 
hours after infection.  In RS cells, HSV-1 grows faster than BHV-1 at a moi of 0.5 or 
lower; however, the end point titers of BHV-1 and HSV-1 are similar when RS cells are 
infected with a moi of 0.5 or higher (data not shown).  We suggest that differences in the 
growth rate of the two viruses was the main reason why higher levels of E2F1 were 
detected in HSV-1 infected RS cells at 8 hours after infection.   
The E2F1 band detected after HSV-1 infection appeared to migrate differently 
compared to E2F1 after BHV-1 infection or in mock-infected cells (Figure 4.4A).  E2F 
can be phosphorylated and phosphorylation is crucial for regulating transcriptional 
activation, localization, and stability (Garcia-Alvarez et al., 2007; Real et al., 2010; Weei-
Chin L., 2011).  To test whether E2F1 was phosphorylated, whole cell extract from HSV-
1 infected cells was treated with calf intestinal alkaline phosphatase (CIAP) and then 
western blot analysis performed using an anti-E2F1 antibody (Figure 4.4B).  CIAP 
treatment resulted in a decrease in the electrophoretic mobility of E2F1 in RS cells 
(Figure 4.4B) suggesting the observed shift in E2F1 mobility after HSV-1 infection was 
the result of phosphorylation.  To visualize E2F1 in mock-infected cells, 200 ug of 
protein in the cell lysate was loaded versus 20 ug protein derived from infected samples.  
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Similar results were observed when comparing BHV-1 and HSV-1 infection in the 
human osteosarcoma cell line (U2OS) that is permissive for both viruses (data not 
shown).    
Additional studies were performed to examine E2F1 protein levels in primary 
human embryonic lung (HEL) fibroblasts after infection with HSV-1. The rationale for 
this study was to compare the results obtained in RS cells to a low passage human cell 
type.  Confluent cultures of HEL fibroblasts were infected with HSV-1 at a moi of 1 and 
whole cell lysate collected at the designated times (hours) after infection.  In HEL cells, 
HSV-1 infection increased the steady state E2F1 protein levels at 16 hours after infection 
(Figure 4.5A).  CIAP treatment resulted in a decrease in the electrophoretic mobility of 
E2F1 in HEL cells (Figure 4.5B).  In summary, both BHV-1 and HSV-1 increased E2F1 
protein levels, and HSV-1 infection led to novel changes in the phosphorylation status of 
E2F1 in RS and HEL cells.  
 
Analysis of E2F1 localization following infection.   
A previous study revealed that E2F1 remained localized to the nucleus following 
infection of bovine kidney cells with BHV-1 (Workman and Jones, 2010).  Conversely, 
E2F1 was reported to localize to the cytoplasm following HSV-1 infection of HeLa cells 
(Advani et al., 2000b).  Confocal microscopy suggested that a subset of E2F1 was 
localized to the cytoplasm of HSV-1 infected cells (data not shown).  To confirm these 
findings and to compare them to BHV-1 productive infection, biochemical fractionation 
studies were conducted in RS cells.  Two low moi, 0.1 or 0.5 pfu/cell, were used for the 
HSV-1 studies.  A moi of 5 pfu/cell was used for BHV-1 because BHV-1 does not grow 
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as quickly as HSV-1 in RS cells (data not shown).  Consistent with previous studies 
(Advani et al., 2000b), E2F1 was detected in the nuclear extract, but not the cytoplasm, of 
BHV-1 infected cells at 16 or 24 hours after infection (Figure 4.6A). At lower moi, E2F1 
was also detected in the nucleus of RS cells infected with BHV-1 (data not shown).  
Alternatively, E2F1 was detected in the nuclear and cytoplasmic extract following 
infection with HSV-1 for 16 hours regardless of whether the moi was 0.1 or 0.5 (Figure 
4.6B).  Eight hours after infection (moi of 0.1 and 0.5 pfu/ml) with HSV-1, E2F1 was 
primarily detected in the nucleus of infected cells.  As a control for nuclear proteins, we 
examined histone H3 and found, as expected, that histone H3 was detected only in the 
nucleus after infection (Figure 4.6A and B). 
 
Analysis of E2F-dependent transcription following infection 
 Studies in Figures 4.3-4.6 indicated that HSV-1 and BHV-1 increased E2F1 
protein levels, but these studies did not reveal whether E2F dependent transcription 
correlated with increased E2F1 protein levels.  Therefore, we examined the effect of 
BHV-1 or HSV-1 productive infection on E2F dependent transcription.  RS cells were 
initially transfected with a luciferase construct containing a minimal promoter with three 
consensus E2F binding sites (3xE2F) or the Cyclin D promoter (CycD).  Cells were then 
infected with BHV-1 or HSV-1 at a moi of 0.1, 0.5, or 5 for 24 hours.  BHV-1 infection 
increased 3xE2F promoter activity approximately 5 fold and CycD promoter activity 
approximately 4 fold in RS cells (Figure 4.7).  In contrast, HSV-1 had little or no effect 
on the 3xE2F promoter construct, and CycD promoter activity was consistently reduced.  
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These results indicated that E2F dependent transcription was stimulated following 
infection of RS cells with BHV-1, but not HSV-1.  
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DISCUSSION  
 In this study, we compared the effect that BHV-1 had on the cell cycle regulated 
transcription factor E2F1 versus HSV-1.  For these studies, we used a spontaneously 
immortalized rabbit skin cell line that supports productive infection of both viruses.  The 
studies clearly demonstrated that a siRNA directed against E2F1 reduced the plaque 
forming efficiency of HSV-1 (Figure 4.1) and BHV-1 (Workman and Jones, 2010).  For 
HSV-1, this was somewhat surprising because E2F dependent transcription was not 
activated after infection.  In this study and a previous study, we demonstrated that BHV-1 
infection induced E2F dependent transcription and binding to a probe containing E2F 
consensus binding sites (Workman and Jones, 2010).  We suggest that silencing E2F1 
prior to infection reduces the number of cells that are cycling, which consequently 
reduces the efficiency of productive infection.  This conclusion is supported by other 
studies demonstrating that cyclin dependent kinase inhibitors, roscovitine and olomucine, 
reduce HSV-1 virus replication and transcription (Schang et al., 1998; Schang et al., 
1999).  Roscovitine also efficiently reduces BHV-1 productive infection (data not 
shown). 
 Following infection with HSV-1, E2F1 appeared to be differentially 
phosphorylated and a fraction of the total E2F1 protein was localized in the cytoplasmic.  
In contrast, E2F1 was localized to the nucleus after BHV-1 infection, as judged by 
biochemical fractionation (Figure 4.6) and confocal microscopy (Workman and Jones, 
2010).  Since HSV-1 inactivated E2F dependent transcription, we suggest that 
phosphorylation of E2F1 promotes localization of E2F1 to the cytoplasm, resulting in a 
loss of E2F dependent transcription.  Inactivation of E2F1 by HSV-1 may be important 
117 
 
for efficient productive infection because E2F1 induces apoptosis following DNA 
damage (Nip et al., 1997).  HSV-1 encodes two protein kinases, US3 and UL13 that are 
packaged in the virion and tegument respectively (Chee et al., 1989; Frame et al., 1987; 
Purves et al., 1987; Smith and Smith, 1989).  Plasmids over-expressing the two viral 
kinases were cotransfected with E2F1 and there was no obvious changes in the mobility 
of E2F1 (data not shown) suggesting the viral encoded protein kinases do not directly 
phosphorylate E2F1.  E2F1 is directly phosphorylated by several cellular protein kinases, 
including glycogen synthase kinase-3, ATM (Ataxia telangiectasia mutated), and 
mitogen activated protein kinases (MAPK) (Garcia-Alvarez et al., 2007; Real et al., 2010; 
Weei-Chin L., 2011). MAPK and ATM protein kinases are activated by HSV-1 (Boutell 
and Everett, 2004; Corcoran et al., 2006; Hargett et al., 2005) suggesting that E2F1 may 
be phosphorylated by cellular protein kinases after infection.  It is not presently known 
whether BHV-1 infection induces MAPK or ATM protein kinases during the course of 
productive infection. 
Transcriptionally competent E2F family members are associated with a family of 
DP proteins (Helin et al., 1993) suggesting BHV-1 stimulates E2F dependent 
transcriptional activity by promoting interactions between E2F1 and DP family member.  
Conversely, HSV-1 may uncouple E2F1 dependent transcription by inactivating DP 
family members.  A recent study identified a novel DP family member (DP-4) in several 
human cell types that exhibits high levels of expression following DNA damage (Ingram 
et al., 2011).  Interestingly, DP-4 binds to E2F1 resulting in a complex that does not bind 
DNA.  Consequently, E2F1 does not induce apoptosis when associated with DP-4.  There 
is no commercially available DP-4 antibody, thus it is not possible to test whether DP-4 is 
118 
 
induced by HSV-1 infection in RS cells, or whether BHV-1 induces DP-4.  It will be of 
interest to examine the effect that HSV-1 has on DP-4 in human cells in the future.   
In summary, it was surprising to find that E2F dependent transcription was 
activated by BHV-1, but not HSV-1.  Activation of E2F dependent transcription appears 
to be important for BHV-1 productive infection because E2F1 and E2F2 strongly 
stimulate the bICP0 E promoter and to a lesser extent the IE promoter that controls 
expression of bICP0 and bICP4 (Geiser and Jones, 2003; Workman and Jones, 2010).  
We suggest that BHV-1 encodes or induces a protein that maintains E2F1 transcriptional 
activity during productive infection.  Conversely, HSV-1 may encode or induce a factor 
that prevents activation of E2F dependent transcription during productive infection.   
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Figure 4.1. Suppression of E2F1 reduced the levels of HSV-1 productive infection. 
Panel A: To test whether E2F-specific siRNA affected HSV-1 productive infection, RS 
cells were transfected with 100 nM E2F1 siRNA or 100 nM control siRNA for 24 hours, 
followed by transfection of HSV-1 genomic DNA as described in the methods.  Forty-
eight hours after transfection of genomic DNA cells were collected, subjected to three 
rounds of freeze/thaw cycles and plaque assays performed on RS cells.  The data is an 
average of three independent studies and the error bars are standard deviations.   
Panel B: To examine the effect of the siRNAs on cell cycle, RS cells were transfected 
with 100 nM E2F1 siRNA or 100 nM control siRNA. At 24 or 48 hours after 
transfection, cells were collected, fixed, stained and analyzed by flow cytometry as 
described in the methods section.  These studies are representative of at least three 
independent studies.   
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Figure 4.1. 
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Figure 4.2. Analysis of E2F1 transactivation of HSV-1 promoter constructs. 
Panel A: To examine the effect of E2F1 on HSV-1 promoters, neuro-2A cells were 
cotransfected with 1 μg of the designated promoter-CAT construct and 0.1 ug of the 
E2F1 expression plasmid. At 48 hours post-transfection, cells were collected and CAT 
activity measured. The data is an average of three independent studies and the error bars 
are standard deviations. 
Panel B: To test whether silencing E2F1 protein levels reduced basal activity of HSV-1 
promoters, neuro-2A cells were cotransfected with 1 μg of the designated promoter-CAT 
construct and 100 nM E2F1 siRNA or a control siRNA (contsi). At 48 hours post-
transfection, cells were collected and processed for CAT activity. The data is an average 
of three independent studies and the error bars are standard deviations. 
Panel C: Neuro-2A cells were cotransfected with 1 μg of the designated promoter-
luciferase construct and 0.1 μg of the E2F1 expression plasmid. At 48 hours post-
transfection, cells were collected and processed for luciferase expression. The data is an 
average of three independent studies and the error bars are standard deviations. 
pGL3basic is the promoterless luciferase construct. UL42 and ICP6 are early promoters 
while gC and VP16 are late promoters.  
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Figure 4.2. 
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Figure 4.3. Analysis of E2F1 protein levels during productive infection. 
The effect of BHV-1 or HSV-1 infection on E2F1 protein levels was measured by 
western blot analysis.  RS cells were infected with BHV-1 at a moi of 5 (Panel A), HSV-
1 at a moi of 5 (Panel B), or HSV-1 at a moi of 0.5 (Panel C) for the designated times 
after infection (hours). Cells were collected, lysed, and 100 μg of protein was analyzed by 
western blot using an E2F1 polyclonal antibody diluted 1:10,000. As a control, the blot 
was also probed with antiserum against -actin. Lanes M4 or M24 are 4, or 24 hours 
respectively after mock infection. 
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Figure 4.3. 
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Figure 4.4. Analysis of E2F1 protein levels in infected RS cells. 
 Panel A: Cell lysate prepared from RS cells infected with BHV-1 (moi of 5) or HSV-1 
(moi of 5) for 24 hours were separated on the same SDS-polyacrylamide gel to show 
mobility differences of E2F1.  
Panel B: To determine whether phosphorylation was responsible for the altered mobility 
of E2F1, 20 μg of protein derived from cell lysate prepared from RS cells infected with 
HSV-1 for 24 hours was treated (or not) with calf intestinal alkaline phosphatase (CIAP). 
As a control, 200 μg of mock-infected cells was analyzed.  More protein was loaded in 
the mock lane to readily visualize the E2F1-specific bands. 
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Figure 4.5. Analysis of E2F1 protein levels in primary human lung fibroblasts. 
Panel A: Low passage human embryonic lung fibroblasts (HEL) were infected with 
HSV-1 at a moi of 1 for the designated times after infection (hours).  Cells were 
collected, lysed, and 100 μg of protein analyzed by western blot using an E2F1 
polyclonal antibody diluted 1:10,000.  As a control, the blot was also probed with 
antiserum directed against -actin. 
Panel B: Twenty μg of protein from the sample at 24 hours after infection of HEL cells 
were treated (or not) with calf intestinal alkaline phosphatase (CIAP) and ran next to 200 
μg of cell lysate from mock-infected cells.  More protein was loaded in the mock-infected 
lane (lane M) to visualize E2F1.  
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Figure 4.6.  Localization of E2F1 after infection with BHV-1 or HSV-1. 
Panel A: RS cells were infected with BHV-1 at a moi of 5 for 16 or 24 hours. Cells were 
then harvested and cell fractionation conducted as described in the methods section. 
Cytoplasmic and nuclear fractions (100 μg) were analyzed by western blot using an E2F1 
polyclonal antibody diluted 1:10,000.  As a control for proteins that are in the nucleus, 
the respective fractions were probed with an antibody directed against Histone H3 
(abcam) that was diluted 1:500. 
Panel B: RS cells were infected with HSV-1 at a moi of 0.1 or 0.5 for 8 or 16 hours. 
Cellular fractions were analyzed as described in panel A. Lane M was cell lysate derived 
from mock-infected cells.   
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Figure 4.7. Activity of E2F-responsive promoters following BHV-1 or HSV-1 
infection. 
 RS cells were transfected with 1 μg of the designated promoter-luciferase 
construct (a promoter containing 3 consensus E2F1 binding sites: 3xE2F or the cyclin D 
promoter: CycD). Twenty-four hours after transfection, cells were infected with BHV-1 
or HSV-1 at a moi of 0.1, 0.5 or 5. At 24 hours after infection, cell lysate was collected 
and luciferase activity measured. The results are the average of 3 independent 
experiments. The data is an average of three independent studies and the error bars are 
standard deviations.   
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Chapter 5 
 
A Protein (ORF2) Encoded by the Latency Related Gene of Bovine Herpesvirus 1 
Interacts with Notch1 and Notch3. 
 
 
These studies are included in a manuscript published in 2011 in the Journal of virology, 
volume 85, pages 2536-2546. 
 
The authors of this manuscript are Aspen Workman, Devis Sinani, Daraporn 
Pittayakhajonwut, and Clinton Jones 
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ABSTRACT 
  
Like other alpha-herpesvirinae subfamily members, bovine herpes virus 1 (BHV-1) 
establishes latency in sensory neurons.  The latency-related RNA (LR-RNA) is 
abundantly expressed in latently infected sensory neurons.  A LR mutant virus with stop 
codons at the amino-terminus of the first ORF in the LR gene (ORF2) does not reactivate 
from latency, in part, because it induces higher levels of apoptosis in infected neurons. 
ORF2 is not the only viral product expressed during latency, but it is important for the 
latency-reactivation cycle because it inhibits apoptosis.  In this study, a yeast 2-hybrid 
screen revealed ORF2 interacted with two cellular transcription factors, Notch1 and 
Notch3.  These interactions were confirmed in mouse neuroblastoma cells by confocal 
microscopy, and in an in vitro “pull down” assay.  During reactivation from latency, 
Notch3 RNA levels in trigeminal ganglia were higher compared to latency suggesting 
Notch family members promote reactivation from latency or reactivation promotes Notch 
expression.  A plasmid expressing the Notch1 intercellular domain (ICD) stimulated 
productive infection and promoters that encode the viral transcription factor (bICP0). 
Notch3 ICD did not stimulate productive infection as efficiently as Notch1 ICD and had 
no effect on bICP0 promoter activity.  Plasmids expressing the Notch1 ICD or Notch3 
ICD trans-activated a late promoter encoding glycoprotein C.  ORF2 reduced the trans-
activation potential of Notch1 and Notch3 suggesting ORF2 interfered with the trans-
activation potential of Notch.  These studies provide evidence that ORF2, in addition to 
inhibiting apoptosis, has the potential to promote establishment and maintenance of 
latency by sequestering cellular transcription factors. 
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INTRODUCTION 
 Bovine herpesvirus 1 (BHV-1) is an alpha-herpesvirinae subfamily member that 
causes significant economical losses to the cattle industry (Turin et al., 1999).  The ability 
of BHV-1 to suppress the immune system can result in life-threatening pneumonia due to 
secondary bacterial infections, and this multi-factorial disorder is known as bovine 
respiratory disease complex {reviewed in (Jones, 2009; Jones, 2008; Workman, 2010b)}.  
Like other human alpha-herpesvirinae subfamily members, the primary site for BHV-1 
latency is sensory neurons within trigeminal ganglia (TG).  Viral gene expression 
(Schang and Jones, 1997) and infectious virus (Inman, 2002) are detected in TG from 1-6 
d after infection, but latency is then established.  Stress (due to confinement, transporting 
cattle, restricting food and water, or weaning) increases corticosteroid levels, and can 
initiate reactivation from latency (Workman et al., 2009).  Administration of a synthetic 
corticosteroid, dexamethasone (DEX), to calves or rabbits latently infected with BHV-1 
reproducibly leads to reactivation from latency, as judged by virus shedding from ocular 
or nasal cavities and a secondary antibody response (Inman et al., 2002; Jones, 1998; 
Jones, 2003a; Jones et al., 2006; Jones et al., 2000; Rock et al., 1992).  Induction of lytic 
cycle viral gene expression is also consistently detected in TG neurons of calves latently 
infected with BHV-1 following DEX treatment.    
Many alpha-herpesvirinae subfamily members, including human herpes simplex 
virus type 1 (HSV-1) and HSV-2, express abundant levels of a latency-associated 
transcript (Prbhakaran) during latency {reviewed by (Jones, 1998; Jones, 2003a; Perng 
and Jones, 2010)}.  The BHV-1 latency related (LR) gene, which is in a similar genomic 
position as LAT, expresses an abundant transcript (LR-RNA) in latently infected sensory 
136 
 
neurons (Rock et al., 1987a; Rock and Mayfield, 1987).  LAT and the LR gene are 
antisense with respect to an important viral transcriptional regulator, ICP0 or bICP0 
respectively, suggesting they reduce the levels of ICP0 or bICP0.  A mutant BHV-1 strain 
with 3 stop codons at the N-terminus of ORF-2 (LR mutant virus) does not express ORF-
2 or RF-C (Jiang et al., 2004) but it expresses reduced levels of ORF1 (Meyer et al., 
2007b).  The LR mutant virus does not reactivate from latency following DEX treatment 
(Inman et al., 2002) suggesting that expression of LR proteins regulates the latency-
reactivation cycle.  Insertion of the LR gene into a HSV-1 LAT null mutant increases the 
frequency of reactivation from latency (Mott et al., 2003; Perng et al., 2002) indicating 
that the LR gene can substitute for LAT functions in small animal models of infection.  
Although LR gene products or LAT are important for the latency-reactivation cycle, it is 
not clear whether they directly participate in reactivation from latency or if they promote 
establishment and/or maintenance of latency.    
The LR gene encodes more than one product that may be important for the 
latency-reactivation cycle.  For example, the LR gene contains two-well defined ORFs 
(ORF2 and ORF1; Figure 5.1) and two reading frames that lack an initiating methionine 
(RF-B and RF-C).  As a result of alternative splicing of polyA+ LR-RNA in TG of 
infected calves (Devireddy and Jones, 1998; Devireddy et al., 2003), ORF2 can be fused 
with ORF1 protein coding sequences (7 dpi cDNA) or RF-B (15 dpi cDNA).  At 1 day 
after infection of calves and during latency, splicing occurs in TG such that ORF2 is 
intact (Figure 1).  Two micro-RNAs that are expressed during latency are located 
upstream of ORF2 (Jiang et al., 2004; Meyer et al., 2007b; Shen et al., 2009).  LR gene 
products inhibit cell proliferation, bICP0 RNA expression (Bratanich and Jones, 1992; 
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Geiser et al., 2002; Schang et al., 1996; Shen et al., 2009), and apoptosis (Ciacci-Zanella 
et al., 1999).  The LR mutant virus induces higher levels of apoptosis in TG neurons of 
infected calves during establishment of latency (Lovato et al., 2003), and plasmids with 
the same stop codon mutations exhibit little or no anti-apoptosis activity (Ciacci-Zanella 
et al., 1999; Henderson et al., 2004a).  ORF2 coding sequences inhibit apoptosis in 
transiently transfected cells (Shen and Jones, 2008) suggesting ORF2 is the most 
important function encoded by the LR gene in the context of the latency-reactivation 
cycle.  
 Notch receptor family members (Notch1-4) are membrane tethered transcription 
factors that regulate numerous developmental and physiological processes (Bray, 2006; 
Ehebauer et al., 2006b).  For example, Notch promotes neuronal maintenance, 
development, and differentiation (Berezovska et al., 1999; Cornell and Eisen, 2005; 
Justice and Jan, 2002).  Notch3 and Notch1 (Nair et al., 2003; Sade et al., 2004) promote 
cell survival by activating a protein kinase, AKT, that inhibits apoptosis.  Other studies 
have concluded that Notch family members induce apoptosis (Bray, 2006; Ehebauer et 
al., 2006a) suggesting Notch influences cell survival in a cell-type dependent fashion.  
When the Notch receptor is engaged by one of its five transmembrane ligands (Jagged1, 
Jagged2, Delta-like1, Delta-like3, or Delta-like4), the Notch intracellular domain (ICD) is 
cleaved by specific proteases, and is subsequently translocated to the nucleus.  The Notch 
ICD interacts with members of the CSL family of transcriptional repressors, CBF1, 
Su(H), or Lag1 (also referred to as RBPj binding proteins).  In general, the Notch ICD-
CSL complex binds to specific DNA sequences in certain promoters and subsequently 
activates genes that regulate growth, cell survival, and differentiation (Bray, 2006; 
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Ehebauer et al., 2006a).  
In this study, we provide evidence that ORF2 interacts with Notch3 and Notch1 
proteins.  Additional studies suggest that Notch family members promote reactivation 
from latency or reactivation from latency activates the Notch signaling pathway.  For 
example, the Notch1 ICD stimulates productive infection; Notch1 protein expression 
increased during the course of productive infection, ands Notch1 ICD trans-activated the 
bICP0 immediate early and early promoters.  Notch1 and Notch3 trans-activated a late 
BHV-1 promoter, glycoprotein C (gC).  In addition, ORF2 interfered with the ability of 
the Notch1 or Notch3 ICD to trans-activate the bICP0 E and gC promoters.  Finally, 
during DEX-induced reactivation from latency, Notch3 RNA levels in TG were higher 
compared to that during latency.  
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MATERIALS AND METHODS 
Cells and viruses  
 Murine neuroblastoma cells (neuro-2A), rabbit skin cells (RS), and CRIB (bovine 
kidney) cells were grown in Earle’s modified Eagle’s medium (EMEM) supplemented 
with 5% FCS, penicillin (10 U/ml), and streptomycin (100 μg/ml). 
 The Cooper strain of BHV-1 was obtained from the National Veterinary Services 
Laboratory, Animal and Plant Health Inspection Services, Ames, Iowa. Stock cultures of 
BHV-1 were prepared in CRIB cells.  A BHV-1 mutant containing the Lac Z gene in 
place of the gC gene was obtained from S. Chowdury (Baton Rouge, LA) (gCblue virus).  
The virus grows to similar titers as the wild type virus and expresses the Lac Z gene as a 
true late gene.  
 
Plasmids 
 The construction and characteristics of the bICP0 E promoter-CAT 
(chloramphenicol acetyltransferase) constructs (EP-172, EP-143, EP-133, EP-71, EP-50, 
and EP-42) used in this study were described previously (Workman and Jones, 2010; 
Workman et al., 2009).  The numbers in the plasmid name refer to the length of the 
bICP0 E promoter fragment cloned into the promoterless vector, pCAT-basic.  
 The mammalian ORF2 construct was described previously (Shen and Jones, 
2008).  Briefly, sequences derived from cDNA at 1 day post infection (dpi) were cloned 
into pCMV-Tag-2B (Stratagene, La Jolla, CA) downstream of a Flag epitope using 
BamHI-HindIII restriction enzymes. ORF2 was also codon-optimized for bacterial 
expression and synthesized by IDT (Coralaville, IA).  XhoI and HindIII restriction 
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enzyme sites were introduced at 5’ and 3’ ends of the ORF2 gene, respectively.  The 
ORF2 fragment was cleaved with XhoI and HindIII and subsequently ligated in frame 
into similar sites of a polyhistidine tag within the vector pRSET-A (Invitrogen, USA).   
 Constructs containing Notch1 ICD or Notch3 ICD were cloned into a human 
cytomegalovirus expression construct.  These constructs were gifts from U. Lendahl, 
Karolinska Institute, Sweden (Lardelli et al., 1996).   
 The bICP0 plasmid contains the bICP0 coding sequence under control of the 
human cytomegalovirus (CMV) promoter and was described previously (Inman et al., 
2001b).  The empty vector pcDNA3.1 was purchased from Invitrogen. 
 
Yeast 2-hybrid analysis 
 The yeast 2-hybrid analysis was performed by Hybrigenics (France) using ORF2 
as the prey.  The screen was performed using a mouse cDNA library from brain as bait.   
 
CAT reporter assays  
 Neuro-2A cells grown in 60 mm dishes were co-transfected with the designated 
plasmids as indicated in the respective figure legends using with TransIT Neural 
according to the manufacturer’s instructions.  After 48 hours, cell extract was prepared by 
three freeze/thaw cycles in 0.25 M Tris-HCl, pH 7.4.  Cell debris was pelleted by 
centrifugation, and protein concentration determined. CAT activity was measured in the 
presence of 0.1 uCi {
14
C-chloramphenicol} (CFA754; Amersham Biosciences) and 0.5 
mM Acetyl-CoA (A2181; Sigma).  The reaction was incubated at 37
o
 C for 15 minutes to 
1 hour.  All forms of chloramphenicol were separated by thin-layer chromatography. 
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CAT activity in 50-ug cell lysate was quantified using a Bio-Rad Molecular Imager FX 
(Molecular Dynamics, CA).  Levels of CAT activity are expressed as fold induction 
relative to the vector control. 
 
-gal assay 
 The gCblue virus grows to similar titers as wt BHV-1 and was grown in CRIB 
cells.  Procedures for preparing BHV-1 genomic DNA were described previously. RS 
cells grown in 6 well plates were cotransfected with 0.83 ug of the gCblue viral genome 
and the designated amounts of plasmid expressing bICP0, Notch1 ICD, or Notch3 ICD 
using Lipofectamine 2000 (11668-019; Invitrogen).  Twenty-four hours after 
transfection, cells were fixed (2% Formaldehyde, 0.2% Glutaraldehyde in PBS) and the 
number of -gal+ cells counted as described previously (Workman and Jones, 2010). The 
number of -gal+ cells in cultures expressing the blank vector was set to 100%.  The 
number of blue cells in cultures transfected with the blank vector to calculate fold 
difference divided the number of blue cells in cultures transfected with bICP0 or Notch.  
The results are an average of three independent experiments.   
 
RNA preparation and Reverse Transcription 
 Neuro-2A cells were cultured in the presence of 1 uM dexamethasone (D2915; 
Sigma) for the indicated amounts of time.  Total RNA was prepared from cells using 
TRIzol reagent (Life Technologies, USA) as previously described (Workman and Jones, 
2010).  Three micrograms of RNA were treated with Amplification Grade DNAse I 
(Invitrogen, USA).  Reverse Transcription (RT) was performed using SuperScript III 
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Reverse Transcriptase (Invitrogen, USA) according to the manufacturer's directions.  
RNA was reverse transcribed using oligo(dT) primers (Invitrogen, USA).  A 100 ng of 
the resulting cDNA were used as a template
 
for PCR using specific primers for Notch.  
PCR was performed using GoTaq
 
DNA Polymerase (Promega, USA) and initiated at 95° 
C for 5 min. 
  
This was followed by 30 cycles of 95° C for 45 seconds, 55° C (Notch3) or 
65° C (Notch1) for 45 seconds, and 72° C for 45 seconds.  Final extension was at 72° C 
for 10 minutes.  PCR products were analyzed on a 1.2% agarose gel. The following
 
primer sequences were used for Notch:  
Notch1 forward 5’-TCCTACCTCTGCTTATGCCTCAAG-’3,  
Notch1 reverse 5’-GTATCCAGCGACATCATCAATGC-’3,  
Notch3 forward 5’-GCTTTGGTCTGCTCAATCCTGTAG-3’,  
Notch3 reverse 5’-TTGGGGGTAACTTCTGGTTGG-3’.  
GAPDH was used as a control for equivalent sample loading (forward primer; 5’ 
CCATGGAGAAGGCTGGGG-‘3, reverse primer; 5’CAAAGTTGTCATGGATGACC-
‘3.   
TG from BHV-1-infected calves was collected at necropsy at 60 days after infection and 
at 6 or 24 hours after DEX treatment.  TG was stored at -80
o 
C for nucleic acid extraction. 
TG were minced into small pieces, placed into 3 ml of TRIzol reagent, and processed as 
stated above.  
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RESULTS 
Notch1 and Notch3 interacted with ORF2 in a yeast two-hybrid screen.   
We previously found that a protein encoded by an alternatively spliced LR 
transcript (7 dpi cDNA) interacts with a cellular transcription factor, c/EBP-alpha (Meyer 
et al., 2007b).  The protein encoded by the 7 dpi cDNA is a fusion between ORF2 and 
ORF1 (Devireddy and Jones, 1998; Devireddy et al., 2003) (Figure 5.1).  Approximately 
2/3 of this fusion protein is derived from ORF1.  Recent studies have demonstrated that 
just ORF2 aa sequences (Figure 5.1) reduces cold-shock induced apoptosis in transfected 
mouse neuroblastoma cells (neuro-2A) (Shen and Jones, 2008).  The LR mutant virus 
does not express LR proteins, including ORF2, (Jiang et al., 2004) and induces higher 
levels of apoptosis in TG neurons during late stages of acute infection (Lovato et al., 
2003) indicating that the anti-apoptosis functions of ORF2 are important for the latency-
reactivation cycle.  Consequently, we were interested in identifying cellular proteins that 
interact with just ORF2.  To this end, a yeast two-hybrid assay was performed using only 
ORF2 sequences.  Multiple clones of Notch3 and Notch1 were identified in the yeast 
two-hybrid screen suggesting that ORF2/Notch interactions were stable.  Additionally, 
ORF2 was found to co-localize with Notch 1 and Notch 3 when overexpressed in neuro-
2A cells and ORF2 was able to interact with Notch1 and Notch3 using an in vitro in pull 
down assay (Workman et al., 2011).  Since Notch family members regulate many 
developmental processes (Berezovska et al., 1999; Cornell and Eisen, 2005; Justice and 
Jan, 2002), we focused our studies on the interactions between ORF2 and Notch1 or 
Notch3, and whether Notch family members have the potential to regulate productive 
infection.    
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DEX increases steady state levels of Notch RNA in neuro-2A and TG of latently 
infected calves 
We previously found that the protein encoded by the 7 dpi cDNA interacted with 
C/EBP-alpha, a cellular transcription factor, and C/EBP-alpha expression was stimulated 
during DEX induced reactivation from latency (Meyer et al., 2007b).  To examine 
Notch1 and Notch3 RNA expression in TG, we performed RT-PCR with RNA samples 
prepared from TG of latently infected calves or latently infected calves treated with DEX 
to initiate reactivation from latency.  In TG of calves treated with DEX, Notch3 RNA 
levels were induced at 6 and 24 hours after DEX treatment (Figure 5.2A).  Notch1 levels 
were increased slightly 24 hours after DEX treatment (Figure 5.2B). 
C/EBP-alpha RNA levels are also stimulated by DEX treatment in neuro-2A cells 
(Workman et al., 2009).  Thus, it was of interest to compare Notch expression in neuro-
2A cells after DEX treatment.  Following treatment of neuro-2A cells with DEX, Notch1 
levels, but not Notch3, cDNA levels were increased 8 hours after DEX treatment (Figure 
5.2C and D).  Notch3 RNA levels were elevated slightly at 40 hours after DEX treatment 
(Figure 5.2C).  GAPDH levels remained the same after DEX treatment, which was 
expected.  
 
Effect of Notch on productive infection 
Studies in Figure 2 demonstrated that in TG of calves latently infected with BHV-
1 DEX treatment led to increased Notch3 RNA levels and to a lesser extent Notch1.  
Since DEX stimulates BHV-1 reactivation from latency {reviewed in (Jones, 2003b; 
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Jones, 2008)}, we speculated that Notch family members regulate certain aspects of 
productive infection. 
To test whether Notch1 or Notch3 regulated productive infection, rabbit skin cells 
(RS) were cotransfected with increasing concentrations of a plasmid expressing the 
Notch1 or Notch3 ICD with the BHV-1 gCBlue virus and the efficiency of productive 
infection measured.  The gCblue virus contains the Lac Z gene downstream of the gC 
promoter, which allows one to measure productive infection by counting -Gal+ (beta-
galactosidase positive) cells.  The number of -Gal+ cells directly correlates with plaque 
formation (Geiser et al., 2002; Geiser and Jones, 2003; Inman et al., 2001b; Meyer et al., 
2007b).  The gCblue virus grows to similar titers as wt BHV-1 in bovine cells (Geiser et 
al., 2002; Geiser and Jones, 2003; Inman et al., 2001b; Meyer et al., 2007b).  RS cells 
were used for these studies because they are permissive for BHV-1 and they do not 
express high levels of Notch proteins.  At 24 hours after transfection, Notch1 (52, 210, 
830, or 2000 ng plasmid DNA) significantly increased (p< 0.05) the number of -Gal+ 
cells relative to the empty vector (pcDNA3.1; Figure 5.3A, open columns).  In contrast, 
only the highest concentration of Notch3 (2000 ng plasmid DNA) significantly increased 
(p< 0.05) the number of -Gal+ cells compared to pcDNA3.1 (Figure 5.3A, black 
columns).  As expected, bICP0 (Geiser et al., 2002; Geiser and Jones, 2003; Inman et al., 
2001b; Meyer et al., 2007b) increased the number of -Gal+ cells.  
During productive infection of RS cells, we observed an increase in Notch1 
proteins levels (Figure 5.3B).  By 4 or 8 hours after infection, we detected higher levels 
of Notch1 protein levels when compared to mock infected cells.  The size of the Notch1 
specific band was the predicted size of Notch1 ICD (Bray, 2006; Ehebauer et al., 2006b) 
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suggesting productive infection stimulated the Notch1 signaling pathway.  Confocal 
microscopy confirmed that higher levels of Notch1 were detected in the nucleus of 
infected cells (data not shown), which supported the finding that Notch1 ICD protein 
levels were higher in RS cell after infection.  As expected, -actin protein levels did not 
increase after infection.  We also examined Notch3 protein levels during the course of 
productive infection, but the results were inconclusive (data not shown).  
 
Notch1 ICD induces bICP0 promoter activity. 
Additional studies were performed to test whether Notch1 or Notch3 trans-
activated the immediate early transcription unit 1 (IEtu1) promoter or bICP0 early (E) 
promoter.  Neuro-2A cells were used for these studies because they are neuronal like 
cells and they do not express detectable levels of Notch1 or Notch3 proteins.  The IEtu1 
promoter activates immediate early expression of two transcripts, IE2/9 and IE/4.2, which 
encode the transcriptional regulatory proteins bICP0 and bICP4 respectively (Wirth et al., 
1992; Wirth et al., 1991) (see Figure 5.4A for a schematic of the IEtu1 region).  Although 
the largest IETu1 promoter construct was not trans-activated by Notch1 or Notch3, the 
two smaller constructs (∆1024 IEtu1 or ∆1391 IEtu1) were trans-activated by Notch1 
approximately 3 fold or 5 fold respectively (Figure 5.4B), which was significantly 
different than the pCATbasic values (p< 0.05).  Basal promoter activity of IEtu1cat was 
more than 20 fold higher than IEtu1cat∆1391 in neuro-2A cells suggesting that Notch1 
activation was only evident when basal levels of the IEtu1 promoter activity were low. 
Alternatively, upstream sequences may have a negative impact of Notch induced trans-
activation.  Notch3 did not stimulate any of the IEtu1 promoter constructs, but 
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consistently reduced the promoter activity of ∆1024 IEtu1 or ∆1391 IEtu1 approximately 
2 fold.   
The bICP0 E promoter also activates bICP0 expression (Wirth et al., 1992) (see 
Figure 5.4A for location of the bICP0 E promoter).  Recent studies concluded that the 
bICP0 E promoter is preferentially stimulated during reactivation from latency 
(Workman et al., 2009).  Three bICP0 E promoter constructs (EP-172, EP-143, and EP-
133) were stimulated approximately 13 fold by Notch1, but not Notch3 (Figure 5.5A).  
Conversely, EP-71, EP-50, and EP-42 were not trans-activated more than 4 fold by 
Notch1 or Notch3.  Sequences that are present in EP-133, but lacking in EP-71, were 
important for Notch1 trans-activation and basal activity.  Conversely, the additional 
sequences in EP-172 played no role in Notch1 trans-activation, but these sequences 
enhanced basal promoter activity of EP-172 approximately 2 fold relative to EP-133.  In 
summary, these studies demonstrated that Notch1 trans-activated the IEtu1 and bICP0 E 
promoter.   
 
ORF2 inhibits Notch induced trans-activation  
Since ORF2 interacted with Notch1 and Notch3 ICD, we tested whether ORF2 
affected trans-activation of the bICP0 E promoter by Notch1.  The ORF2 plasmid that 
expresses the ORF2 protein (ORF2 B) reduced the ability of Notch1 to trans-activate EP-
172 promoter activity approximately 4 fold (Figure 5.5B), which was significantly 
different than the trans-activation value of Notch1 (p< 0.05).  Conversely, the ORF2B 
construct had no effect on EP-172 promoter activity, in the absence of Notch1.  We also 
examined a construct that was cloned such that the ORF2 protein is not expressed, but 
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LR-RNA is expressed, because it is not in frame with the FLAG tag (ORF2 C) (Shen and 
Jones, 2008).  Relative to the ORF2 B construct, the ORF2 C construct reduced trans-
activation of EP-172 by Notch1 less than 2 fold, which was not significantly different 
than the trans-activation value of Notch1 alone.  
 
Notch1 and Notch3 ICD stimulate a viral late promoter 
To further examine the ability of Notch1 and Notch3 ICD to regulate viral 
transcription, we tested whether a late promoter, glycoprotein C (gC), could be trans-
activated by Notch1 or Notch3 ICD.  For these studies, we used three gC promoter 
constructs, which were previously described (Zhang et al., 2006) (Figure 5.6A).  As 
expected, deletion of the gC promoter sequences led to reduced the basal promoter 
activity.  In neuro-2A cells, a plasmid expressing Notch1 ICD trans-activated the smallest 
gC promoter construct (gC-PstI-CAT) 10 fold whereas it stimulated the larger constructs 
less efficiently (Figure 5.6A).  The Notch3 ICD expressing plasmid stimulated gC-CAT 
approximately 8 fold, but lower levels of trans-activation were observed with the two 
smaller constructs (gC-XhoI-CAT and the gC-PstI-CAT). 
Although ORF2 reduced the ability of Notch1 ICD to trans-activate the gC-CAT 
promoter approximately 2 fold (Figure 5.6B), expression of ORF2 (ORF2B) had little 
effect on basal promoter activity.  The ability of ORF2 to inhibit gC promoter activity 
was not as efficient as observed with the bICP0 E promoter (Figure 5.5B).  The ORF2 
construct that was out of frame (ORF2C) had little effect on Notch1 ICD trans-activation 
(Figure 5.6B).  Likewise, ORF2 inhibited the ability of Notch3 ICD to trans-activate gC-
PstI-CAT promoter activity approximately 2 fold, but the ORF2B construct had little 
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effect on basal promoter activity.  ORF2B, but not ORF2C, significantly reduced the 
levels of Notch1 and Notch3 trans-activation (p< 0.05).  In summary, these studies 
demonstrated that Notch1 and Notch 3 ICD stimulated gC promoter activity, and that 
ORF2 protein expression reduced Notch trans-activation. 
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DISCUSSION 
Several lines of evidence presented in this study indicated that ORF2 interacted, 
directly or indirectly, with Notch1 and Notch3.  To the best of our knowledge, this is the 
first example of a protein encoded by a herpesvirus member that directly interacts with a 
Notch family member.  Notch family members control the developmental pathway of 
many cell types in mammals and Drosophila {reviewed in (Bray, 2006; Ehebauer et al., 
2006b)}.  A previous study demonstrated that a protein encoded by the alternatively 
spliced LR transcript (7 dpi cDNA) interacts with C/EBP-alpha, a cellular transcription 
factor (Meyer et al., 2007b).  In the previous two-hybrid screen, we did not detect an 
interaction between Notch1 or Notch3 and the protein encoded by the 7 dpi cDNA 
(Devireddy and Jones, 1998; Devireddy et al., 2003).  Since the protein encoded by the 7 
dpi cDNA contains 2/3 of its aa sequences from ORF1 and the rest from ORF2, the two-
hybrid screen likely detected cellular proteins that interacted with ORF1 sequences.  
These findings also suggested that alternative splicing of LR-RNA in TG of infected 
cattle leads to expression of a family of LR protein.  The LR family of proteins is 
predicted to interact with different cellular proteins, and perform specific functions 
during the latency-reactivation cycle.   
Eleven known consensus binding sites for CSL (RBP-jk)  (Persson and 
Wilson, 2010).  The BHV-1 genome contains 82 potential binding sites for CSL, of 
which 23 are located in non-coding regions (Figure 5.7A).  Interestingly, six CSL binding 
sites are near the 5’ terminus of bICP4 and bICP22 (Figure 5.7B).  We suggest that CSL 
binding sites in the BHV-1 genome were partially responsible for the ability of Notch1 to 
stimulate productive infection.  Further support for Notch stimulating productive 
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infection comes from the finding that the Notch1 ICD trans-activated the bICP0 E 
promoter, the IEtu1 promoter, and certain gC promoter constructs.  With respect to the 
IEtu1 promoter, we observed higher levels of trans-activation with the smallest promoter 
fragment (IEtu1cat∆1391; Figure 5.4B).  All three promoter constructs are efficiently 
trans-activated by b-TIF, the BHV-1 functional homologue of VP16.  The basal activity 
of IEtu1cat was higher than ∆1024 IETu1 or ∆1391 IEtu1 basal promoter activity (Figure 
5.4A), suggesting the high basal activity of IEtu1cat masked the trans-activation of Notch 
1.  Conversely, it is possible that upstream sequences within the IEtu1 promoter have a 
negative impact on Notch1 induced trans-activation.  The Notch1 responsive domain 
within the bICP0 E promoter was localized to 62 bases present in EP-133, but lacking in 
EP-71 (Figure 5.5A).  Within these 62 bases, there are no identical matches to known 
CSL binding sites. However, there are 8 CSL-like motifs that contain mismatches in 2 
bases. This may be significant because a recent report concluded that over-lapping CSL-
like binding sites can confer Notch responsiveness dependent on dimerization of Notch 
family members (Liu et al., 2010).  Additional studies will be necessary to identify the 
cis-acting sequences in the bICP0 E, IEtu1, or gC promoter that are necessary for Notch 
trans-activation and whether activation is by a direct mechanism.  
In the absence of Notch family members, CSL binding proteins interact with 
transcriptional repressors (Borggrefe and Oswald, 2009), including the histone 
demethylase KDM5A (Liefke et al., 2010).  These findings suggest that CSL binding 
proteins may help maintain latency by recruiting transcriptional repressor complexes to 
the BHV-1 genome.  During the course of DEX-induced reactivation, increased 
expression levels of Notch family members may result in the displacement of repressors 
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from the BHV-1 genome.  Micro-array analysis revealed that several genes in the Notch 
signaling pathway, including the proteases that cleave and activate Notch, are stimulated 
in TG of latently infected calves following DEX treatment for 6 hours (unpublished data) 
adding further support to the concept that the Notch signaling pathway is activated during 
early stages of reactivation from latency.  Productive infection also activates the Notch1 
signaling pathway because we detected higher levels of Notch1 ICD after infection, 
which correlated with the finding that Notch1 stimulated productive infection.  Although 
we believe the Notch signaling pathway may promote reactivation from latency, it is 
unlikely that Notch family members are the only cellular transcription factors that 
stimulate reactivation from latency.   
Notch3 had little or no effect on the bICP0 E promoter or the IEtu1 promoter, and 
stimulated productive infection only two fold.  The finding that Notch3 RNA levels were 
induced within 6 hours after DEX treatment and Notch3 trans-activated a late promoter 
(gC) suggested that Notch3 has different effects on productive infection relative to 
Notch1.  In keeping with these observations, Notch3 is known to possess novel functions 
when compared to other Notch family members.  For example, the Y box protein-1 is a 
novel ligand that specifically binds to Notch3 (Rauen et al., 2009).  Furthermore, the 
Notch3 ICD is generally considered to be a poor activator of transcription (Beatus et al., 
1999), which partially explains why it did not efficiently stimulate productive infection.  
Thirdly, mutations in Notch3 are the cause of cerebral autosomal dominant arteriopathy 
with subcortical infarcts and leukoencephalopathy (CADASIL), a hereditary angiopathy 
that causes stroke and vascular dementia (Dichgans et al., 2001).  Fourth, Notch3 is 
differentially expressed relative to Notch1 in the developing nervous system (Ichinohe, 
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2004).  Finally, Notch1 and Notch 2 knockout mice die during embryogenesis (Conlon et 
al., 1995; Swiatek et al., 1994), whereas Notch3 knockout mice are viable and do not 
apparently have redundant functions compared to the Notch1 gene (Krebs et al., 2003).  
Consequently, we predict that the novel properties of Notch3 promoted gC promoter 
activity, and perhaps expression of additional late genes.  
The Notch signaling pathway is known to play a role in the latency-reactivation 
cycle of two human herpesviruses, KSHV (Kaposi’s sarcoma-associated herpesvirus) 
(Liang et al., 2002) and EBV (Epstein Barr virus) (Strobl et al., 1997).  In contrast to the 
finding that Notch itself plays a role in the BHV-1 latency-reactivation cycle, the CSL 
family of proteins (RBP-Jk) is the key component of the Notch signaling pathway that 
participates in the latency-reactivation cycle of EBV and KSHV.  For example, RBP-
protein RTA (replication and transcriptional activator) (Liang et al., 2002).  Conversely, 
EBNA2 (EBV nuclear antigen 2) interacts with RBP-Jk and trans-activates two EBV 
promoters that encode 7 proteins necessary for stabilizing the EBV genome, stimulating 
B cell growth, inhibiting B cell apoptosis, and consequently promoting Latency III (Kieff 
et al., 1971).  Notch ICD cannot entirely replace RTA to reactivate KSHV latency 
(Carroll et al., 2006; Chang et al., 2005; Liang et al., 2002) or EBNA-2 for establishing 
and maintaining Latency III (Gordadze et al., 2001; Strobl et al., 1997).  Although KSHV 
and EBV usurp the Notch signaling pathway, they do not appear to encode a protein that 
physically interacts with Notch family members, and negatively regulates Notch-
dependent transcription.   
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Since LR gene expression, and presumably ORF2 expression, is dramatically 
reduced during DEX induced reactivation from latency (Rock et al., 1992), ORF2 does 
not appear to directly stimulate reactivation from latency.  We propose that ORF2 
increases the pool of latently infected neurons capable of supporting reactivation from 
latency.  Interactions between ORF2 and Notch1 or Notch3 are thus expected to promote 
the establishment and/or maintenance of latency.  Although ORF2 inhibits apoptosis 
(Shen and Jones, 2008), this study suggested ORF2 also regulates viral transcription by 
interacting with cellular transcription factors.  Two additional studies provide evidence 
that ORF2 may regulate transcription (Devireddy et al., 2003; Meyer et al., 2007b).  
Consequently, we suggest that the ability of ORF2 to inhibit apoptosis and interact with 
cellular transcription factors promote life-long latency.  The LR gene encodes other 
proteins and at least 2 micro-RNAs that reduce bICP0 protein levels (Jiang et al., 2004; 
Meyer et al., 2007b; Shen et al., 2009) suggesting these functions play a supportive role 
during the latency-reactivation cycle.   
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Figure 5.1.  Schematic of protein coding regions within the LR genes and ORF2 
isoforms encoded by alternatively spliced LR transcripts. 
ORF-1 and ORF-2 are the open reading frames present in the LR gene (Kutish et al., 
1990b).  Reading Frame B and C (RF-B and RF-C) each contain an open reading frame 
that lacks an initiating methionine.  The numbers in parenthesis are the approximate size 
of ORFs (Kd) that are located in LR gene sequences.  The ORF2 isoforms encoded by 
alternatively spliced LR transcripts detected in TG at 1 dpi and latency, 7 dpi, and 15 dpi, 
(Devireddy et al., 2003) are shown as a comparison to ORF2 present in the LR gene.  
Although the LR-RNA is differentially spliced at 1 day after infection in TG of cattle, 
both transcripts encode an intact ORF2.  The (*) denotes the position of stop codons that 
are in frame with the respective ORF.   
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Figure 5.1. 
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Figure 5.2. DEX treatment induces Notch RNA levels. 
Panel A and B.  TG from BHV-1-infected calves was collected at 60 days after infection 
(latency) and at 6 or 24 hours after DEX treatment of latently infected calves. These TG 
were obtained during the course of other published studies (Inman et al., 2002; Perez et 
al., 2005).  TG were minced into small pieces and then processed as described in the 
Materials and Methods.  Total RNA was collected and RT-PCR performed using 
oligo(dT) primers. cDNA was used as the template for semi-quantitative PCR using 
specific primers for Notch1 (panel B) or Notch3 (panel A).  
Panel C and D.  Neuro-2A cells were cultured in the presence of 1uM DEX for the 
designated times (hours). Total RNA was collected and RT-PCR performed using 
oligo(dT) primers. cDNA was used as the template for semi-quantitative PCR using 
specific primers for Notch1 (panel D) or Notch3 (panel C) as described in the Materials 
and Methods. GAPDH was used as a loading control for all studies. 
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Figure 5.3. Notch1, but not Notch3, stimulated productive infection. 
Panel A:  Rabbit Skin (RS) cells were co-transfected with increasing amounts of the 
Notch1 ICD (open columns) or Notch3 ICD plasmid (black columns) (15 ng, 52 ng, 0.21 
ug, 0.83 ug, or 2 ug) or bICP0 (52 ng), and the BHV-1 gCblue virus genome (0.83 ug) 
using Lipofectamine 2000.  A blank expression vector (pcDNA 3.1) was used to maintain 
equivalent amounts of DNA.  Twenty-four hours after transfection, cells were fixed, 
stained, and the number of -gal+ cells was counted.  The number of -gal+ cells in the 
vector control was set to 1 and the number of -gal+ cells in each plate was calculated as 
the fold difference relative to the vector control.  The results are the average of three 
independent experiments.  An asterisk denotes significant differences (p<0.05) from the 
pcDNA3.1 value as determined by the Student T-test. 
Panel B:  RS cells were infected with wt BHV-1 (moi = 1) for the designated times after 
infection (hours).  Cell lysate was prepared as described previously and Western blot 
assays performed.  The rabbit anti-Notch1 primary antibody was purchased from Cell 
Signaling (catalogue #32685).  Rabbit IgG was detected using a donkey anti-rabbit IgG 
(GE Healthcare; catalogue # NA934V).  The goat anti-actin antiserum was purchased 
from Santa Cruz Biotechnology (catalogue # sc-1616).  Donkey anti-goat IgG was 
purchased from Santa Cruz Biotechnology (catalogue # sc-2020). 
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Figure 5.4.  Notch1, but not Notch3, stimulates IEtu1 promoter activity. 
Panel A:  Position of transcripts that encode bICP4 and bICP0 are shown.  The 
immediate early transcription unit 1 (IEtu1) encodes bICP4 (IE/4.2) and bICP0 (IE/2.9) 
(Wirth et al., 1989; Wirth et al., 1991).  The IEtu1 promoter (denoted by the black 
rectangle) activates IE expression of IE/4.2 and IE/2.9.  E/2.6 is the early transcript that 
encodes bICP0 and an early promoter (denoted by the grey rectangle) activates 
expression of this early transcript (Wirth et al., 1992).  Exon 2 (e2) of bICP0 contains all 
of the protein coding sequences of bICP0.  The dashed lines are intron sequences.  
IETu1-CAT contains 1.5 kb of upstream sequences cloned at the 5’ terminus of 
pSV0CAT (a promoter minus CAT expression vector).  V. Misra, Saskatoon, Canada, 
provided the IEtu1CAT plasmid (Misra et al., 1994).  Two deletion constructs 1024 and 
1391 IEtu1 have 1024 or 1391 bp sequences removed from the 5’ terminus.  The basal 
promoter activity of the respective constructs was measured in neuro-2A cells.  Basal 
promoter activity of IEtu1cat was normalized to 100% and the other 2 promoters 
compared to this value. These results were the average of 3 independent experiments. 
Panel B: Neuro-2A cells were cotransfected with the designated IETu1 promoter 
construct (1ug DNA) and plasmids expressing Notch1 ICD (open columns) or Notch3 
ICD (black columns) using 1ug of plasmid DNA. CAT activity of cells transfected with 
the control CAT vector was set to one.  All other values are expressed as fold activation 
with respect to the control.  These studies are the average of three independent 
experiments. An asterisk denotes significant differences (p<0.05) from the pCAT basic 
trans-activation value as determined by the Student T-test. 
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Figure 5.5.  Notch1 stimulates bICP0 E promoter activity.  
Panel A:  Neuro-2A cells were co-transfected with 1ug of the designated bICP0 E 
promoter construct and 1ug of a plasmid that expresses Notch1 ICD or Notch3 ICD.  
DNA amounts were equalized for all transfections using pcDNA3.1, a blank expression 
vector.  For further details of the respective bICP0 E promoter construct, see the materials 
and methods and (Workman and Jones, 2010; Workman et al., 2009).  At 48 hours post 
transfection, cells were collected and processed for CAT activity as described in the 
materials and methods.  Basal promoter activity of EP-172 was set at 100 and the values 
of the other constructs were compared to EP-172.  CAT activity of cells transfected with 
the control CAT vector was set to one.  All other values are expressed as fold activation 
with respect to the control.  These studies are the average of three independent 
experiments.   
Panel B:  Neuro-2A cells were co-transfected with 1ug EP-172 and 1ug of the plasmid 
that expresses Notch1 ICD along with 1ug of empty vector (pcDNA3.1), ORF2 in the 
correct reading frame (ORF2-B), or ORF 2 in the incorrect reading frame (ORF2-C).  At 
48 hours after transfection, cells were collected and processed for CAT activity as 
described in the Materials and Methods. CAT activity of cells transfected with the control 
CAT vector was set to one fold. All other values are expressed as fold activation with 
respect to the control.  The results are the average of three independent experiments. An 
asterisk denotes significant differences (p<0.05) from the Notch1 trans-activation value 
as determined by the Student T-test. 
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Figure 5.5. 
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Figure 5.6.  Notch stimulates glycoprotein C promoter activity. 
Panel A:  Neuro-2A cells were co-transfected with 1ug of the designated glycoprotein C 
(gC) promoter construct and 1ug of a plasmid expressing Notch1 ICD or Notch3 ICD.  
DNA amounts were equalized for all transfections using pcDNA3.1.  The gC promoter 
constructs were previously described (Zhang et al., 2006) and the basal promoter activity 
of gC-Cat was assigned the value of 100.  
Panel B:  Neuro-2A cells were co-transfected with 1ug gC-PstI-CAT or gC-CAT, 1ug of 
Notch1 ICD or Notch3 ICD respectively, and ORF2 in the correct reading frame (ORF2-
B), or ORF 2 in the incorrect reading frame (ORF2-C). As a control for basal promoter 
activity, the respective promoters were cotransfected with ORF2B. Empty vector 
(pcDNA3.1) was used to keep the same amount of DNA in the transfection mixture.  At 
48 hours after transfection, cells were collected and processed for CAT activity as 
described in the Materials and Methods. CAT activity of cells transfected with the control 
CAT vector was set to one fold. All other values are expressed as fold activation with 
respect to the control.  The results are the average of three independent experiments. An 
asterisk denotes significant differences (p<0.05) from the Notch alone trans-activation 
value as determined by the Student T-test. 
 
166 
 
Figure 5.6. 
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Figure 5.7.  Predicted CSL binding sites in the BHV-1 genome. 
Panel A:  Eleven variants of known canonical CSL binding sites have been identified 
(Persson and Wilson, 2010).  The number of each CSL consensus binding sites identified 
in the non-coding or coding regions of the BHV-1 genome is denoted.   
Panel B:  Schematic of the entire BHV-1 genome, which consists of two unique regions; 
UL and US, terminal repeats; TRL and TRS, and internal repeats between the unique 
regions; IRL and IRS.  Six potential CSL sites binding sites are located within the 
intergenic region between bICP4 and bICP22 coding regions.  At least one CSL binding 
site is detected upstream of bICP0. 
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Chapter 6 
 
 
 Identification and Characterization of Cellular Factors that are Expressed During 
Dexamethasone Induced Reactivation from Bovine Herpesvirus 1 (BHV-1) Latency 
in Neurons. 
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ABSTRACT  
Bovine herpesvirus 1 (BHV-1) is an alphaherpesvirinae subfamily member that 
establishes latency in sensory neurons. Elevated corticosteroid levels, due to stress or 
immune suppression, can initiate reactivation from latency. The BHV-1 latency-
reactivation cycle is crucial for virus transmission; however, the molecular events that 
occur during a successful reactivation from latency are unknown. Our central hypothesis 
is that latency is established in sensory neurons due to the lack of permissive transcription 
factors and/or the presence of cellular factors that repress viral transcription. We 
hypothesize that stress alters cellular gene expression in sensory neurons, which 
consequently initiates BHV-1 gene expression and reactivation from latency. In this 
study, we used a Bovine Gene Chip, which contains more than 23,000 genes, to compare 
cellular gene expression in latently infected calves versus calves treated with 
Dexamethasone (Dex; a synthetic corticosteroid) to initiate reactivation from latency.  
Relative to TG prepared from latently infected calves, 97 cellular genes were induced 
more than 10 fold at 3 hours after Dex treatment.  From this subset, 6 cellular 
transcription factors were induced more than 10 fold. In this study, we show that these 
cellular transcription factors stimulate BHV-1 productive infection and viral transcription 
when analyzed in transient transfection assays.  This suggests these transcription factors 
may play a role in the early events of reactivation from BHV-1 latency. 
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INTRODUCTION 
Bovine herpesvirus 1 (BHV-1) is an alphaherpesvirinae subfamily member that 
causes significant economical losses to the cattle industry (Turin et al., 1999).  The ability 
of BHV-1 to suppress the immune system can result in life-threatening pneumonia due to 
secondary bacterial infections, and this multi-factorial disorder is referred to as bovine 
respiratory disease complex {reviewed in (Jones, 2009; Jones, 2008; Jones, 2010)}.  Like 
other human alphaherpesvirinae subfamily members, the primary site for BHV-1 latency 
is sensory neurons within trigeminal ganglia (TG).  Viral gene expression (Schang and 
Jones, 1997) and infectious virus (Inman, 2002) are detected in TG from 1-6 days after 
acute infection.  Lytic cycle viral gene expression is subsequently extinguished in sensory 
neurons, and latency is established.  The BHV-1 genome is stably maintained in sensory 
neurons as an episome, but infectious virus is not detected by standard virological 
methods {reviewed in (Jones, 1998; Jones, 2003b)}.  The only viral gene abundantly 
expressed in latently infected sensory neurons is the latency-related (LR) gene, reviewed 
in (Jones, 2006).  Stress (due to confinement, transportation of cattle, restriction of food 
and water, or weaning) increases corticosteroid levels and reactivation from latency 
occurs (Jones, 2010).  The latency-reactivation cycle of BHV-1 is crucial for virus 
transmission and survival in nature. 
Administration of a synthetic corticosteroid, dexamethasone (Dex), to latently 
infected calves or rabbits consistently initiates reactivation from latency (Inman et al., 
2002; Jones, 1998; Jones, 2003a; Jones et al., 2000; Rock et al., 1992).  Dex represses LR 
promoter activity (Jones et al., 1990) and reduces LR-RNA levels, which culminates in a 
reduction of the number of TG neurons that express LR-RNA at 18-21 hours after 
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treatment (Rock et al., 1992).  A single injection of Dex also leads to viral lytic cycle 
transcript expression in neurons within 6 hours after treatment of latently infected calves 
(Winkler et al., 2002a; Winkler et al., 2000a). Calves latently infected with wild type 
BHV-1 and the LR mutant virus frequently express bICP0 mRNA after Dex treatment, 
but only wild type BHV-1 expresses late genes (Workman et al., 2009), which correlates 
with virus shedding during reactivation from latency (Inman et al., 2002).  These findings 
are consistent with an earlier study that concluded Dex induces viral gene expression in 
many latently infected neurons, but only a subset of neurons produce infectious virus 
(Rock et al., 1992).  Dex treatment of latently infected calves also induces apoptosis of T 
cells that persist in TG after infection (Winkler et al., 2002a).  Persistence of T cells in 
TG of humans or mice latently infected with HSV-1 also occurs (Cantin et al., 1995a; 
Halford et al., 1996b; Liu et al., 1996; Shimeld et al., 1995a; Shimeld et al., 1996; 
Shimeld et al., 1997; Theil, 2003), and persistent CD8+ T cells in TG produce factors 
(presumably cytokines) that inhibit reactivation from latency (Khanna et al., 2003; 
Knickelbein et al., 2008; Liu et al., 2001; Liu et al., 2000a; Liu et al., 2000b; Prbhakaran, 
2005). Although it seems clear that Dex has many effects on TG that leads to reactivation 
from latency, the mechanism by which Dex stimulates lytic viral gene expression is not 
understood.  
 In this study, cellular gene expression was examined in TG during the early stages 
of Dex induced reactivation from BHV-1 latency.  We identified genes that were 
regulated by Dex in TG of calves latently infected with BHV-1.  Cellular transcription 
factors identified by microarray were then examined for their ability to stimulate 
productive infection and viral promoter activity using transient transfection assays.  
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MATERIALS AND METHODS 
Cells and Virus 
 Murine neuroblastoma (neuro-2A), rabbit skin (RS), human osteosarcoma 
(U2OS) and bovine kidney (CRIB) cells were grown in Earle’s modified Eagle’s medium 
(EMEM) supplemented with 10% fetal calf serum, penicillin (10 U/ml), and streptomycin 
(100 μg/ml). 
 A BHV-1 recombinant virus (gCblue) containing the Lac Z gene in place of the 
viral gC gene was obtained from S. Chowdury (Louisiana State University, Baton Rouge, 
LA).  The virus grows to similar titers as the wild type parent virus and expresses the -
Gal gene as a true late gene.  
 
RNA preparation for Microarray Analysis and Reverse Transcription 
BHV-1-free crossbred calves ( 200 kg) were randomly assigned
 
and housed in 
isolation rooms to prevent cross-contamination.
 
Calves were inoculated with 10
6
 PFU of 
wtBHV-1 into
 
each nostril and eye, without scarification, for a total of
 
4 x 10
6
 PFU per 
animal, as described previously (Inman et al., 2002). TG from BHV-1-infected calves 
were collected at necropsy at 60 days after infection (latency) and at 1.5, 3, 6 or 24 hours 
after Dex treatment.  TG was stored at -80
o 
C for nucleic acid extraction. TG were 
minced into small pieces and total RNA was prepared from cells using TRIzol reagent 
(Life Technologies, USA) as previously described (Workman et al., 2009; Workman et 
al., 2011). RNA was labeled and changes in cellular gene expression were examined 
using the Bovine Gene Chip (Affymetrix, Santa Clara, CA), which contains more than 
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23,000 genes. These studies were performed by Jim Eudy at the University of Nebraska 
Medical Center (UNMC) in Omaha, Nebraska.   
For validation of microarray data, RT-PCR was performed. One microgram of 
RNA was treated with Amplification Grade DNAse I (Invitrogen, USA).  Reverse 
Transcription (RT) was performed using SuperScript III Reverse Transcriptase 
(Invitrogen, USA) according to the manufacturer's directions.  RNA was reverse 
transcribed using oligo(dT) primers (Invitrogen, USA).  One-hundred ng of the resulting 
cDNA were used as a template
 
for PCR using specific primers for the cellular gene of 
interest.  PCR was performed using GoTaq
 
DNA Polymerase (Promega, USA) and 
initiated at 95° C for 5 min. 
  
This was followed by 30 cycles of 95° C for 45 seconds, 
annealing (at temperature listed in table below) for 45 seconds, and 72° C for 45 
seconds.  Final extension was done at 72° C for 10 minutes.  PCR products were 
analyzed on a 1.3% agarose gel. The following
 
primer sequences and PCR conditions 
were used: 

-gal Assay 
The gCblue virus grows to similar titers as wt BHV-1 and was grown in CRIB 
cells. Procedures for preparing genomic DNA were described previously. RS cells grown 
in 6 well plates were co-transfected with 1 µg of the gCblue viral genome and the 
designated amounts of plasmid expressing bICP0 or the Dex-inducible cellular 
 Forward primer (5’-3’) Reverse Primer (5’-3’) Anneal 
temp 
SPDEF CAAGAAGGGCATCATCCG CCCTCTTTCCCAGCTCTG 48 
PLZF TCTTTGGCATATGGGCTCAGTC AGGCTGACTTCTGTCTCCACA 51 
SLUG GACCCCAGAATGGAACAGC CAGGATTGCCTAACACACAGC 51 
Pentraxin AAGGAGAGAGTTGAGAT TTCTCCAGTCTCCCT T 46 
GAPDH CCATGGAGAAGGCTGGGG CAAAGTTGTCATGGATGACC 55 
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transcription factor of interest using Lipofectamine 2000 (11668-019; Invitrogen).  
Twenty-four hours after transfection, cells were fixed (2% Formaldehyde, 0.2% 
Glutaraldehyde in PBS), stained (1% bluo-gal, 5 mM Kferric, 5 mM Kferro, 0.5 M 
MgCl2 in PBS), and the number of -gal+ cells counted as described previously 
(Workman and Jones, 2010).  The number of -gal+ cells in cultures expressing the blank 
vector was set to 100%.  To calculate percent plaque formation, the number of blue cells 
in cultures transfected with the cellular transcription factor were divided by the number 
of blue cells in cultures transfected with the blank vector.  This representation of the data 
minimized the differences in cell density, Lipofectamine lot variation, and transfection 
efficiency. The results are an average of at least three independent experiments. 
 siRNA knockdown of cellular transcription factors was accomplished by 
transfection of U2OS cells with  100 nM of specific siRNA or control siRNA using 
Lipofectamine 2000 according to the manufacture’s specifications (11668-019; 
Invitrogen). The Block-iT-Fluorescent Oligo was used as a control siRNA (44-2926; 
Invitrogen). It is a fluorescent conjugated control containing a scrambled sequence that 
does not reduce the levels of any known mammalian gene. Twenty-four hours after 
transfection of the siRNA, cells were transfected with 1 µg of gCblue viral genome. 
Twenty-four hours after transfection of viral genome, cells were fixed, stained, and -gal 
positive cells were counted as described above. 
siRNA Target Santa Cruz Biotech Catalog Number 
GATA6 sc-37907 
SPDEF sc-45845 
PLZF sc-37149 
SLUG sc-38393 
KLF6 sc-38021 
KLF4 sc-35480 
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Western Blot analysis and siRNA knock down of cellular transcription factors 
To evaluate the efficiency of siRNA knock down, U2OS cells were co-transfected 
with 0.5 µg of the plasmid encoding a Dex-inducible transcription factor and 100 nM of 
the respective siRNA or control siRNA as described above. At 36 hours after 
transfection, whole cell lysate was prepared.  Cells were washed with phosphate-buffered 
saline
 
(PBS) and re-suspended in NP-40 lysis buffer (100 mM Tris [pH 8.0], 1 mM 
EDTA,
 
100 mM NaCl, 1% NP-40, 1 mM phenylmethylsulfonyl fluoride, and
 
one tablet 
of complete protease inhibitor [Roche Molecular Biochemicals]
 
per 10 ml).  Cell lysate 
was incubated on ice for 30 min, sonicated, and then clarified
 
by centrifugation at 10,000 
x g at 4°C for 15 min. Protein
 
concentrations were quantified by the Bradford assay. For 
SDS-PAGE, proteins
 
were mixed with an equal amount of 1x sample loading buffer
 
(62.5 
mM Tris-HCl [pH 6.8], 2% sodium dodecyl sulfate, 50 mM
 
dithiothreitol, 0.1% 
bromophenol blue, 10% glycerol) and boiled
 
for 5 min. Proteins were separated in a 12% 
SDS-PAGE gel. After electrophoresis, proteins were transferred
 
onto a polyvinylidene 
difluoride membrane (Immobilon-P; Millipore) and blocked for 4 hours in 5% nonfat dry 
milk with Tris-buffered saline-0.1% Tween 20 (TBS-T).  Membranes were then 
incubated with primary antibody overnight at 4
o 
C (see table below). The primary 
antibody was diluted 1:1000 in the blocking solution.  An antibody directed against -
actin (Santa Cruz Biotechnology, Santa Cruz, CA) was used as a loading control. After 
45 minutes of washing with TBS-T, the blots were incubated with donkey anti-rabbit 
horseradish peroxidase-conjugated immunoglobulin G (Amersham Biosciences), which 
was diluted 1:2000 in 5% nonfat milk in TBS-T. Blots were washed 45 minutes with 
TBS-T and exposed to Amersham ECL reagents, and then autoradiography performed.  
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Primary Antibody Santa Cruz Biotech Catalog Number 
GATA6 sc-9055 
SPDEF sc-67022 
PLZF sc-22839 
KLF6 sc-7158 
KLF4 sc-20691 
 
 
RT-PCR analysis of siRNA knock down of Slug 
As we were unable to detect Slug by western blot, RT-PCR was performed to 
evaluate the effectiveness of the Slug siRNA. U2OS cells were transfected with 100 nM 
Slug siRNA (sc-38393; Santa Cruz Biotechnology) or a fluorescent control siRNA (44-
2926; Invitrogen) using Lipofectamine 2000 as described above.  At 24 hours after 
transfection, total RNA was prepared from cells using TRIzol reagent (Life 
Technologies, USA) as previously described (Workman and Jones, 2010).  One 
microgram of RNA was treated with Amplification Grade DNAse I (Invitrogen, USA).  
Reverse Transcription (RT) was performed using SuperScript III Reverse Transcriptase 
(Invitrogen, USA) according to the manufacturer's directions.  RNA was reverse 
transcribed using oligo(dT) primers (Invitrogen, USA).  A 100 ng aliquot of the resulting 
cDNA was used as a template
 
for PCR using specific primers for Slug (listed 
above). PCR products were analyzed on a 1.3% agarose gel. 
 
Plasmids and promoter activity measured in transfected cells 
The construction and characteristics of the BHV-1 bICP0 E promoter-CAT 
constructs (EP-172, EP-143, EP-133, EP-71, EP-50, and EP-42) used in this study were 
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described previously (Workman, 2009; Workman, 2010a).  The numbers in the plasmid 
name refer to the length of the bICP0 E promoter fragment cloned into the promoterless 
vector, pCAT-basic (Promega).  Truncations to the promoter were made from the 5’ 
terminus. IETu1-CAT contains 1.5 kb of upstream sequences cloned at the 5’ terminus of 
pSV0CAT (a promoter minus CAT expression vector).  V. Misra, Saskatoon, Canada, 
provided the IEtu1CAT plasmid (Misra et al., 1994).  Two deletion constructs 1024 and 
1391 IEtu1 have 1024 or 1391 bp sequences removed from the 5’ terminus.  The gC 
promoter constructs (gC-CAT, gC-PstI-CAT, and gC-XhoI-CAT) were previously 
described (Zhang et al., 2006).  The empty vector pcDNA3.1 was purchased from 
Invitrogen. SPDEF was purchased from Origene (Rockville, MD). The remaining Dex-
inducible genes were graciously provided to us from labs studying these transcription 
factors. PLZF: Derek Sant’Angelo (Sloan Kettering Cancer Center). SLUG: Paul Wade 
(NIH). KLF4: Jonathan Katz (University of Pensylvania).  GATA6: Brian Herring 
(Indiana University Medical Center) KLF6: Bing Guo (North Dakota State University). 
Neuro-2A cells grown in 60 mm dishes were co-transfected with the designated 
plasmids as indicated in the respective figure legends using with TransIT Neural 
according to the manufacturer’s instructions.  Measurement of chloramphenicol 
acetyltransferase (CAT) activity in Neuro-2A cells was performed as described 
previously (Workman and Jones, 2010; Workman et al., 2009; Workman et al., 2011).   
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RESULTS 
Microarray analysis of cellular gene expression during BHV-1 reactivation from 
latency 
Our central hypothesis is that latency is established in sensory neurons due to the 
lack of permissive transcription factors and/or the presence of cellular factors that repress 
viral transcription. We further hypothesize that reactivation stimuli alter cellular gene 
expression in sensory neurons, which consequently initiates BHV-1 gene expression and 
reactivation from latency.  To test this hypothesis, we examined cellular gene expression 
during Dex-induced reactivation from latency in trigeminal ganglia (TG).  
A single injection of Dex into the jugular vein of latently infected calves (100 mg) 
consistently and reproducibly initiates reactivation from latency (Jones, 1998; Jones, 
2003a; Jones, 2006).  Calves latently infected with BHV-1 were injected with Dex and 
TG was harvested at 1.5, 3, 6, or 24 hours after Dex treatment.  TG were collected and 
frozen at -80
o
 C.  As controls, TG were collected from calves latently infected with BHV-
1 (no Dex treatment), or mock infected controls.  Total RNA was prepared from the 
respective TG, RNA was labeled, and changes in cellular gene expression were examined 
using the Bovine Gene Chip (Affymetrix, Santa Clara, CA), which contains more than 
23,000 genes.   
We first examined cellular genes stimulated by Dex. Relative to RNA prepared 
from TG of latently infected calves, 97 cellular genes were induced more than 10 fold at 
3 hours after Dex treatment (Table 1 shows a subset of these genes).  Two of the top 4 
cellular genes stimulated at 3 hours after Dex treatment were transcription factors: 1) zinc 
Ring finger and BTB domain protein (PLZF) that is a member of the Kruppel 
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transcription factor family (Bieker, 2001), and 2) Snail Homolog 2 (SLUG) (Nakakura et 
al., 2001).  Two other Kruppel transcription family members (KLF4 and KLF6) were also 
stimulated more than 10 fold at 3 hours after Dex treatment.  Finally, transcription factors 
SPDEF (Sood et al., 2009) and GATA-6 (Yin and Herring, 2005) were stimulated more 
than 10 fold at 3 hours after Dex treatment.  Although certain genes were stably induced 
by Dex, others were only stimulated 3 hours after Dex treatment, and then their 
expression was reduced.  For example, Kruppel-like factor 6 (KLF6) and GATA-6 were 
stimulated more than 10 fold at 3 hours after Dex treatment but were induced less than 4 
fold at 6 hours after Dex treatment. In summary, 6 cellular transcription factors were 
induced more than 10 fold when latently infected calves were treated with Dex to initiate 
reactivation from latency. 
 
RT-PCR confirmation of Dex-inducible cellular genes 
 To verify these changes in cellular gene expression by an alternate method, we 
analyzed the expression of 4 cellular genes using RT-PCR. These included Pentraxin, the 
gene stimulated most by Dex, and three cellular transcription factors: PLZF, SLUG, and 
SPDEF. Bovine GAPDH was assayed as a normalization control. PCR products were 
separated by agarose gel electrophoresis (Figure 6.1A), and the relative amounts of PCR 
products were evaluated by densitometry using a biomolecular imager (Bio-Rad) (Figure 
6.1B). The graph represents the average density of three TG samples from three calves at 
each time point.  As shown in Figure 6.1, Pentraxin expression increased following Dex 
treatment with a peak at 6 hours after Dex treatment. PLZF and SLUG were expressed 
with similar kinetics with a peak in gene expression at 3 hours after Dex treatment with 
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reduced expression at later times. These kinetics were similar to that observed by 
microarray analysis. Alternatively, SLUG was shown to be stably induced following Dex 
treatment by microarray. While we observed an increase in SLUG mRNA levels over the 
latency control, we were unable to detect a significant increase after averaging the levels 
from three individual TG.  In general, we were able to validate changes in expression of 
specific genes of interest by RT-PCR. 
 
Dex-inducible transcription factors stimulate BHV-1 productive infection 
 To determine whether Dex-inducible genes activated productive infection, a 
plasmid expressing the specific cellular gene of interest was co-transfected with genomic 
DNA from a BHV-1 strain called gCblue virus and efficiency of productive infection was 
measured. The gCblue virus contains the Lac Z gene downstream of the glycoprotein C 
(gC) promoter. This allows measurement of  productive infection by counting -Gal+ 
(beta-galactosidase) cells, which directly correlates with plaque formation (Geiser et al., 
2002; Geiser and Jones, 2003; Inman et al., 2001b; Meyer et al., 2007a). Previous studies 
have demonstrated that transfection of BHV-1 genomic DNA yields low levels of 
infectious virus unless co-transfected with bICP0, a viral transactivator which activates 
expression of all classes of viral promoters (Inman et al., 2001b). Therefore, cellular 
transcription factors which activate viral transcription could, in part, substitute for bICP0 
functions in stimulating productive infection. We initially focused on the six transcription 
factors that were stimulated by Dex more than 10 fold at 3 hours after Dex treatment. At 
24 hours after transfection, GATA6, SPDEF, SLUG, and KLF6 were all found to 
increase the number of -gal+ cells approximately 4 fold (Figure 6.2). KLF4 increased 
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the number of -gal+ cells 9 fold, while PLZF increased the number of -gal+ cells 21 
fold (Figure 6.2). In summary, all 6 Dex-inducible transcription factors stimulated BHV-
1 productive infection in cell culture. 
 In addition to over expression studies, we also examined the effect of siRNA 
knock down of Dex-inducible transcription factors on BHV-1 productive infection in 
cultured cells. These studies were performed in a human osteosarcoma (U2OS) cell line 
that is permissive to BHV-1 infection so commercially available siRNAs targeting the 
human transcription factor could be used. Cells were transfected with 100 nM of specific 
siRNA or a scrambled control siRNA 24 hours prior to transfection with gCblue viral 
genome. Twenty four hours after transfection with the viral genome, cells were fixed, 
stained, and -gal+ cells were counted. With the exception of SPDEF, knock down of 
Dex-inducible cellular transcription factors reduced the number of -gal+ cells between 
40 and 60 percent (Figure 6.3A). Western blot analysis shows efficiency of siRNA 
knockdown (Figure 6.3B). The SLUG antibody was unable to recognize a specific band; 
therefore, RT-PCR was performed to show knock down of endogenous SLUG mRNA 
(Figure 6.3C).  
 
Dex-inducible cellular transcription factors activate viral gene expression 
 To further examine the mechanism by which the 6 Dex-inducible cellular 
transcription factors stimulate productive infection, we examined their ability to 
transactivate BHV-1 promoters that regulate expression of important viral genes. For 
these studies, we tested the immediate early transcription unit 1 promoter (IEtu1), bICP0 
early (E) promoter, or the gC late (L) promoter.  The IEtu1 promoter activates expression 
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of bICP0 and bICP4, the major transcriptional regulatory proteins encoded by BHV-1 
(see Figure 6.5A) (Wirth et al., 1992; Wirth et al., 1991).  The bICP0 E promoter also 
activates bICP0 expression, and recent studies suggest it is preferentially stimulated 
during reactivation from latency (Workman et al., 2009).  
Neuro-2A cells were co-transfected with the designated promoter construct and a 
plasmid expressing the designated Dex-inducible gene, and CAT activity was measured 
at 48 hours after transfection. PLZF, which activated productive infection 21 fold, was 
unable to directly activate viral promoters (Figure 6.4), suggesting an alternative 
mechanism for stimulating productive infection. KLF4 activated the IE and E promoter 
constructs 50 fold and 120 fold respectively, but did not activate the L promoter (Figure 
6.4). KLF6 was unable to activate the IE or E promoter constructs, but activated the L 
promoter approximately 3 fold. SLUG activated the IE promoter 5 fold and the L 
promoter 13 fold. SPDEF was able to activate all three classes of viral promoters between 
4 and 10 fold. As GATA6 was able to activate the promoter minus control, no data could 
be obtained for the remaining CAT constructs. These studies suggest that a subset of 
Dex-inducible transcription factors enhanced productive infection by trans-activating 
viral promoter activity. 
 
IETu1 and the bICP0 E promoter contain putative KLF4 binding sites 
 The results shown in Figure 6.4 demonstrate that KLF4 was able to activate the 
IETu1 and bICP0 E promoter greater than 50 fold in transient transfection assays. 
Therefore, we were interested in localizing the KLF4 binding sites within these 
promoters. We used a panel of 5’ promoter deletion mutants which contained consecutive 
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5’ deletions to map the KLF4 responsive regions.  Neuro-2A cells were co-transfected 
with the designated promoter construct along with KLF4 and CAT reporter activity was 
measured. KLF4 was found to activate the full length IEtu1 25 fold and IETu1Δ1024 and 
IETu1Δ1391 approximately 50 fold (Figure 6.5B).  We next examined the promoter for 
KLF4 consensus sequences. The KLF4 consensus has been described as CACCC or 
RCRCCYY.  Within the full length IETu1, there were 3 CACCC motifs as well as 4 
RCRCCYY motifs. IETu1Δ1024 lost 3 RCRCCYY motifs, yet no promoter activity was 
lost, suggesting these motifs were not important for KLF4 responsiveness. Additionally, 
IETu1Δ1391 lost 1 CACCC motif without losing any activity. The two remaining 
CACCC motifs are located just upstream of the initiation ATG and are shown in Figure 
6.5D. Finally, all three promoter constructs contained the first 500bp upstream of the 
initiation ATG. This sequence contained an additional RCRCCYY motif. In summary 
there are three putative KLF4 biding sites in the IETu1 promoter.  
 We next mapped the bICP0 E promoter to localize the KLF4 responsive domains. 
EP-638, EP-398 and EP-328 were all activated approximately 100 fold when co-
expressed with a KLF4 expression plasmid. EP-172 was activated approximately 50 fold 
while EP-133 and EP-71 were activated less than 5 fold (Figure 6.6B). When we 
analyzed the promoter sequence for KLF4 consensus motifs, we found 2 CACCC in the 
forward orientation as well as 1 in the reverse orientation. Additionally, there was one 
RCRCCYY motif in the forward orientation. From EP-328 to EP-172, approximately half 
of the promoter activity is lost. This is accompanied by the loss of one CACCC 
consensus in the forward orientation as well as the RCRCCYY motif.  From EP-172 to 
EP-133, there is a second dramatic drop in promoter responsiveness to KLF4. This 
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deletion is accompanied by the loss of one CACCC consensus in the reverse orientation. 
Maintained in EP-133 and EP-71 is one CACCC consensus; however, this motif does not 
appear to be important for KLF4 responsiveness in the bICP0 E promoter (see Figure 
6.6C). In summary, we were able to identify KLF4 binding sites in the IETu1 promoter as 
well as the bICP0 E promoter that are important for KLF4 activation of these viral 
promoters.  
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DISCUSSION 
During latency, the viral genome is in a transcriptionally repressed state, and the 
latency related (LR) gene is the only abundant transcript. During corticosteroid-induced 
reactivation, Dex represses LR promoter activity, reducing LR gene expression (Jones et 
al., 1990; Rock et al., 1992). Thus, LR is not believed to directly play a role in 
reactivation from latency; although, LR may actively inhibit reactivation from latency. In 
the absence of viral transactivators, we hypothesize that stress-induced cellular factors act 
directly on viral promoters to activate viral gene expression, and subsequently induce 
reactivation from latency.  
Several lines of evidence support this hypothesis and suggest that Dex-induced 
cellular transcription factors stimulate production of infectious virus during reactivation 
from latency. For example, Dex stimulates the expression of a cellular transcription 
factor, C/EBP-alpha, which directly activates the bICP0 early (E) promoter (Meyer and 
Jones, 2009; Meyer et al., 2007a; Meyer, 2008; Workman et al., 2009). Furthermore, 
Notch 1 and Notch 3 expression is stimulated by Dex during reactivation from latency, 
and Notch 1 stimulates viral promoters and productive infection (Workman et al., 2011). 
Therefore, in this study we used microarrays to examine global changes in cellular gene 
expression in the TG of calves during Dex-induced reactivation to identify additional 
cellular factors that may regulate the latency-reactivation cycle.    
In as little as 3 hours after Dex treatment, 97 cellular genes were activated in the 
TG. Six of these were cellular transcription factors: 1) promyelocytic leukemia zinc 
finger (PLZF), a member of the Kruppel like transcription factor (KLF) family, 2) SLUG, 
a zing finger protein involved in neuronal development, cancer, and apoptosis, 3) KLF4, 
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4) KLF6, 5) SAM pointed domain containing ets (erythrocyte transformation specific) 
like transcription factor (SPDEF), which is a zinc finger containing protein that regulates 
cell lineage specification, proliferation, angiogenesis and apoptosis, and 6) GATA6 
which is important for regulating terminal differentiation or proliferation (see Table 6.1).  
Following RT-PCR validation of these results (Figure 6.1), cellular transcription factors 
were examined for their ability to stimulate productive infection and viral promoter 
activity using transient transfection assays (Figures 6.3 and 6.4).  
PLZF induced productive infection 21 fold in transient transfection assay (Figure 
6.2), but was unable to significantly activate viral promoters (Figure 6.4). PLZF is a 
member of the ‘‘BTB/POZ’’ (bric a´ brac, tramtrack, broad complex/poxvirus zinc 
finger) family of transcription factors. The N-terminal BTB/POZ domain mediates 
interactions with proteins such as transcriptional co-repressors (Melnick et al., 2000) 
resulting in chromatin remodeling and transcriptional silencing (Chauchereau et al., 2004; 
David et al., 1998; Guidez et al., 2005; Hong et al., 1997; McLoughlin et al., 2002).  The 
C-terminal 9 C2H2 Kruppel-like zinc fingers interact with DNA in a sequence specific 
manner to confer specificity of the repressor activity. Contrary to the previous 
designation of PLZF as a repressor of transcription, a recent study showed that PLZF is 
required for the activation of a subset of interferon stimulated genes which are important 
in the innate immune response to viruses (Xu et al., 2009). Interferon led to the 
phosphorylation of PLZF within the BTB domain, which transformed the protein from a 
transcriptional repressor to an activator.  Therefore, it is possible that PLZF acts to 
activate transcription under certain conditions. For example, viral infection induces 
interferon expression. Therefore, interferon-induced phosphorylation of PLZF may lead 
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to the subsequent activation of viral promoters in our productive infection assays. 
Promoter activity was evaluated using reporter plasmids in the absence of viral infection, 
and therefore the absence of interferon induction. It is possible that PLZF was not 
phosphorylated and could not activate viral promoter activity in the absence of interferon. 
It will be of interest to determine whether interferon stimulation of cells can convert 
PLZF to an activator of viral promoters in our reporter assay. It is also possible that other 
signaling cascades lead to PLZF phosphorylation and activation.    
Another Kruppel like transcription factor, KLF4, activated productive infection 9 
fold, and activated the IETu1 and bICP0 E promoter 50 fold and 120 fold, respectively. 
This suggests that KLF4 activates productive infection by directly or indirectly activating 
viral promoters. We hypothesized that KLF4 may directly bind viral promoters, because: 
i) KLF4 binds GC rich motifs resembling Sp1 binding sites, ii) the BHV-1 genomes is  
approximately 70% GC rich (Tikoo et al., 1995), and iii) most viral promoters contain 
multiple Sp1 consensus sequences (Jones and Tjian, 1985). Therefore, we examined the 
IETu1 and bICP0 E promoter for known KLF4 binding sites. The KLF4 consensus has 
been described as CACC or RCRCCYY. Using 5’ deletions of the bICP0 E promoter, we 
were able to identify three potential KLF4 binding sites that confer KLF4 responsiveness 
using reporter assays (Figure 6.6). For the IETu1, we identified two putative KLF4 
binding sites upstream of the transcription start site as well as 1 binding sites within 
500bp downstream of the transcription start (Figure 6.5).  
Recent work by Thompson et al. (Thompson et al., 2009), using an in vivo 
approach to study HSV-1 reactivation, show that the tegument protein VP16, which is 
normally expressed with late kinetics, is expressed prior to IE genes during reactivation 
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from latency. During productive infection, VP16 is delivered in the tegument of the 
virion and serves to initiate IE gene expression. From these findings, they conclude de 
novo synthesis of VP16 (due to specific activation of the VP16 promoter) is responsible 
for the initial events of reactivation from latency. Therefore, we examined the effect of 
these Dex-inducible transcription factors to regulate bTIF (the BHV-1 homolog of HSV-
1 VP16) promoter activity.  None of the cellular factors tested were able to trans-activate 
the bTIF promoter (data not shown). 
In summary, we have identified 6 cellular transcription factors that are induced 
during Dex-induced BHV-1 reactivation from latency. These cellular transcription factors 
stimulate BHV-1 productive infection and a subset of these activates viral transcription 
when analyzed in transient transfection assays.  This suggests these transcription factors 
may play a role in the early events of reactivation from BHV-1 latency by activating viral 
gene expression and infectious virus production. Since BHV-1 is the only 
alphaherpesvirinae subfamily member that can be reproducibly induced to reactivate 
from latency, these findings have impact on other important members of this virus 
family.  
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Table 6.1 Identification of cellular genes induced by Dex within TG of latently 
infected calves.  
Three latently infected calves were treated with Dex for 3 hours, 6 hours, or 24 hours.  
Cellular gene expression was analyzed using the Affymetrix bovine Gene Chip. The 
common name of the gene is provided in the first column. Second column (Fold 
Induction):  the numbers are levels of induced gene expression at 3 (1
st
 number), 6 (2
nd
 
number), or 24 hours (3
rd
 number) after Dex treatment.  The base line of expression was 
derived from 3 calves latently infected with BHV-1.  Known functions of the respective 
genes are summarized in the third column. 
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Table 6.1. 
  
Gene Name Fold 
Induction 
Functions 
PTX3: Pentraxin-related gene 65, 101, 5 Innate immunity, neuronal degeneration 
SHISA3: Shisha homolog 3 (Xenopus 
laevis) 
37, 23, 3 Wnt signaling 
PLZF: Zn finger and BTB domain protein  
 (Kruppel transcription factor)  
37, 17, 8 Transcription factor: differentiation, 
growth control 
SNAI2: snail homolog 2 (Drosophila) also 
called SLUG in mammals 
28, 10, 2 Transcription factor: neuronal 
development, apoptosis, cancer 
HBB: hemoglobin, beta 26, 2, 1  
COL1A1: Collagen, type I, alpha 1 25, 4, 1  
LYVE1: Lymphatic vessel endothelial 
hyaluronan receptor 1 
25, 11, 3 Lymph-specific Receptor for Hyaluronan 
CYR61: Cysteine-rich, angiogenic inducer, 
61 
24, 11, 4 Stimulates chemotraxis 
DKK1: dickkopf homolog 1 (Xenopus 
laevis) 
23, 8, 2 Inhibits Wnt signaling 
ACTG2: actin, gamma 2, smooth muscle, 
enteric 
22, 5, 6  
ASPN: Asporin 20, 13, 4 Leu-rich protein assoc with cartilage 
SPOP: speckle-type POZ protein 20, 4, 1 Adaptor for DAXX (Cul-3 Ub system) 
KLF4: Kruppel-like transcription factor 4  12, 9, 3 Transcription factor: GC binding (SP1 
like binding activity) 
SPDEF: SAM pointed domain containing 
ets like transcription factor  
11, 10, 6 Transcription factor: contains Zinc finger  
GATA-6 11, 3, 2 Transcription factor: binds GGA(A/T) 
sequences 
KLF6: Kruppel-like factor 6  11, 2, 2 Transcription factor: GC binding (SP1 
like binding activity) 
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Figure 6.1. RT-PCR confirmation of Dex-inducible cellular genes. 
Panel A: RT-PCR using specific primers was performed to analyze expression of cellular 
genes identified by microarray analysis.  Three latently infected calves were treated with 
Dex for 1.5 hours, 3 hours, 6 hours, or 24 hours. Additionally, three mock (M) infected 
calves as well as 3 latently infected calves (no Dex; L) were used as controls for baseline 
expression values. TG was collected at necropsy and total RNA was isolated. RT-PCR 
was performed using specific primers as described in the materials and methods. Products 
were separated by agarose gel electrophoresis and visualized using ethidium bromide.  
Panel B: Graphical representation of RT-PCR results. The amount of PCR products were 
quantified using a biomolecular imager (Bio-Rad) and density values were normalized to 
a GAPDH control. Values represent the average of 3 TG from 3 calves at each time point.  
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Figure 6.2. Dex-inducible transcription factors stimulate BHV-1 productive 
infection. 
Rabbit skin (RS) cells were cotransfected with 62 ng of a plasmid encoding bICP0 or 
increasing concentrations of the respective plasmids (62 ng, 250 ng, 1 µg, or 2 µg) 
encoding Dex inducible transcription factors along with 1 µg of gCblue BHV-1 DNA, 
which contains the Lac Z gene inserted into the gC locus of BHV-1. At 24 hours after 
transfection, cells were fixed, stained, and -gal positive cells were counted. The results 
are the average of three independent experiments.  
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Figure 6.3. Suppression of Dex-induced transcription factors reduced the levels of 
productive infecton. 
Panel A: Human osteosarcoma cells (U2OS) were transfected with 100 nM siRNA 
targeting the designated cellular transcription factor or a control siRNA which does not 
reduce the expression of any known mammalian gene. Twenty four hours later, cells 
were transfected with gCblue viral genome and efficiency of productive infection was 
measured. The results are the average of three independent experiments. 
Panel B: To show the efficiency of the siRNAs, human osteosarcoma cells (U2OS) were 
co-transfected with 100 nM siRNA and 0.5 µg of the designated plasmid expressing the 
Dex-inducible transcription factor. Twenty four hours after transfection, cells were 
collected and processed for western blot. Actin was assayed as a loading control.  
Panel C: The slug antibody was unable to recognize a specific protein. Therefore, U2OS 
cells were transfected with 100 nM Slug siRNA, control siRNA, or no siRNA, and RT-
PCR was performed as described in the material and methods. PCR products were run on 
a 1.3% agarose gel and visualized with ethidium bromide.  
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Figure 6.4. Dex-inducible cellular transcription factors activate viral gene 
expression. 
Mouse neuroblastoma cells (neuro-2A) were cotransfected with 1 µg of a CAT reporter 
plasmid with the IETu1 promoter (IETu1Δ1024), bICP0 E promoter (EP-638), or the gC 
L promoter and 1µg of pcDNA3.1 empty vector or 1 µg of a plasmid expressing the 
designated Dex-inducible transcription factor. At 48 hours after transfection, CAT 
reporter activity was measured. The numbers represent fold induction over the empty 
vector control. The results are the average of three independent experiments. 
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Figure 6.5. Localization of KLF4 binding sites in the IETu1. 
Panel A: Position of transcripts that encode bICP4 and bICP0 are shown.  The immediate 
early transcription unit 1 (IEtu1) encodes bICP4 (IE/4.2) and bICP0 (IE/2.9) (Wirth et al., 
1989; Wirth et al., 1991).  The IEtu1 promoter (denoted by the black rectangle) activates 
IE expression of IE/4.2 and IE/2.9.  E/2.6 is the early transcript that encodes bICP0 and 
an early promoter (denoted by the grey rectangle) activates expression of this early 
transcript (Wirth et al., 1992).  Exon 2 (e2) of bICP0 contains all of the protein coding 
sequences of bICP0.  The dashed lines are intron sequences. The basal promoter activity 
of the respective constructs was measured in neuro-2A cells.  Basal promoter activity of 
IEtu1cat was normalized to 100% and the other 2 promoters compared to this value. 
These results were the average of 3 independent experiments. 
Panel B: Mouse neuroblastoma cells (neuro-2A) were cotransfected with the designated 
IETu1 promoter-CAT reporter plasmid (1 µg) and 1 µg of pcDNA3.1 empty vector or 1 
µg of KLF4. At 48 hours after transfection, CAT activity was measured. The numbers 
represent fold induction over the empty vector control. The results are the average of 
three independent experiments. 
Panel C: KLF4 consensus sequences were located in the IETu1 promoter using the free 
online program fuzznuc (http://emboss.open-bio.org/wiki/Appdocs). The KLF4 
consensus has been described as CACC or RCRCCYY. Table includes the number of 
consensus sequences found without mismatch in the IETu1 promoter and 5’ UTR 
included in CAT constructs.  
Panel D: First 56 base pairs in the IETu1. Includes two CACCC consensus sequences.  
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Figure 6.6. Localization of KLF4 binding sites in bICP0 E promoter.  
Panel A: Schematic of bICP0 E promoter constructs with corresponding basal promoter 
activities. Basal promoter activity of EP-638 was set at 100% and the values of the other 
constructs were compared to EP-638. The results are the average of three independent 
experiments.  
Panel B: Mouse neuroblastoma cells (neuro-2A) were cotransfected with the designated 
bICP0 E promoter-CAT reporter plasmid (1 µg) and 1 µg of pcDNA3.1 empty vector or 
1 µg of KLF4. At 48 hours after transfection, CAT activity was measured. The numbers 
represent fold induction over the empty vector control. The results are the average of 
three independent experiments. 
Panel C: KLF4 consensus sequences were located in the bICP0 E promoter using the 
free online program fuzznuc (http://emboss.open-bio.org/wiki/Appdocs). The KLF4 
consensus has been described as CACC or RCRCCYY. Highlighted are consensus 
sequences found with no mismatches. Underlined are the primer sequences used for 
constructing the bICP0 E promoter constructs.  
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Chapter 7 
 
Certain Dexamethasone Inducible Transcription Factors have the Potential to 
Regulate Herpes Simplex Virus 1 (HSV-1) Productive Infection and Promoter 
Activity in Cultured Cells. 
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ABSTRACT 
 Bovine herpesvirus 1 (BHV-1) and herpes simplex virus type 1 (HSV-1) are 
alphaherpesvirinae subfamily members that establish latency in sensory neurons. In 
contrast to acute infection where all viral genes are expressed; latency is characterized by 
minimal viral gene expression, the absence of lytic viral proteins, and the absence of 
infectious virus production. These viruses can periodically be induced to reactivate from 
latency, facilitating the spread of the virus to susceptible hosts. The latency-reactivation 
cycle is crucial for virus transmission and complicates disease control; however, the steps 
that occur during a successful reactivation have not been well characterized. We 
hypothesize that stressful stimuli induce cellular transcription factors which activate viral 
promoters to increase lytic viral gene expression, culminating in infectious virus 
production. We have identified 6 cellular transcription factors which are induced greater 
than 10 fold following dexamethasone (Dex) induced reactivation from BHV-1 latency. 
These transcription factors activate BHV-1 productive infection and certain viral 
promoters, suggesting they play a role in the early events of reactivation from BHV-1 
latency. In this study, we tested the effect of these Dex-inducible cellular transcription 
factors on HSV-1 productive infection and viral promoter activity. These studies 
suggested that certain transcription factors induced during BHV-1 reactivation from 
latency can also stimulate certain HSV-1 promoters and productive infection in cultured 
cells.  
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INTRODUCTION 
 The lifecycle of herpes simplex virus 1 (HSV-1) can be divided into three phases: 
i) productive replication of the virus on mucosal surfaces, ii) establishment and 
maintenance of latency in sensory neurons, and iii) periodic reactivation of the virus from 
latency. The regulated pattern of gene expression, during the first phase, productive 
replication, has been extensively studied in permissive cell types in culture. Here it was 
discovered that viral gene expression is temporally regulated in three distinct phases: 
immediate early (IE), early (E) and late (L) (Clements et al., 1977; Honess and Roizman, 
1974).  Unlike other large DNA viruses, herpesvirus IE genes are not controlled by 
constitutively active promoters within the context of the viral genome. Rather, a tegument 
protein packaged in the virion serves to activate IE gene expression {reviewed in 
(Wysocka and Herr, 2003)}. The tegument protein VP16 (virion protein 16) associates 
with host cell factor 1 (HCF-1) in the cytoplasm and this complex translocates to the 
nucleus where it binds to the cellular transcription factor Oct-1 (Octamer binding protein 
1) bound to specific motifs in the promoters of all IE genes (Kristie et al., 1989; LaMarco 
and McKnight, 1989). This brings the potent VP16 acidic activation domain in the 
vicinity of the transcription start site of these genes in order to recruit and stabilize 
elements of the basal transcription complex (Goodrich et al., 1993; Ingles et al., 1991; 
Klemm et al., 1995; Lin et al., 1991; Uesugi et al., 1997). During productive infection, all 
viral genes are expressed, new virus particles are made, and cell death ensues.  
The second and third phases of the HSV-1 lifecycle, latency and reactivation, 
respectively, have been experimentally studied in animal models of HSV-1 infection in 
mice and rabbits. From these studies, we have learned that during the second phase, 
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establishment and maintenance of latency, the HSV-1 viral genome is maintained in 
sensory neurons as an episome (Efstathiou et al., 1986; Rock and Fraser, 1983), but 
infectious virus is not detected by standard virological methods (Baringer and 
Swoveland, 1973; Cook et al., 1974; McLennan and Darby, 1980; Stevens and Cook, 
1971).  In contrast to productive infection, the only viral gene abundantly expressed in 
latently infected sensory neurons is the latency associated transcript (LAT; (Stevens, 
1987a)). Latency is therefore characterized by minimal viral gene expression, the absence 
of lytic viral proteins, the absence of new virion synthesis, and neuronal viability.  
In the third phase, reactivation from latency, various stressors induce lytic viral 
gene expression and infectious virus production. The latency-reactivation cycle is crucial 
for virus transmission and survival in nature. However, due to the lack of a suitable cell 
culture model to study reactivation from latency, the molecular mechanisms that control 
the exit from latency remain to be elucidated.   
Bovine herpesvirus 1 (BHV-1) is an alphaherpesvirinae subfamily member that 
shares a number of biological properties with HSV-1 (Jones, 2003a). Unlike HSV-1, 
BHV-1 can be studied in vivo in its natural host. Furthermore, BHV-1 can be predictably 
reactivated from all latently infected animals following a single intravenous dose of the 
synthetic corticosteroid, dexamethasone (Dex) (Inman et al., 2002; Jones, 1998; Jones, 
2003a; Jones et al., 2006; Jones et al., 2000; Rock et al., 1992). This makes BHV-1 a 
suitable model to study alpha-herpesvirus reactivation from latency. In a recent study to 
identify cellular factors that may stimulate BHV-1 reactivation from latency, cellular 
gene expression was examined in TG of calves during the early stages of Dex induced 
reactivation from BHV-1 latency (Chapter 6). A Bovine Gene Chip (Affymetrix) 
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identified 6 cellular transcription factors that were induced greater than 10 fold at 3 hours 
after Dex treatment. A subset of these Dex-inducible genes stimulated BHV-1 productive 
infection, in part, by trans-activating viral promoters. Since BHV-1 and HSV-1 are both 
alphaherpesvirinae subfamily members, we hypothesized that both viruses utilize similar 
transcription factors to stimulate viral promoters necessary for reactivation from latency. 
Therefore, in this study, we tested the effect of the Dex-inducible cellular transcription 
factors on HSV-1 productive infection and viral promoter activity. These studies show 
that certain transcription factors induced during BHV-1 reactivation from latency can 
stimulate certain HSV-1 promoters and productive infection.  
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MATERIALS AND METHODS 
Cells and Virus 
 Murine neuroblastoma (neuro-2A), rabbit skin (RS) and African green monkey 
kidney cells (Vero) were grown in Earle’s modified Eagle’s medium (EMEM) 
supplemented with 10% fetal calf serum, penicillin (10 U/ml), and streptomycin (100 
μg/ml). 
 An HSV-1 recombinant virus (KOS6) contains the -Gal gene driven by the 
viral ICP6 promoter and is expressed as an early gene (David Davido, University of 
Kansas). The recombinant virus grows to wild type levels when grown in human or 
mouse cells (Davido, 2002).  
 
-gal Assay 
The KOS6 virus grows to similar titers as the parental strain and was grown in 
Vero cells. Procedures for preparing genomic DNA were described previously. RS cells 
grown in 6 well plates were cotransfected with 1 ug of the viral genome and the 
designated amounts of plasmid expressing bICP0 or the Dex-inducible cellular 
transcription factor of interest using Lipofectamine 2000 (11668-019; Invitrogen).  
Twenty-four hours after transfection, cells were fixed (2% Formaldehyde, 0.2% 
Glutaraldehyde in PBS), stained (1% bluo-gal, 5 mM Kferric, 5 mM Kferro, 0.5 M 
MgCl2 in PBS), and the number of -gal+ cells counted as described previously 
(Workman and Jones, 2010; Workman et al., 2009; Workman et al., 2011).  The number 
of -gal+ cells in cultures expressing the blank vector was set to 100%.  To calculate 
percent plaque formation, the number of blue cells in cultures transfected with the 
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cellular transcription factor were divided by the number of blue cells in cultures 
transfected with the blank vector.  This representation of the data minimized the 
differences in cell density, Lipofectamine lot variation, and transfection efficiency. The 
results are an average of at least three independent experiments. 
 
Plasmids  
CAT (chloramphenicol acetyltransferase) constructs used in this study, HSV-1 
ICP0-CAT (pAB5) and ICP4-CAT were described previously (Devireddy and Jones, 
2000). Luciferase promoter constructs used in this study, pGL3basic, VP16-luc, gC-Luc, 
UL42-Luc, ICP6-Luc, and LAT-Luc were obtained from Priscilla Schaffer and have been 
previously described (Kushnir et al., 2010).  The empty vector pcDNA3.1 was purchased 
from Invitrogen. SPDEF was purchased from Origene (Rockville, MD). The remaining 
Dex-inducible genes were graciously provided to us from labs studying these 
transcription factors. PLZF: Derek Sant’Angelo (Sloan Kettering Cancer Center). SLUG: 
Paul Wade (NIH). KLF4: Jonathan Katz (University of Pensylvania).  GATA6: Brian 
Herring (Indiana University Medical Center) KLF6: Bing Guo (North Dakota State 
University). The Notch1 and Notch 3 intracellular domain (ICD) were cloned into a 
CMV expression construct, and were provided by Urban Lendahl (Karolinska Institute, 
Sweeden). 
 
CAT and Luciferase Reporter Assays 
Neuro-2A cells grown in 60 mm dishes were co-transfected with the designated 
plasmids as indicated in the respective figure legends using TransIT Neural according to 
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the manufacturer’s instructions.  Measurement of chloramphenicol acetyltransferase 
(CAT) activity in Neuro-2A cells was performed as described previously (Workman and 
Jones, 2010; Workman et al., 2009; Workman et al., 2011).  Luciferase activity in 
transfected Neuro-2A cells was performed using the Promega Luciferase Assay System 
as described by the manufacturer (E4030; Promega).  
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RESULTS 
Analysis of DEX-inducible transcription factors on HSV-1 productive infection 
In a previous study (Chapter 6 of this dissertation) we identified 6 Dex-inducible 
transcription factors which promote BHV-1 productive infection by directly or indirectly 
activating viral promoters. Since BHV-1 and HSV-1 are both alphaherpesvirinae 
subfamily members, we hypothesized that both viruses may utilize similar cellular 
transcription factors for activating viral gene expression during reactivation from latency. 
To test this hypothesis, we examined the effects of the 6 Dex-inducible transcription 
factors on HSV-1 productive infection (see Table 7.1 for a list of Dex-inducible 
transcription factors that were tested in this study). 
To determine whether Dex-inducible genes activated productive infection, a 
plasmid expressing the specific cellular gene of interest was co-transfected with genomic 
DNA from a HSV-1 strain called KOS6 and efficiency of productive infection was 
measured. The KOS6   virus contains the Lac Z gene downstream of the early ICP6 
promoter. This allows measurement of productive infection by counting -Gal+ (beta-
galactosidase) cells, which directly correlates with plaque formation. GATA6 and PLZF 
did not have a significant effect on the number of β-gal positive cells (Figure 7.1). In 
contrast, SPDEF, KLF4, and KLF6 all reduced the number of β-gal positive cells relative 
to the empty vector control.  SLUG was only transcription factor to increase HSV-1 
productive infection, with a 2.5 fold induction (Figure 7.1). In contrast, PLZF was able to 
activate BHV-1 productive infection 20 fold and KLF4 activated BHV-1 productive 
infection approximately 9 fold (Chapter 6). The remaining transcription factors each 
activated BHV-1 productive infection approximately 4 fold. In summary, the Dex-
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inducible transcription factors that stimulated BHV-1 productive infection did not have 
the same effect on HSV-1 productive infection.  
 
Analysis of DEX-inducible transcription factors on viral gene expression 
 We next examined the ability of the 6-Dex inducible transcription factors to 
transactivate HSV-1 promoters that regulate expression of important viral genes. For 
these studies, we tested the immediate early ICP0 and ICP4 promoters as well as the early 
ICP6 promoter and the late VP16, gC, and UL42 promoters. Finally, the latency 
associated transcript (LAT) promoter was tested. Neuro-2A cells were co-transfected 
with the designated promoter construct plus a Dex-inducible gene, and reporter activity 
was measured at 48 hours after transfection.  GATA6 was found to activate the ICP6, gC, 
UL42, and VP16 promoters greater than 5 fold (Table 7.2). As GATA6 was able to 
activate the promoter-minus CAT expression vector, no data could be obtained for the 
ICP0 and ICP4 promoter constructs. SPDEF activated the VP-16, UL42, and ICP0 
promoters greater than 5 fold and the ICP4 promoter 4 fold. PLZF activated the ICP0 
promoter 6 fold. Slug activated the ICP0 and ICP4 promoters approximately 6 fold. 
KLF4 activated the ICP0 promoter 21 fold. KLF6 did not activate any of the promoter 
constructs examined (Table 7.2). None of the Dex-inducible transcription factors 
activated the LAT promoter. In summary, several of the Dex-inducible genes were able 
to trans-activate HSV-1 promoters. In particular, the ICP0 promoter was activated more 
than 17 fold by SPDEF and 21 fold by KLF4. 
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Analysis of Notch Induction of HSV-1 productive infection and promoter activity 
 We recently found that the Notch family of transcription factors play a role in the 
latency-reactivation cycle of BHV-1 ((Workman et al., 2011); Chapter 5). Notch receptor 
family members (Notch1-4) are membrane tethered transcription factors that regulate 
numerous developmental and physiological processes (Bray, 2006; Ehebauer, 2006). 
When the Notch receptor is engaged by its ligand, the intracellular domain (ICD) is 
cleaved by specific proteases, and is subsequently translocated to the nucleus. In the 
nucleus, NICD interacts with CSL family members to stimulate target promoter activity. 
The BHV-1 latency related (LR) protein ORF2 was found to interact with Notch 1 
and Notch 3 proteins in a yeast-two-hybrid assay (Workman et al., 2011). This interaction 
was further confirmed by pull down assays and co-localization by confocal microscopy. 
Notch 1 activated all three classes of BHV-1 promoters, while Notch 3 activated the late 
gC promoter alone. Trans-activation of viral promoters was attenuated by co-expression 
of ORF2, suggesting ORF2 negatively regulates Notch function. This data further 
suggests ORF2 promotes the establishment and maintenance of latency by reducing viral 
transcription (Chapter 5). Microarray analysis also revealed that several genes in the 
Notch signaling pathway, including the proteases that cleave and activate Notch, are 
stimulated in TG of latently infected calves following DEX treatment for 6 hours, adding 
further support to the concept (Chapter 6). Finally, the Notch signaling pathway plays a 
role in the latency-reactivation cycle of two human herpesviruses, KSHV (Kaposi’s 
sarcoma-associated herpesvirus) (Liang et al., 2002) and EBV (Epstein Barr virus) (Kieff 
et al., 1971). Therefore, we were interested in analyzing the effect of Notch on HSV-1 
productive infection and promoter activity.  
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Previous studies revealed that the BHV-1 genome contained 82 consensus CSL 
binding sites (Workman et al., 2011). We hypothesize that these binding sites are 
important for Notch induced viral promoter activation. Within the HSV-1 genome there 
are over a hundred CSL binding sites (CBS; Figure 7.2). This suggests that Notch family 
members have the potential to regulate some aspect of HSV-1 infection. 
 To determine whether Notch family members activated productive infection, a 
plasmid expressing Notch was co-transfected with KOS6 genomic DNA and efficiency 
of productive infection was measured.  Notch 3 increased the number of -gal positive 
cells approximately 2.5 fold while Notch 1 consistently reduced the number of -gal 
positive cells approximately 50% when compared to the empty vector control (Figure 3). 
Notch 2 was unable to stimulate productive infection when compared to the empty vector 
control (Figure 7.3). This is in contrast to BHV-1 productive infection where Notch 1 and 
Notch 3 stimulated productive infection 6 fold and 2 fold, respectively (Chapter 5; Figure 
5.3). 
 We next examined the ability of Notch family members to trans-activate HSV-1 
promoters that regulate expression of important viral genes. For these studies, we tested 
the immediate early ICP0 and ICP4 promoters as well as the early ICP6 promoter and the 
late VP16, gC, and UL42 promoters. Additionally, the latency associated transcript 
(LAT) promoter was tested. Neuro-2A cells were co-transfected with the designated 
promoter construct and Notch family member, and reporter activity was measured at 48 
hours after transfection. Notch 1 stimulated the ICP0 promoter approximately 3 fold 
(Figure 7.4A), the UL42 promoter 4 fold and the gC promoter 5.5 fold (Figure 7.4B).  
Notch 2 activated the ICP4 promoter approximately 4.5 fold, but was unable to activate 
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the other promoters tested. Finally, Notch 3 was unable to activate any of the promoters 
we tested (Figure 7.4). In summary, these studies provide evidence that Notch 1, but not 
Notch 3 stimulated several HSV-1 promoters. Notch 2 was the only Notch family 
member that was able to stimulate the ICP4 promoter.   
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DISCUSSION 
 In general, recurrent diseases caused by HSV-1 are the direct result of reactivation 
from latency (Asbell et al., 1984; Lewis et al., 1984; Sakaoka et al., 1995). For example, 
two-thirds of HSV-1 induced infections, corneal blindness, and encephalitis are the result 
of recurrent disease. Stress, trauma, and/or immune suppression can result in reactivation 
from latency; however, the steps that occur during a successful reactivation have not been 
well characterized. While many attempts at cell culture models for latency have been 
made, none give a true representation of the events that occur during an in vivo latency-
reactivation cycle. Therefore, our lab studies BHV-1 in its natural host in an attempt to 
identify virus-host interactions important in the latency-reactivation cycle of alpha-
herpesviruses. 
 In a previous study, we analyzed the cellular gene expression in the TG of calves 
latently infected with BHV-1 following treatment with a synthetic corticosteroid (Dex) to 
induce reactivation from latency (Chapter 6). In as little as 3 hours after Dex treatment, 
approximately 100 cellular genes were activated in the TG. Six of these were cellular 
transcription factors: 1) promyelocytic leukemia zinc finger (PLZF), a member of the 
Kruppel like transcription factor (KLF) family, 2) Slug, a zing finger protein involved in 
neuronal development, cancer, and apoptosis, 3) KLF4, 4) KLF6, 5) SAM pointed 
domain containing ets (erythrocyte transformation specific)  like transcription factor 
(SPDEF), which is a zinc finger containing protein that regulates cell lineage 
specification, proliferation, differentiation, angiogenesis and apoptosis, and 6) GATA6 
which is important in regulating terminal differentiation or proliferation (see Table 7.1).  
We were initially interested in the KLF family members because they bind GC rich 
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motifs resembling Sp1 binding sites, and the herpesvirus genomes are >70% GC rich 
(Tikoo et al., 1995). Additionally, most viral promoters contain multiple Sp1 consensus 
sequences (Jones and Tjian, 1985). Indeed, KLF family members activated viral 
transcription and BHV-1 productive infection in cultured cells (Chapter 6).   
Further analysis of the microarray dataset using the Ingenuity program further 
concluded that the Notch signaling pathway was activated in the TG following Dex-
induced reactivation. Notch family members were found to regulate viral promoter 
activity and stimulate BHV-1 productive infection (Chapter 5). Therefore, this technique 
was successful at identifying host factors that may play a role in the early events during 
BHV-1 reactivation from latency.  
 In this study, we wanted to test the hypothesis that other alphaherpesvirinae 
subfamily members utilize similar host cellular factors to regulate lytic gene expression. 
To this end, we examined the effect of the 6 Dex-inducible transcription factors as well as 
the Notch family of transcription factors to regulate HSV-1 promoter activity and 
productive infection. Slug and Notch 3 each activated HSV-1 productive infection 2.5 
fold. Slug activated the ICP0 and ICP4 promoters approximately 6 fold, suggesting Slug 
may activate productive infection by activating the expression of important viral 
transcription factors. In contrast, Notch 3 did not activate any of the viral promoters 
tested. Notch 3 may promote productive infection by activating a viral gene which was 
not analyzed in this study or Notch 3 may enhance productive infection indirectly by 
creating a cellular environment more suitable for viral replication.  
 While none of the other transcription factors activated HSV-1 productive 
infection, several stimulated expression of important viral promoters. Notably, GATA6 
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activated the VP16 promoter 16 fold. SPDEF also activated the VP16 promoter 5 fold. 
Recent work by Thompson et al. (Thompson et al., 2009), using an in vivo approach to 
study HSV-1 reactivation, show that VP16 is expressed prior to IE genes during 
reactivation from latency. Furthermore, they conclude de novo synthesis of VP16 (due to 
specific activation of the VP16 promoter) is responsible for the initial events of 
reactivation from latency. The stress-induced cellular factors that regulate HSV-1 VP16 
expression during reactivation and the promoter sequences that are important for the 
regulated expression of VP16 in neurons were not identified. These studies suggest 
GATA6 or SPDEF activation of the VP16 promoter could potentially induce reactivation 
from HSV-1 latency.  
 SPDEF and KLF4 activate the ICP0 promoter 17 fold and 21 fold respectively. 
Exogenous expression of ICP0, independent of other viral gene products, can initiate 
HSV-1 (Halford et al., 2001) or HSV-2 (Zhu et al., 1990) reactivation from latency using 
an in vitro system. Furthermore, in the absence of VP16, ICP0 enhances the ability of 
transfected viral DNA to initiate productive infection in Vero cells by 10,000-fold (Cai 
and Schaffer, 1989). Based on these and other observations, it has been hypothesized that 
ICP0 has the potential to initiate reactivation from latency in vivo. Therefore, it is 
possible that induction of ICP0 protein expression by SPDEF or KLF4 could initiate 
reactivation from latency.  
While no definitive conclusions can be drawn regarding the relevance of these 
findings to the events that occur during in vivo reactivation in humans, these studies 
suggest several Dex-inducible transcription factors identified to stimulate BHV-1 viral 
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gene transcription and production infection, also have the potential to regulate HSV-1 
transcription and/or productive infection.  
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Table 7.1. Dex-induced cellular transcription factors. 
Three latently infected calves (60 days post infection with BHV-1) were treated with Dex 
for 3 hours, 6 hours, or 24 hours.  TG were collected and total RNA was isolated as 
described previously (Workman et al., 2011). Cellular gene expression was analyzed 
using the Affymetrix bovine Gene Chip. The common name of the gene is provided in 
the first column. Second column (Fold Induction):  the numbers are levels of induced 
gene expression at 3 (1
st
 number), 6 (2
nd
 number), or 24 hours (3
rd
 number) after Dex 
treatment.  The base line of expression was derived from 3 calves latently infected with 
BHV-1 (no Dex).  Known functions of the respective genes are summarized in the third 
column.  
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Table 7.1 
 
  
GENE NAME FOLD 
INDUCTION
FUNCTIONS
PLZF 37,17,8 Transcription Factor: differentiation, 
growth control
SLUG 28,10,2 Transcription Factor: neural 
development, apoptosis, cancer
KLF4 12,9,3 Transcription Factor: SP-1 like
binding activity, GC binidng
SPDEF 11,10,6 Transcription Factor: contains zinc
finger
GATA6 11,3,2 Transcription Factor: binds 
GGA(A/T) sequence
KLF6 11,2,2 Transcription Factor: SP-1 like
binding activity, GC binidng
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Figure 7.1. Analysis of Dex-inducible transcription factors on HSV-1 productive 
infection.  
Rabbit skin (RS) cells were cotransfected with 1 ug of the respective plasmids encoding a 
Dex inducible transcription factors along with 1 ug of KOS6 HSV-1 DNA, which 
contains the Lac Z gene inserted into the ICP6 locus of HSV-1. At 24 hours after 
infection, cells were fixed, stained, and -gal positive cells were counted as described in 
the material and methods. The results are the average of at least three independent 
experiments.  
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Figure 7.1. 
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Table 7.2. Analysis of Dex-inducible transcription factors on HSV-1 promoter 
activity. 
Mouse neuroblastoma cells (neuro-2A) were cotransfected with 1 ug of the designated 
reporter plasmid and 1ug of pcDNA3.1 empty vector or 1 ug of a plasmid expressing the 
designated Dex-inducible transcription factor. At 48 hours after transfection, reporter 
activity was measured as described in the material and methods. The numbers represent 
fold induction over the empty vector control. The results are the average of three 
independent experiments. 
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Table 7.2. 
 
 
  
 GATA6  SPDEF  PLZF  SLUG  KLF6  KLF4  
ICPO-CAT  NA  17±3.4  6±0.2  6.2±1  3.7±1  21.4±3  
ICP4-CAT  NA  4±0.2  3±0.4  5.4±0.7  3.4±0.2  3.8±0.2 
VP16-Luc  16±3  5.1±0.4  0.5±0.3  0.8±0.1  0.33±0.1  3.5±0.6  
UL42-Luc  6.1±1.5  8.2±1.2  0.6±0.1  1.3±0.1  0.3±0.1  0.6±0.1  
ICP6-Luc  5.7±0.8  1.8±0.2  0.76±0.1  0.7±0.1  0.5±0.2  3.4±0.6  
gC-Luc  5.9±1.1  2.3±0.3  0.7±0.1  0.75±0.1  0.59±0.1  0.65±0.1  
LAT-Luc  1±0.3  0.95±0.2  0.5±0.1  1.3±0.3  0.46±0.1  2.4±1  
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Figure 7.2. Predicted CSL binding sites in the HSV-1 genome.  
Eleven variants of known canonical CSL binding sites have been identified (Persson and 
Wilson, 2010). A schematic of the HSV-1 genome, which consists of two unique regions 
(UL and US) flanked by terminal repeats (TRL and TRS) and internal repeats (IRL and 
IRS), is shown. Listed are the number of CSL binding sites (CBS) located upstream of 
several important viral genes. Listed below are the functions of some of these important 
viral genes.  
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Figure 7.2. 
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ICP4: transcriptional regulator, specific DNA binding protein
ICP0: transcriptional regulator, modulator of cell state
UL8: component of DNA helicase-primase
UL29: single stranded DNA binding protein
UL30: DNA polymerase, catalytic subunit
UL36: large tegument protein
UL40: small subunit of ribonucleotide reductase
UL48: tegument protein, trans-activator of IE gene expression (VP16)   
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Figure 7.3. Analysis of Notch family members on HSV-1 productive infection. 
Rabbit skin (RS) cells were cotransfected with 1 ug of the respective plasmids encoding 
Notch along with 1 ug of KOS6 HSV-1 DNA, which contains the Lac Z gene inserted 
into the ICP6 locus of HSV-1. At 24 hours after infection, cells were fixed, stained, and 
-gal positive cells were counted as described in the material and methods. The results 
are the average of at least three independent experiments.  
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Figure 7.3. 
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Figure 7.4. Analysis of Notch family members on HSV-1 promoter activity. 
Panel A: Mouse neuroblastoma cells (neuro-2A) were cotransfected with 1 ug of the 
designated CAT plasmid and 1ug of pcDNA3.1 empty vector or 1 ug of a plasmid 
expressing the designated Notch family member. At 48 hours after transfection, CAT 
activity was measured. The numbers represent fold induction over the empty vector 
control. The results are the average of three independent experiments. 
Panel B: Neuro-2A cells were co-transfected with 1 ug of the designated Luciferase 
construct and 1ug of pcDNA3.1 empty vector or 1 ug of a plasmid expressing the 
designated Notch family member. At 48 hours after transfection, Luciferase activity was 
measured. The numbers represent fold induction over the empty vector control. The 
results are the average of three independent experiments. 
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Figure 7.4. 
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General Conclusions  
 The work presented in this dissertation was aimed at elucidating the role of 
cellular factors in the latency-reactivation cycle of alpha-herpesviruses.  Although 
considerable effort has been focused on how alpha-herpesviruses establish, maintain, and 
reactivate from latency, there remain significant gaps in our knowledge. The molecular 
mechanisms controlling the exit from latency are of central importance to recurrent 
disease and transmission, yet the cellular factors that play a role in this process remain 
unknown.  Therefore, our lab studies BHV-1 in its natural host in an attempt to identify 
virus-host interactions important in the latency-reactivation cycle of alpha-herpesviruses. 
A previous study demonstrated that the cellular transcription factor C/EBP-alpha 
is stimulated when latently infected calves are treated with Dexamethasone  (Dex) to 
induce reactivation from latency (Meyer et al., 2007a).  Furthermore, C/EBP-alpha 
stimulates productive infection when over-expressed (Meyer et al., 2007a), and C/EBP-
alpha plus bICP0 stimulate IETu1 promoter activity more efficiently than just the viral 
trans-activator alone (Meyer and Jones, 2009). Additionally, C/EBP-alpha was unable to 
stimulate the IETu1 in the absence of bICP0 (Meyer and Jones, 2009). Previous studies 
also demonstrated that the bICP0 E promoter may be preferentially activated over the 
IETu1 during reactivation from latency (Workman et al., 2009). Therefore, we 
hypothesized that C/EBP-alpha may activate the bICP0 E promoter first, and then bICP0 
and C/EBP-alpha together activate the IETu1 to stimulate reactivation from latency.  
To test this hypothesis, the bICP0 E promoter was cloned into a reporter plasmid 
and the effect of C/EBP-alpha on reporter gene expression was evaluated. C/EBP-alpha 
stimulated bICP0 E promoter activity by directly binding to the viral promoter (Workman 
et al., 2009). However, activation of the bICP0 E promoter does not necessarily lead to 
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late gene expression and reactivation from latency (Workman et al., 2009).  Therefore, 
although C/EBP-alpha appears to be an important component in the Dex-induced 
signaling cascade that stimulates viral gene expression, it seems clear that additional 
Dex-inducible cellular proteins are required for infectious virus to be produced (Chapter 
2; Workman et al., 2009). 
 It was also known that during Dex-induced reactivation from latency, cyclin 
expression is stimulated in infected sensory neurons (Winkler et al., 2000b).  Cyclin 
dependent kinase activity phosphorylates Rb (retinoblastoma tumor suppressor gene 
product) family proteins and consequently releases the E2F family of transcription 
factors. Over-expression of E2F4 stimulates BHV-1 productive infection and E2F1 or 
E2F2 trans-activates IETu1 promoter activity (Geiser and Jones, 2003). This suggests 
that E2F family members could have the potential to stimulate productive infection 
and/or reactivation from latency. Therefore, I silenced E2F1 using a siRNA to examine 
the effect of E2F1 on BHV-1 productive infection. Silencing E2F1 reduced productive 
infection approximately 5 fold (Workman and Jones, 2010). Furthermore, E2F1 activated 
the bICP0 E promoter more than 100 fold in transient transfection assays by directly 
binding to the promoter, suggesting E2F1 may play a role in the latency-reactivation 
cycle of BHV-1 by stimulating lytic cycle transcription (Chapter 3; Workman and Jones, 
2010).  
 After characterization of previously identified cellular factors, we set out to 
identify and characterize a set of new cellular factors that may be involved in the latency-
reactivation cycle of BHV-1. Microarrays were performed to identify cellular factors 
induced in the TG of latently infected calves following Dex treatment to induce 
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reactivation from latency. Six cellular transcription factors were identified to be induced 
greater than 10 fold at 3 hours after Dex treatment. Further studies showed that these 
Dex-inducible transcription factors were able to stimulate BHV-1 productive infection 
and specific BHV-1 promoters when analyzed in transient transfection assays, suggesting 
they may play a role in the latency-reactivation cycle of BHV-1 (Chapter 6).  
 Analysis of the microarray dataset using the Ingenuity program concluded that the 
Notch signaling pathway was activated in TG following Dex treatment of latently 
infected calves. This was of interest as the LR protein ORF2 was found to interact with 
Notch1 and Notch3 using yeast-two-hybrid analysis (Workman et al., 2010). I found that 
Notch1, but not Notch3, activates BHV-1 productive infection by activating expression 
of all 3 classes of viral promoters. Notch-induced activation of productive infection or 
viral gene expression is attenuated by co-expression of ORF2 (Workman et al., 2010). 
Although ORF2 inhibits apoptosis (Shen and Jones, 2008), this study suggested ORF2 
also regulates viral transcription by interacting with cellular transcription factors.  Two 
additional studies provide evidence that ORF2 may regulate transcription (Devireddy et 
al., 2003; Meyer et al., 2007a).  Consequently, we suggest that the ability of ORF2 to 
inhibit apoptosis and interact with cellular transcription factors promote life-long latency 
(Chapter 5; Workman et al., 2010). 
 As BHV-1 and HSV-1 are both alphaherpesvirinae subfamily members, we 
hypothesized that they may require similar cellular factors for productive infection and 
reactivation from latency. Therefore, I analyzed the effect of Dex-inducible cellular genes 
on HSV-1 productive infection and viral promoter activity. These studies show that 
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certain transcription factors induced during BHV-1 reactivation from latency can 
stimulate certain HSV-1 promoters and productive infection (Chapter 7).  
 Based on the data presented in this dissertation, we hypothesize that stressful 
stimuli promotes exit from latency by activating specific cellular transcription factors, 
which consequently activate lytic viral gene expression and production of infectious 
virus. We further hypothesize that LR gene products maintain the latent infection by 
promoting cell survival and preventing lytic gene expression.  
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